

PHARMACEUTICAL ENGINEERING®

The Official Magazine of ISPE

July/August 2025 | Volume 45, Number 4

AI AND DIGITAL TRANSFORMATION

The AI Paradox: Cybersecurity
Threats and Defenses

Digital Transformation
in the Life Sciences

A Pharma 4.0™ Future for
Brownfield Challenges

**CASE
STUDY**


Applying Process Data Mapping Methodology for Systematic
and Sustainable Transformation Toward Pharma 4.0™



ISPE.org/pharmaceutical-engineering

Integration of legacy equipment is easy

with the zenon Software Platform



Integrating legacy equipment into existing IT systems is a challenge when it comes to maintaining accurate electronic batch records (EBR). zenon Automation Integration Layer (AIL) provides this missing link, enhancing **data integrity** and reducing time for **batch release**. Get ready for your digitalization journey in life sciences manufacturing.



zenon
by COPA-DATA



Körber Ecosystem Partner
PAS-X MSI Plug & Produce
Ready

For more info, go to
www.copadata.com/ail

A photograph of two scientists in a laboratory setting. They are wearing blue lab coats, blue hairnets, and white face masks. The scientist on the right is pointing towards a large, vertical, stainless steel industrial vessel. The scientist on the left is looking at the vessel. The background shows other laboratory equipment and a clean, bright environment.

#TeamUpToImprove

Process improvement is enabling faster time to market.

By optimizing processes from lab to production, we help life sciences companies get to market faster. Leveraging a complete portfolio for GMP-regulated single- and multi-use processes, we provide instrumentation, engineering support and seamless tech transfer for increased productivity and reduced risk.



Do you want to learn more?
endress.com/life-sciences

Endress+Hauser 
People for Process Automation



17 THE AI PARADOX

The increasing digitalization of the pharmaceutical and medical device industry has created novel cybersecurity challenges, particularly with the rapid advancement of artificial intelligence (AI) technologies. This article examines the dual nature of AI as both a potential threat vector and a powerful defensive tool.

28 DIGITAL TRANSFORMATION: DEVELOPING A FULLY AUTOMATED PHARMA MANUFACTURING FACILITY

The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies. This article presents a working definition of digital transformation, the components involved in undertaking a transformation initiative, and a phased approach to implementing digital transformation for the pharmaceutical industry.

36 A PHARMA 4.0™ FUTURE FOR BROWNFIELD CHALLENGES

Pharmaceutical companies can use digital maturity assessments to address upgrading brownfield facilities and implementing digital transformation improvements. Through stakeholder workshops, these assessments can quickly generate actionable plans and priorities to guide a facility's development delivering business value and enabling continuous improvement.

IN THIS ISSUE We focus on applying advances in AI and digital transformation—technologies that are revolutionizing how drugs are developed, produced, and delivered.

GF Piping Systems

+GF+

SYGEF PVDF – The thermoplastics solution for RO/DI, WFI, & Ultrapure water systems in Life Sciences

SYGEF® Standard PVDF Engineered for Excellence

- SYGEF® Standard certified to UL723/ASTM E-84 through 75mm
- Well suited for use in RO/DI, USP Water and WFI Systems (never requires passivation)
- High Temperature Tolerance: Operates effectively between -4°F and 284°F
- Material of Construction: Produced from high performance polyvinylidene fluoride resins
- Optimum Connection Options for BioPharm/LS: Integral assembly through IR (Infrared) and BCF (Bead and Crevice Free) fusion methods
- Measurably smoother surfaces than those found in stainless steel



gfps.com

GF Piping Systems

9271 Jeronimo Road, Irvine, CA 92618

Phone (714) 731-8800 • Toll Free (800) 854-4090

e-mail: us.ps@georgfischer.com

FEATURES

43 APPLYING STRATEGIC SKILL MANAGEMENT IN PHARMA 4.0™

The complex transformation toward Pharma 4.0™ requires comprehensive skill management. This case study follows the fictional company NewCo as it tackles the challenge of developing a future-ready workforce during a plant expansion project. NewCo systematically addresses critical knowledge gaps using modern virtual reality and augmented reality learning methods.

50 APPLYING PROCESS DATA MAPPING METHODOLOGY FOR SYSTEMATIC AND SUSTAINABLE TRANSFORMATION TOWARD PHARMA 4.0™

Pharma 4.0™ is a reference framework tailored to the pharmaceutical industry, guiding its digital transformation. The ISPE Pharma 4.0™ Subcommittee on Process Data Maps and Critical Thinking has introduced an approach to help organizations develop a holistic perspective on transformation.

55 ADOPTION AND IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES IN CMC

By embracing innovation and rethinking traditional approaches, CMC has the rare opportunity to drive transformative changes that could significantly accelerate the journey from initial concept to a fully realized therapy. This offers the possibility of faster drug availability, lower costs, and more efficient development pathways.

65 KEY INSIGHTS FROM A JOURNEY THROUGH THE PHARMA 4.0™ BASELINE® GUIDE

The *ISPE Baseline® Guide Vol 8: Pharma 4.0™* was published in 2023 to help accelerate the adoption of digital transformation. In citing the 1960s Star Trek television series, Christian Wölbeling, Founder and Chair of the ISPE Pharma 4.0™ Community of Practice, likes to say, "To boldly go where no one has gone before."

70 ADVANCED APPLICATIONS FOR DIGITAL TWINS

With the help of Digital Twins, companies can achieve greater certainty and precision in making informed decisions at various stages of the product lifecycle, driven by a deep understanding of underlying Critical Business Parameters.

77 INFORMED CONSENT IN THE ERA OF COMPLEX TRIAL DESIGNS: THE ROLE OF AI-POWERED AVATARS

As clinical trial designs evolve to include decentralized and adaptive elements, the informed consent process becomes increasingly complex. In response, this article explores the potential application of AI-powered synthetic avatars as an informational tool to support participants during clinical trials.

TECHNICAL

85 PATIENT SAFETY IN COMPOUNDED PRODUCTS

Visual inspection and standardized practices are essential for ensuring patient safety in 503b compounded products.

EDITORIALS AND COLUMNS

6 MESSAGE FROM THE CHAIR

How ISPE Is Empowering Pharma's AI Evolution

8 WOMEN IN PHARMA® EDITORIAL

The Transformative Power of Mentor ISPE

9 EMERGING LEADERS EDITORIAL

Retaining Hidden Talent: A Strategic Imperative Amidst Industry-Wide Scarcity

10 GUEST COLUMN

Culture Matters

NEWS

12 FACILITY OF THE YEAR AWARDS MARKS 20TH ANNIVERSARY, HONORS GLOBAL INNOVATION IN PHARMA

FOYA celebrates 20 years. Honors 17 finalists from 12 countries.

ISPE FOUNDATION

92 THE ANNUAL ISPE FOUNDATION GOLF TOURNAMENT

PEOPLE + EVENTS

95 2025 ISPE Annual Meeting to Deliver Cutting-Edge Education and Networking Across Five Tracks and 70+ Sessions**96 ISPE Europe Annual Conference Reaches New Heights with 1,200 Attendees****97 ISPE Engages with Global Regulators at EMA's GMDP IWG to Advance GMP Standards****99 Celebrating 25 Years of ISPE Singapore's Legacy****100 Volunteer Profiles**

100 Ben Stevens, PhD

101 Andrea Martina Zobel, PhD

102 Meet the Staff: Katie LeChase**104 Ad Index/Classifieds**

PHARMACEUTICAL ENGINEERING®

Volume 45, Number 4

ISSN 0273-8139

Pharmaceutical Engineering is published six times a year by ISPE and is online at ISPE.org/Pharmaceutical-Engineering

Senior Director, Publications: Rochelle May

Editor-in-Chief: Amy Reyes

Production Manager: Marcy Sanford

Technical Copy Editor: Heather E. Saunders

Advertising and Sales

Laneisha Walker, Sales Operations Manager
lwalker@ispe.org

Carol Nettles, Advertising Sales Manager
+1 404-347-1755 cnettles@ispe.org

JT Hroncich, Advertising Sales Manager
+1 404-347-4170 jhroncich@ispe.org

Stock Photography and Illustration

iStock

Art Direction and Graphic Design

THOR Design, Inc., www.thor.design

Printing

Sheridan NH

Letters to the Editor

Letters must include the writer's full name, address, and organization. Letters may be edited for length and clarity. Send correspondence to PEmag@ispe.org

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, or the authors, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© 2025 ISPE. All rights reserved. No part of this publication may be reproduced or copied in any form or by any means—graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems—without written permission of ISPE.

Opinions expressed in *Pharmaceutical Engineering* do not necessarily reflect the views of ISPE.

Article reprints can be ordered through Sheridan Content Solutions at sheridancontentsolutions@sheridan.com

ISPE Headquarters

6110 Executive Blvd., Suite 600
North Bethesda, MD 20852 US
Tel: +1 301-364-9201

ISPE Operations

3001 North Rocky Point Drive East
Suite 200-242
Tampa, Florida 33607
Tel: +1 813-960-2105

US Postmaster

Send change of address to:
Pharmaceutical Engineering Magazine
3001 North Rocky Point Drive East
Suite 200-242
Tampa, Florida 33607 US

Periodicals postage paid at Tampa, Florida, US, and additional post offices

Canada Postmaster

Send change of address and undeliverable copies to:
Pharmaceutical Engineering Magazine
PO Box 122
Niagara Falls, ON L2E 6S8
Canada

Canada Post mail agreement #40012899



Faster. Smarter. Modular.

MMF delivers fast-tracked, pre-engineered, and pre-validated solutions for modular pharma facilities—covering fill-finish processes and specialized categories like oncology and biopharmaceuticals—ensuring speed, efficiency, and reliability.



Cost
Reduction



Effortless Site
Installation



Accelerated Construction
and Seamless Integration



Resource
Efficient



Rapid Launch
Approach



Sustainable-Reduced
CO₂ Footprint

Industry leaders are onboard — are you next?





Jeffrey A. Biskup, PE

How ISPE Is Empowering Pharma's AI Evolution

ISPE is dedicated to advancing AI and digital transformation for the industry. The ISPE International Board of Directors fully supports this initiative. We are making significant strides in supporting the pharmaceutical industry's pursuit of digital transformation, including the exploration and potential strategic implementation of AI.

ADVANCEMENTS IN AI AND DIGITAL TRANSFORMATION

ISPE established the Pharma 4.0™ operating model in 2017 through the work of the Pharma 4.0™ Special Interest Group (SIG). In 2022, recognizing the industry's acceptance of the model and its

principles, the global ISPE Pharma 4.0™ Community of Practice (CoP) was launched. Since then, the Pharma 4.0™ CoP continues to guide and enable digitalization and automation. It is organized into the following subcommittees: Holistic Digital Enablement, Plug and Produce, Digital Maturity, Management Communication Strategy, Validation 4.0, and Continued Process Verification (CPV) and Automation.

CoP members educate the industry about Pharma 4.0™ via ISPE conference sessions, webinars, and training courses. These educational offerings cover emerging practices and further application of the Pharma 4.0™ operating model. Pharma 4.0™ has extended its reach beyond North America and Europe, establishing new local ISPE Affiliate CoPs in several other countries, including Japan, Singapore, and India.

ISPE also announced ISPE AI™ and launched the global ISPE

UPCOMING CONFERENCES



2025 ISPE Annual Meeting & Expo

26-29 October
Charlotte, NC, USA



2026 ISPE Aseptic Conference

23-24 March
Washington D.C., USA



2025 ISPE Pharma 4.0™ Conference

9-10 December
Barcelona, Spain



2026 ISPE Europe Annual Conference

20-22 April
Copenhagen, Denmark



2026 ISPE Facilities of the Future Conference

2-3 February
San Diego, CA, USA



Members enjoy special pricing on all ISPE international conferences. Scan the QR code or visit ISPE.org to view the upcoming conferences.

PHARMACEUTICAL ENGINEERING COMMITTEE

Chair: Dr. Ferdinando Aspesi, *Bridge Associates International*
Siou-Ping (SP) Chew, *Takeda Pharmaceutical Co.*

Robert Dream, *HDR Company, LLC*
Michelle Gonzalez, *Biopharm Consulting*
Matthew Gorton, *GBA Life Sciences*
Wendy Haines, *PharmEng Technology*
Lata Harish, *SynergBiopharma*
Anthony Margetts, PhD, *Factorytalk Co. Ltd.*
Robert Perks, *Performance Validation, Inc.*
Pietro Perrone, *Rentschler Biopharma*
Chris Smalley, *ValSource, Inc.*
Charles Tong, *Suzhou Ribio Life Science Co. Ltd.*
Anders Vidstrup, *NNIT A/S*
Steven Wisniewski, *CAI*
Christian Wölbelling, *Werum IT Solutions*
Vinzenn Zauner, *Zauner Consulting*
Jörg Zimmermann, *Vetter Pharma Fertigung GmbH*

PHARMACEUTICAL ENGINEERING REVIEWERS

Christopher Ames, *Sanofi/Akebia Therapeutics*
Joanne R. Barrick, RPh, *Eli Lilly and Company*
Brian Beck, *Zoetis, Inc.*
Malik Belattar, *Pharma Biot'Expert*
Theodore Bradley, *Pfizer, Inc.*
Rory Budihandjo, *Boehringer Ingelheim*
Magali Busquet, *Sanofi*
Jose A. Caraballo, *Kite Pharma, Inc.*
Chris Clark, *TenTen Consulting Limited*
John T. Connor
Nick Davies, *Verta Life Sciences*
Robert Del Ciello, *Northshire Associates*
Martin A. Döblin, *One One Eleven GmbH*
Paul S. Egee, *IMA North America*
Steven Ensign, *Eli Lilly and Company*
Michael Faia, *Jazz Pharmaceuticals, Inc.*
Petter Gallon, *Gallon Partners AB*
Andrew Gee, *Boehringer Ingelheim*
Charles Gentile, *Sanofi*
Norman A. Goldschmidt, *Genesis Engineers, Inc.*
Adam S. Goldstein, *Thermo Fisher Scientific*
Sean Goudy, *Regeneron Pharmaceuticals*
John T. Hannon, *CPIP, CAI*
Nicholas R. Haycocks, *Amgen*
Tse Siang Kang, *Pfizer*
Nigel D. Lenegan, *Energy & Carbon Reduction Solutions Ltd.*
John V. Lepore, PhD, *Merck & Co., Inc.*
Sarah E. Mancini, *Zoetis, Inc.*
Joseph J. Manfredi, *GMP Systems, Inc.*
Peter J. Marshall, *AstraZeneca*
James W. McGlade, *Longfellow Real Estate Partners, LLC*
Donald Moore, *DRMoore Consulting, LLC*
Lars Olsen, *Sigma Quality & Compliance ApS*
Maurice Parlane, *New Wayz Consulting*
Andre J. Petric, *Kraemer US, LLC*
James T. Robinson
Gregory M. Ruklic
Judith Samardelis, *GlaxoSmithKline*
Terry Seanard, *New England Controls, Inc.*
Stephen J. Sirabian, *Glatt Air Techniques, Inc.*
Alan M. Solomon, *Baxter Healthcare Corp.*
Oliver Stauffer, *PTI USA*
David Stokes, *Convalido Consulting Ltd.*
Robert Sussman, PhD, *SafeBridge Regulatory & Life Sciences Group*
Andrzej J. Szarmanski, *Steriscience Sp. z o.o.*
Zam Shabeer Thahir, *Mace*
Matthew VonEsch, *United Therapeutics*
Terrence Walsh, *TransCelerate BioPharma, Inc.*
Bruce R. Williams, *Williams Process Ltd.*
Siôn Wyn, *Conformity, Ltd.*

FPO SFI LOGO

Artificial Intelligence CoP in mid-2024, which has grown to include over 2,600 members. Three AI CoP subcommittees have been organized around the following topics: (1) applications, models, and data; (2) preparedness and workforce; and (3) regulatory considerations.

All ISPE members are welcome to join the AI CoP subcommittees. These teams discuss challenges and best practices, and share insights via ISPE publications and events.

GUIDANCE DOCUMENTS

The *ISPE GAMP® Guide: Artificial Intelligence* was published in July. Authored by members of the GAMP AI/Machine Learning SIG, this first-of-its-kind ISPE Guide, developed with key regulatory input, provides a much-needed framework for industry as AI-enabled systems are more widely adopted and applied.

The Guide introduces foundational AI concepts, ethical considerations, and challenges specific to pharmaceuticals and some medical devices. It also provides an AI governance framework based on GAMP concepts.

Released in December 2023, the *ISPE Baseline® Guide Volume 8: Pharma 4.0™* outlines how to strategically plan the application of emerging and digital technologies with a true end-to-end focus in mind for products and processes. In recognition of their work, the authoring team received the 2024 ISPE International Honor Award for Committee of the Year. The Guide has set a new standard for industry knowledge, expanded ISPE's influence in the industry, and continues to exemplify innovation paired with strategic alignment.

In April, ISPE published the *ISPE Good Practice Guide: Digital Validation*, which focuses on how increased adoption of digital validation tools in the life sciences industry can support a growing commitment to data integrity, operational efficiency, and regulatory compliance.

MEMBERSHIP ACTIVITIES

ISPE's focus on digital transformation and AI has enhanced the value of ISPE membership and expanded the appeal of ISPE to an extended scope of pharmaceutical professionals, namely those with information technology, information governance, and automation functions. ISPE has 20 CoPs, including the Artificial Intelligence and Pharma 4.0™ CoPs. Engagement with these topics is clear, with over 4,525 members in the Pharma 4.0™ CoP and 2,806 members in the AI CoP. The GAMP AI SIG also engages in AI discussions. To request membership to a Special Interest Group, contact member services at ask@ISPE.org

CONFERENCES

ISPE's largest conference of the year is the 2025 ISPE Annual Meeting & Expo, which will take place 26–29 October in Charlotte, North Carolina, US, and virtually. A key topic of this year's conference will be digital transformation in the pharmaceutical industry, with 14 sessions focusing on the end-to-end implementation of digitalization across all stages of project execution, manufacturing, and regulatory processes.

The 2025 ISPE Pharma 4.0™ Conference, set for 9–10 December in Barcelona, Spain, and virtually, will explore and facilitate effective digital transformation in operations. A key highlight will be the presentation of the annual Pharma 4.0™ survey results, which will provide industry insights and benchmarks on various aspects of Pharma 4.0™. Additionally, regulators and digital transformation champions will have a significant role in this conference.

As digital transformation and AI propel the industry forward, ISPE serves as a bellwether resource for knowledge and expertise—connecting teams with valuable information, insights, and experiences that can help them strategically build, refine, fortify, and continue to evolve their approaches now and in the future. 



Shree Pataskar, PE

THE TRANSFORMATIVE POWER OF A MENTOR

Talk show host Oprah Winfrey once said, “A mentor is someone who allows you to see hope inside yourself.” Mentoring can be a powerful force in shaping an individual’s professional career and growth in a profound way. For some of us, we would not be where we are today without the wisdom and guidance of a mentor.

Mentoring is like steering a ship through vast, uncharted waters—what’s visible on the surface is only a fraction of the journey. Just as an experienced navigator reads the wind, currents, and subtle shifts in the sea, a skilled mentor learns to attune to the unspoken—the body language, energy, and emotional undercurrents that shape every interaction.

Becoming attuned to your mentees’ somatic presence is a significant undertaking. The ability to understand both what is said and what remains unspoken is essential in order to be a successful mentor and coach. Developing self-awareness during sessions benefits both mentors and mentees alike.

True mentoring goes beyond advice-giving. It requires deep presence, self-awareness, and the ability to listen at level three—where you’re not just hearing words, but sensing the whole environment. This kind of listening allows mentors to respond with empathy, insight, and intention, creating a safe harbor for growth.

Women in Pharma® launched Mentor ISPE in 2021 with the goal of guiding others through their professional journeys. Like seasoned captains, we offer our knowledge, encouragement, and support to help our mentees navigate challenges, refine their skills, and ultimately chart a course toward their full potential.

In response to feedback we received during the first two years of the program, we restructured Mentor ISPE last year to better align the experience to meet industry needs. The Mentor ISPE core team—Gaurav Walia, Jennifer Matlack, Amy Washco, and I—gathered resources for mentors and mentees, developed workshops, established new discussion platforms, and created strategies for group cohesion.

To date, we have worked with over 700 individuals of diverse ethnicities, demographics, personalities, and different

expectations and goals. We’re able to pair one mentor with up to four mentees per session, which usually run for up to 12 sessions.

Mentees have access to discussion platforms and other resources to support their growth, such as a resource library which has been expanded and now includes informational manuals with statistics, sources, and questions to prompt important discussions. This year, we’ve added webinars and guest speakers to the program in an effort to expose mentees to different facets of the pharmaceutical industry.

Another recent addition has been the expansion of mentor training initiatives through workshops, guidance, tools, techniques, group discussions, and forums. And, we’ve just introduced a new ‘moderator’ role for aspiring mentors to help with scheduling meetings, tracking action items, and helping manage group dynamics.

Your feedback is important.
Learn more at ispe.org/women-pharma/mentor-ispe-program

Through surveys and general operations, we’ll continue to collect feedback from mentoring sessions which will serve as key performance indicators to guide program improvements and ensure the program continues to meet the needs of its members.

Join us in shaping lives through mentoring with the Mentor ISPE program. As filmmaker Steven Spielberg once said, “The delicate balance of mentoring someone is not creating them in your own image but giving them the opportunity to create themselves.” This is the essence of what Mentor ISPE offers to members who join this program.

We look forward to another year of transformative personal and professional growth for participants. 🌟

Shree Pataskar, EMBA, PE, is an independent consultant and experienced leader specializing in project, program and portfolio management for Engineering, Procurement, and Construction Management Validation (EPCMV) projects in pharmaceutical and chemical manufacturing plants. She is also a professional coach, and owner’s representative for strategic projects. She currently serves as Chair of the Women in Pharma® ISPE Mentor Committee. She joined ISPE in 2022.



RETAINING HIDDEN TALENT: A Strategic Imperative Amidst Industry-Wide Scarcity

Like other industries, the pharmaceutical industry is struggling with pain points of inflation, economic and geopolitical uncertainty, and big waves of retiring employees—all factors that have barely been tackled.

However, there is one further prominent hurdle negatively weighing on businesses: talent scarcity [1]. A 2025 employee turnover and retention survey by NectarHR found that 43% of employees in the US walked away from their jobs in the last year. Multiple industry reports, such as Mercer's 2024 US and Canada Turnover Survey, find that turnover rates are widespread, extraordinarily high, and costly in the US and Canada.

Talent scarcity is not limited to just regions; it's a global challenge. A 2024 report by ManpowerGroup found that 74% of employers worldwide are experiencing difficulties in filling roles, indicating a significant talent shortage in countries like Israel (85% of employers report difficulty), Germany, Japan, and Greece [1]. In the US, 70% of employers face similar challenges [2].

WHY ARE PEOPLE LEAVING THEIR JOBS?

We've all seen promising employees leave for reasons unrelated to salary. In fact, multiple studies show that unsatisfactory pay ranked only sixth or seventh on the list of reasons for quitting. The most prominent reason, according to roughly 32%–36% of employees, is a negative work environment, followed by poor company leadership (30%) or dissatisfaction with one's supervisor (27%) [3].

As innovation cycles accelerate and skill demands shift, retention of high-performing and hidden talent is becoming not just a competitive advantage but a survival strategy. Sometimes organizations overlook “hidden stars”—employees who quietly drive innovation from behind the scenes. Consider the dedicated research associate who regularly troubleshoots complex assays or who mentors junior scientists without formal recognition. These contributors may not be top of mind in succession planning, yet they form the backbone of many successful teams [4].

According to a 2023 research paper by Younis and colleagues, Organizational Network Analysis (ONA) can pinpoint these under-the-radar influencers. By mapping real collaboration

patterns, ONA reveals who is truly connecting departments, fueling knowledge sharing, and keeping projects on track. This is vital information for an industry in which each data point and every trial timeline can mean the difference between market success and costly delays [5].

Once these individuals are identified, retention efforts must be personalized and proactive. In a *Harvard Business Review* article, Roger L. Martin reports that the most effective way to retain top talent is not simply by offering incentives, but rather by regularly redesigning roles to keep pace with employees' evolving goals and strengths. High performers—especially those with untapped leadership potential—need to feel that their career is on a growth trajectory, not stuck in a static job description [6]. Continuous skill development is not just a way to keep promising employees for the long run; it's also necessary to navigate the current global job market [7], which are elaborated in a World Economic Forum “Future of Jobs Report” report [8].

THE “FALLING STAR” PHENOMENON

Recognition also plays a critical role, as employee frustration does not necessarily derive from the work itself but because their work goes unnoticed. Leaders must learn to spot, validate, and elevate hidden contributions—whether through targeted praise, mentorship, or visibility in high-impact projects. However, visibility without protection can backfire. Research by Oldroyd and Morris warns of the “falling star” phenomenon—where standout employees become overloaded, leading to burn-out and eventual departure. To avoid this, pharma leaders must balance exposure with well-being, assigning high-value tasks while also ensuring employees are not stretched too thin [9].

Finally, the work environment must be designed not only for performance but also for a sense of belonging. People spend a high proportion of their lifetime at work; however, global studies show that roughly 20% of the world's employees experience daily loneliness [10]. This may derive from missing bonds at work or home life. But no matter the reason, companies can have a strong impact on that balance. By building inclusive structures and flexible role pathways, companies ameliorate life quality, retain their workforce, and are able to multiply the impact of the talent they already have. When employees were asked to identify the

CONTINUED ON PAGE 11



Lou Schmukler

WHY CULTURE MATTERS

Companies must proactively build a healthy culture, as it lays the foundation for organizational success. Those that foster a culture of innovation, dedication, and enthusiasm among employees are best positioned to achieve sustained success.

In *The Culture Code: The Secrets of Highly Successful Groups*, author Daniel Coyle asks “Why do certain groups add up to be greater than the sum of their parts, while others add up to be less?” In the book, Coyle explores some of the world’s most successful organizations and reveals what makes them tick. He submits that although a successful culture can look and feel like magic, the truth is that it is not. I’d like to further explore and demystify this concept of culture and its relationship to leadership.

WHAT IS CULTURE?

An organization’s culture encompasses shared beliefs, values, attitudes, and behaviors that define how the organization operates and how its employees interact. It’s the “personality” of the organization, shaping employee experiences and influencing everything from workplace relationships to decision-making processes. It sets expectations, establishes standards, and serves to guide employee actions. Culture is the unique way that the organization lives out its purpose and delivers on its promise to its stakeholders. It could be thought of as part of the DNA of the organization. And an organization’s culture can grow and shift as circumstances change.

Great leaders understand the importance of culture. They recognize that shaping an effective culture rests squarely on their shoulders—it’s one of their most important responsibilities. In *Execution: The Discipline of Getting Things Done*, authors Larry Bossidy and Ram Charan write, “The behavior of a leader is, ultimately, the behavior of the organization. As such, it’s the foundation of the culture.”

Culture is a naturally occurring phenomenon—every organization develops one, whether intentionally or not. Good culture doesn’t happen by accident. It must be designed and nurtured. Leaders can shape and influence culture in various ways, such as

by ensuring alignment on mission, purpose, and vision; inspiring confidence in the face of challenges; and learning from past missteps.

There is a clear link between culture and business results. I believe workplace culture is an indicator of future success. For this reason, a strong culture can be a differentiator and yield a competitive advantage. According to research from FTSE Russell, companies on the *Fortune* “100 Best Companies to Work For” list outperformed the market by a factor of three compared to their competitors between 1998 and 2016. Over time, that’s a staggering difference.

Strong culture drives business profitability through higher employee retention, lower levels of burnout, faster innovation cycles, greater resilience to setbacks, and a higher stock return. Case in point: a group of 69 companies that researchers identified as having thriving cultures didn’t follow the 35.5% stock decline of the S&P 500 from 2007–2009. Instead, they saw an increase of 14.4%, according to “The Business of Corporate Culture: Part II,” a blog entry from APCO Worldwide.

CULTURE AS A STRATEGIC IMPERATIVE

Executives talk about culture change as a top strategic imperative, yet we see that it often isn’t prioritized. Organizations can miss the mark on transforming culture when it comes to strategic improvement and major transformation initiatives. I think one reason organizations often prioritize business process change over culture change is due to the perception that processes are more tangible and more measurable, and they directly impact efficiency and outcomes, whereas culture is seen as more intangible and difficult to manage. When leaders mistakenly discount the importance of culture, there is little doubt that it will impair overall business performance.

A culture can become toxic when it is ignored or marginalized. In the article “Toxic Culture Is Driving the Great Resignation,” published in 2022 in *MIT Sloan Management Review*, a toxic workplace is defined as one that lacks diversity, equity, and inclusion; where workers feel disrespected; or when there is unethical behavior within the organization.

Signs of a toxic work culture include unfair treatment and discrimination, a lack of trust and support among teams,

CONTINUED ON PAGE 11

CONTINUED FROM PAGE 10, "WHY CULTURE MATTERS"

excessive workload and unrealistic expectations, poor communications, a high level of burnout and turnover, and an absence of purpose and pride in work. There have been some high-profile examples of these types of cultures mentioned in the press. The failure of the Enron Corp. in 2001 was one of the most publicized case studies.

STEPS FOR A HEALTHY CULTURE

A healthy culture is fundamental to a successful organization. That's why it's essential to proactively build the culture you want to see, rather than leaving it to chance. From a high-level perspective, I've found these five steps to be essential when defining and building organizational culture:

1. Building widespread acceptance that culture is more than a buzzword—it matters
2. Clearly defining and consistently communicating the mission, values, and goals of the organization
3. Establishing robust, two-way communication channels
4. Prioritizing and investing in employee well-being
5. Continuously monitoring and improving cultural alignment

In addition, two other key focus areas are essential: authentic leadership and the use of quantitative data. It's important for leaders to be authentic. A leader's words and actions are always closely scrutinized. Leaders need to create an environment of psychological safety. Equally important is the discipline of

collecting and analyzing data, similar to the military's practice of after-action reports, which helps build a learning organization that sees mistakes as opportunities for growth. Formalizing a mechanism to routinely gather anecdotal and quantitative data about your culture is critical. This feedback can help determine whether your efforts are progressing in the right direction, or alert you to issues requiring course correction. Organizations are never static, so leaders need to watch for trends, keeping their finger on the pulse of the organization. The goal is to create momentum in a positive direction.

BUILDING A BETTER CULTURE

Building a better workplace culture is a messy business. Organizations that foster a culture that inspires innovation, dedication, and enthusiasm among employees are best positioned to achieve sustained success. Conversely, organizations that experience major setbacks and/or fail to adapt to a changing business situation can be correlated with a toxic culture. As we've heard in the familiar, anonymous saying, "Culture eats strategy for breakfast." 🌀

About the author

Lou Schmukler served as Executive Vice President and President of Global Product Development and Supply at Bristol Myers Squibb until his retirement. His pharmaceutical industry career spanned over 40 years. He holds a BS from Temple School of Pharmacy and an MA from Webster University. He joined ISPE in 1993.

CONTINUED FROM PAGE 9, "RETAINING HIDDEN TALENT"

most important factor besides pay influencing their decision to stay with an employer, a positive work environment topped the list of responses (25.7%) [3].

Retaining talent is essential. Why? Because in a sector where every product cycle depends on expertise, every innovation relies on continuity of well-executed qualitative processes that directly or indirectly impact patients' lives. Furthermore, every delay in a project or a postponed product release due to lack of personnel resources costs millions of dollars. Nurturing and retaining both "hidden" and "visible" stars isn't just an HR initiative—it's a business necessity.

Companies that invest in identifying top talent, tailoring roles, recognition strategies, and fostering a strong sense of inclusion will be the ones that rise victoriously from the workforce crisis. 🌀

References

1. ManpowerGroup. "2025 Global Talent Shortage." <https://go.manpowergroup.com/talent-shortage>
2. Executive Network. "Future of Talent Retention: Understanding Why Employees Leave and Why They Stay." 14 November 2024. www.shrm.org/executive-network/insights/future-of-talent-retention-report-why-employees-leave

3. iHire. "Talent Retention Report 2024." Updated 3 December 2024. www.ihire.com/resourcecenter/employer/pages/talent-retention-report-2024
4. Garfinkle, J. "Recognize Employees' Hidden Talent to Boost Retention." 15 August 2022. SmartBrief. www.smartbrief.com/original/hidden-talent
5. Younis, S., A. Ahsan, and F.M. Chatteur. "An Employee Retention Model Using Organizational Network Analysis for Voluntary Turnover." *Social Network Analysis and Mining* 13, no. 28 (2023). <https://pmc.ncbi.nlm.nih.gov/articles/PMC9893187/>
6. Martin, R. L. "The Real Secret to Retaining Talent." *Harvard Business Review* (March–April 2022). <https://hbr.org/2022/03/the-real-secret-to-retaining-talent>
7. World Economic Forum. "Future of Jobs Report 2023." May 2023. www3.weforum.org/docs/WEF_Future_of_Jobs_2023.pdf
8. Institute for Business Management. "The Enterprise Guide to Closing the Skills Gap: Strategies for Building and Maintaining a Skilled Workforce." IBM. ibm.com/downloads/documents/us-en/10a99803f8afda48
9. Oldroyd, J. B., and S. S. Morris. "Catching Falling Stars: A Human Resource Response to Social Capital's Detrimental Effect of Information Overload on Star Employees." *Academy of Management Review* 37, no. 3 (2012):396–418. doi:10.5465/amr.2010.0403
10. Gallup. "State of the Global Workplace." 2023. <https://gallup.com/workplace/349484/state-of-the-global-workplace-2023.aspx> <https://www.gallup.com/topic/workplace.aspx>

About the author

Rebecca Roscher, MSc, is a Project Manager at the GP Grenzach Produktions GmbH, a Bayer-owned production facility in Grenzach–Wyhlen, Germany. As the Ex Officio member of the ISPE International Board of Directors for 2024–2025, Rebecca represents and advocates the interests of young professionals as part of the ISPE Emerging Leaders Community of Practice. She has been a member of ISPE since 2020.

FACILITY OF THE YEAR AWARDS MARKS 20TH ANNIVERSARY

Honors Global Innovation in Pharma Manufacturing

By Marcy Sanford

The 2025 Facility of the Year Awards (FOYA) category winners were announced in May at the ISPE Europe Annual Conference held in London, England. As FOYA celebrates its 20th anniversary this year, it honors 17 finalists whose projects span 12 countries and five continents—a true global showcase of innovation.

Category winners included Touchlight (Innovation), Johnson & Johnson Innovative Medicine–Italy (Operations-Operational Excellence), Johnson & Johnson Innovative Medicine–Ireland (Operations-Project Execution), CSL Behring (Pharma 4.0™), Bayer Healthcare LLC (Social Impact-Unmet Medical Needs), Sanofi (Social Impact-Sustainability Excellence), Erbe Elektromedizin GmbH (Honorable Mention), and United Therapeutics (Honorable Mention).

But the heart of FOYA lies not just in its winners—it's in the 17 groundbreaking finalists. The projects span a wide

range of applications, including biotechnology, cell and gene therapies, fill-and-finish packaging, medical devices, and emerging technologies.

Finalists were chosen for excellence in facility design, construction, and operations, setting new benchmarks for pharmaceutical manufacturing of the future. The FOYA judging committee, composed of industry experts, evaluated submissions based on creativity, technical achievement, and potential industry impact.

“What makes FOYA so inspiring is that it's not just about impressive buildings. It's about visionary ideas brought to life through smart design, cutting-edge technology, and operational excellence. The winners truly set the bar for what pharmaceutical facilities can and should be,” said Mike Martin, President and CEO of ISPE and the ISPE Foundation.

The journey continues as all eyes now turn to the 2025 FOYA Banquet and Awards Celebration on 26 October at the ISPE Annual Meeting & Expo in Charlotte, North Carolina, US, where the achievements of Category Winners will be formally recognized and the Overall Winner will be revealed.

Amgen

Project: Amgen Ohio | Location: New Albany, Ohio, US



Some of Amgen's most advanced and sought-after medicines—including autoinjectors, syringes, and vials—are assembled, labeled, and packaged at the new 293,000-square-foot Amgen

facility in Ohio. The facility was fully approved and operational in just 26 months to ensure that patients continued receiving life-saving and life-enhancing therapies without disruption. Today, the Amgen Ohio facility is the company's most digitally advanced assembly and packaging facility. Meeting business goals within safety and compliance guardrails led the team to explore

a level of technological integration and automation rarely seen in the pharmaceutical industry, tightly connecting over 30 different systems to work together seamlessly.

Bayer Healthcare LLC

Project: Cell Therapy Launch and Manufacturing Facility
Location: Berkeley, California, US



The Bayer Cell Therapy Launch and Manufacturing Facility signifies a major advancement in the production of commercialization of innovative cell therapies aimed at addressing critical unmet medical needs. The 100,000-square-foot facility is one of

the first of its kind in the biotechnology industry and is designed to enhance Bayer's capabilities in the rapidly evolving field of regenerative medicine, enabling the delivery of high-quality therapies to patients on a global scale.

BioNTech SE

Project: BioTainer | Location: Marburg, Germany



During a global health crisis, there can be an urgent need for worldwide vaccine access; but often, regions with fewer resources or less technology get left behind. Through their development of BioTainer units, the BioNTech team aims to contribute to the equitable distribution of mRNA-based medicines, such as vaccines. The BioTainer concept is a novel container-based approach to manufacturing, offering modular design, standardized equipment, and IT components. Infrastructure for the BioTainer units can be built simultaneously, saving precious construction time. This strategy allows for rapid setup of a fully functional mRNA manufacturing facility at a selected site worldwide.

CSL Behring

Project: Project Aurora – Facility F Base Fractionation
Location: Broadmeadows, Victoria, Australia



The largest facility of its kind within the CSL network and globally, Project Aurora is a new AU \$900 million Plasma Base Fractionation Facility (Facility F). It boosts CSL Broadmeadows' plasma processing capacity nine-fold, reaching over 10 million plasma equivalent liters per year. The facility produces intermediates for immunoglobulin, albumin, and hemophilia products, which are vital for the global patient community. These products meet the growing global demand for plasma-based therapies, essential for treating conditions such as immunodeficiencies, neurological disorders, and burns. They are used by patients and healthcare professionals worldwide, including transplant, surgical, and cancer patients.

Erbe Elektromedizin GmbH

Project: Erbe 4.i | Location: Rangendingen, Germany



Erbe Elektromedizin GmbH specializes in the development and production of advanced surgical systems with a focus on the development of medical instruments and equipment for minimally invasive surgeries. Erbe 4.i is the centralized hub for instrument development and certified manufacturing and a global high precision instruments training center. The production facility includes a 25,000 m² building complex that integrates production with 2,400 m² cleanroom, logistics, development, and administration. This facility is one of the first industrial buildings in Germany to achieve the KfW-40 efficiency house standard, setting new environmental benchmarks for the entire industry.

F. Hoffman-LaRoche AG

Project: pRed Innovation Center | Location: Basel, Switzerland



The pRED Innovation Center located at the Roche headquarters in Basel, Switzerland, is a state-of-the-art research center dedicated to the discovery and development of groundbreaking drugs. It replaces aging research and development buildings that could no longer be adapted to the latest developments in technology and science. The need to renew this infrastructure gave Roche the opportunity to set new standards. With the investment of around 1.2 billion Swiss francs, an infrastructure has been created that offers scientists a landmark environment for their important work. Going from 17 outdated buildings to one modern lab and office facility with a total of 42 flexible and configurable floors, the approach to design the pRED Center was based on the evaluation of more than 30 leading research institutes and sites worldwide.

Grünenthal

Project: Master Program LatAm Kairos
Location: Penalolen, Santiago, Chile



Grünenthal is a pharmaceutical production facility where hormonal products are produced and is a key supplier of medicines for the public health service in Chile. The Kairos Project delivered a state-of-the-art solids plant, which included areas from dispensing to secondary packaging using advanced technology to ensure an efficient and state-of-the-art production facility. The plant had to be revamped during ongoing production, which required exact time planning to not disrupt ongoing production and supply of medicines to patients.

Johnson & Johnson Innovative Medicine

Project: Flexible Bottle Packaging Line
Location: Latina, Italy



Johnson & Johnson manufactures and packages solid products spanning multiple therapeutic areas including oncology, immunology, neuroscience, infectiology, and cardiopulmonary at their Latina, Italy, site. Over the past few years, the demand for small and medium-sized batches (portion below 3,000 units) has increased by almost 70%. Their innovative project implemented a new flexible packaging line and an optimized organizational model which successfully shortened changeover from six hours to a mere 45 minutes, significantly enhancing efficiency.

Johnson & Johnson Innovative Medicine

Project: Pollux | Location: Sassenheim, Leiden, The Netherlands



Johnson & Johnson's site in Leiden includes biopharmaceutical production facilities that produce clinical and commercial bulk active pharmaceutical ingredient (API) monoclonal antibodies using fed-batch and continuous perfusion cell culture processes followed by various purification steps, research and development operations, and analytical testing services, including stability and release testing for their global portfolio of large molecule products and vaccines. Pollux was designed to be a Centre of Expertise on lentiviral vectors (LVV). The project scope encompasses a manufacturing facility in Sassenheim to produce LVV and is designated as the future commercial manufacturing site for LVV to support Johnson & Johnson's global CAR T cell supply chain.

Johnson & Johnson Innovative Medicine

Project: BioCork 3.2 Expansion Project

Location: Ringaskiddy, Cork, Ireland



Expanding the BioCork 3.2 facility enables Johnson & Johnson to pursue innovative solutions to advance how medicines are manufactured to treat and prevent some of the world's most devastating and complex diseases. The expansion of the existing manufacturing facility in Cork, Ireland, incorporates additional capacity in large-scale fed-batch technology, which will guarantee efficient and sustainable delivery of biologic medicines in the areas of immunology and oncology. It increases the existing manufacturing capacity by 80% and provides full-time employment for an additional 180 people.

Kindeva Drug Delivery

Project: Kindeva Bridgeton | Location: Bridgeton, Missouri, US



Kindeva Drug Delivery is a leading global powerhouse contract development and manufacturing organization (CDMO) for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dose. This modular, expandable approximately 200,000-square-foot facility makes Kindeva one of only a few CDMOs in the world capable of servicing sterile fill, device manufacture, and final assembly in one geographic location. It's also fully Annex 1 compliant with an initial annual capacity to fill greater than 100 million units of vials, cartridges, and syringes of a range of sizes. The rapid execution of this fill-finish facility, combined with Kindeva's strategic focus on future expansion, helps address the soaring demand for sterile filling capacity in the industry.

Nitto Denko Avecia

Project: Project M5 | Location: Milford, Massachusetts, US



Nitto Denko Avecia is a contract developer and manufacturer of oligonucleotide products. The two-story 92,000-square-foot plant was built to manufacture a diverse blend of products for both clinical and commercial needs, and for wide-scale capability from multi-kilogram to metric tons per year of individual products within the same equipment. This project is part of a wider plan that expands the site into a three-property campus to provide full oligonucleotide services from clinical development to commercial manufacturing.

Oncomed Manufacturing A.S.

Project: Syringe Line 3 Installation and Facility Modernization

Location: Brno, Czech Republic



Oncomed Manufacturing A.S. is a CDMO specializing in aseptic processing of oncology injectables in clinical and commercial scales. The company delivers drugs with high potent and cytotoxic characteristics used to fight cancer. The production focuses both on small molecules (so-called end-to-end solution) and more innovative drugs based on biomolecules (fill-and-finish service), such as antibody-drug conjugates, human-virus protein interactions (HPAPI) proteins, monoclonal antibodies (mAbs), and oligonucleotides. Their new state-of-the-art technology comprises two production commercial lines dedicated to the manufacture of oncology vial injectables and one syringe line.

Sanofi

Project: Building 99 – Wastewater Treatment and Recovery Plant

Location: Toronto, Ontario, Canada



Sanofi Toronto manufactures and distributes up to 100 million pediatric and adult vaccines and other pharmaceutical products a year. The Wastewater Treatment and Recovery Plant (WWTRP) at the facility

has been equipped with state-of-the-art technologies and advanced engineering solutions to implement innovative solutions to treat and reuse wastewater on-site, addressing global water scarcity challenges and providing an example of how pharmaceutical manufacturing can align with the principles of green chemistry and circular economy. This project not only supports Sanofi's internal needs but also contributes to reducing the environmental footprint of pharmaceutical production, while helping create local economic opportunities and ensure reliable essential human vaccine production.

WINNER
CELEBRATION


To learn more about the FOYA program and this year's finalists, visit [ISPE.org/FOYA](https://ispe.org/foya)

Intelligen Suite®



The Market-Leading Engineering Suite for Modeling, Evaluation, Scheduling, and Debottlenecking of Multi-Product Facilities

SuperPro®


SchedulePro®




Use SuperPro Designer to model, evaluate, and optimize batch and continuous processes




Migrate to SchedulePro to model, schedule, and debottleneck multi-product facilities



Easy production tracking, conflict resolution and rescheduling



Tracking demand for resources (e.g., labor, materials, utilities, etc.)



Managing inventories for input, intermediate, and output materials

SuperPro Designer is a comprehensive process simulator that facilitates modeling, cost analysis, debottlenecking, cycle time reduction, and environmental impact assessment of integrated biochemical, bio-fuel, fine chemical, pharmaceutical (bulk & fine), food, consumer product, mineral processing, water purification, wastewater treatment, and related processes. Its development was initiated at the Massachusetts Institute of Technology (MIT). SuperPro is already in use at more than 500 companies and 900 universities around the globe (including 18 of the top 20 pharmaceutical companies and 9 of the top 10 biopharmaceutical companies).

SchedulePro is a versatile production planning, scheduling, and resource management tool. It generates feasible production schedules for multi-product facilities that do not violate constraints related to the limited availability of equipment, labor, utilities, and inventories of materials. It can be used in conjunction with SuperPro (by importing its recipes) or independently (by creating recipes directly in SchedulePro). Any industry that manufactures multiple products by sharing production lines and resources can benefit from the use of SchedulePro. Engineering companies use it as a modeling tool to size shared utilities, determine equipment requirements, reduce cycle times, and debottleneck facilities.

Visit our website to download detailed product literature and functional evaluation versions of our tools

INTELLIGEN, INC. • 2326 Morse Avenue • Scotch Plains, NJ 07076 • USA

Tel: (908) 654-0088 • Fax: (908) 654-3866

Email: info@intelligen.com • Website: www.intelligen.com

Intelligen also has offices in Europe and representatives in countries around the world

Takeda Pharmaceutical Company Limited

Project: Enoshima Light House | Location: Tokyo, Japan



Takeda's facility manufactures Chinese hamster ovary cell-based biologic drug substances for early-phase clinical trial materials, focusing on cell culture and purification processes. This innovative

facility features a fully single-use process that eliminates cross-contamination during early-stage development of products having limited toxicity data and also offers the option of partial continuous processing. The facility combines rigorous GMP management with collaboration between research and chemistry, manufacturing, and controls functions. The facility is designed for flexibility in development scheduling to enable first-in-human trials, which can lead to more timely availability of innovative treatments for patients, ultimately improving patient outcomes and healthcare.

Touchlight

Project: Development and Manufacture of Novel Synthetic DNA to Enable the Future of Genetic Medicines

Location: Hampton, London, UK



Touchlight's proprietary unique doggybone DNA (dbDNA™) is a fully synthetic, linear DNA vector produced enzymatically. The process leverages rolling circle amplification powered by enzymes to rapidly synthesize large quantities of DNA. dbDNA

production eliminates the need for fermentation, antibiotic resistance sequences, or plasmid extraction, drastically reducing timelines and simplifying manufacturing, achieving higher purity and greater sequence flexibility, and enabling the rapid production of DNA at scales suited for genetic medicines. Touchlight's operations are located in the historic waterworks buildings in Hampton, London. With this expansion, they can triple production capacity, over 8 kg of dbDNA annually, which exceeds current global plasmid DNA demand, making it one of the world's largest DNA manufacturing facilities.

United Therapeutics

Project: Clinical Xenotransplantation DPF Facility

Location: Christiansburg, Virginia, US



To revolutionize organ transplantation and overcome the critical shortage of human organs, United Therapeutics (UT) initiated the Clinical Xenotransplantation DPF Facility project. Their work to manu-

facture organ alternatives with human cells has yielded a variety of approaches including xenotransplantation, sourcing transplantable organs from other animals. No facilities existed to support the first in-human clinical trials in xenotransplantation. So, UT built the first, with a total design and construction timeline of 31 months. UT has developed a clinical scale designated pathogen-free (DPF) facility to produce tolerable, transplantable organs for patients with end-stage organ disease. 



20
YEARS OF INNOVATION

ISPE CONGRATULATES
**THE 2025 FOYA
CATEGORY WINNERS**



LEARN ABOUT 2025 FOYA ACTIVITIES

Join us for the 20th Annual
FOYA Banquet and Awards Celebration

2025 ISPE Annual Meeting & Expo | 26–29 October | Charlotte, NC, USA
Plus, the announcement of the 2025 FOYA Overall Winner.



INNOVATION

Touchlight

Location: Hampton, London, UK

Project: Development and Manufacture of Novel Synthetic DNA to Enable the Future of Genetic Medicines



OPERATIONS

OPERATIONAL EXCELLENCE

Johnson & Johnson Innovative Medicine

Location: Latina, Italy

Project: Flexible Bottle Packaging Line



OPERATIONS

PROJECT EXECUTION

Johnson & Johnson Innovative Medicine

Location: Ringaskiddy, Cork, Ireland

Project: BioCork 3.2 Expansion Project



PHARMA 4.0™

CSL Behring

Location: Broadmeadows, Victoria, Australia

Project: Project Aurora - Facility F Base Fractionation



SOCIAL IMPACT

UNMET MEDICAL NEEDS

Bayer Healthcare LLC

Location: Berkeley, California, USA

Project: Cell Therapy Launch and Manufacturing Facility



SOCIAL IMPACT

SUSTAINABILITY EXCELLENCE

Sanofi

Location: Toronto, Ontario, Canada

Project: Wastewater Treatment and Recovery Plant (WWTRP) Building 99



HONORABLE MENTION

Erbe Elektromedizin GmbH

Location: Rangendingen, Germany

Project: Erbe 4.i



HONORABLE MENTION

United Therapeutics

Location: Christiansburg, Virginia, USA

Project: Clinical Xenotransplantation DPF Facility



THE AI PARADOX

By Danilo Maruccia and Gianluca Costa

The increasing digitalization of the pharmaceutical and medical device industry has created novel cybersecurity challenges, particularly with the rapid advancement of artificial intelligence (AI) technologies. This article examines the dual nature of AI as both a potential threat vector and a powerful defensive tool.

We analyze how cybercriminals leverage AI to develop sophisticated attacks, including AI-driven software supply chain attacks, deepfakes, data poisoning, and automated social engineering campaigns that target the sensitive data and operations of pharmaceutical and medical device companies. Conversely, we examine how AI enhances cybersecurity by improving defenses against deepfakes, data poisoning, LLM vulnerabilities, advanced phishing, and supply chain attacks.

We introduce the concept of integrated assurance (IA) as an essential framework for handling AI-related risks and achieving responsible implementation. Our research emphasizes that while AI is a force multiplier for cybersecurity teams, it requires careful governance and human oversight. We conclude with strategic recommendations for companies to effectively leverage AI in their cybersecurity programs while maintaining regulatory compliance.

INTRODUCTION

The pharmaceutical and medical device industries face growing threats from cybercriminals, as their heavy reliance on digital systems exposes them to the risk of compromised sensitive information, disruptions in operations, damage to revenue and reputation, and threats to their overall commercial viability. The modern enterprise operates through interconnected digital networks and systems that support its entire range of activities,

including advanced research and development, complex manufacturing processes, intricate supply chains, and sensitive clinical trials.

The digital transformation that drives progress has expanded the attack surface, exposing organizations to an increasing number of cyberthreats. Disruption of operations—whether targeting manufacturing facilities, medical device functionality, or critical clinical trials—can heavily impact patients. Exploited vulnerabilities in medical devices can lead to direct patient harm and, as a theoretical threat, even to death.

Data breaches involving sensitive patient health information, business information, or confidential research findings erode public trust, and may cause severe regulatory penalties, and compromise patient privacy, potentially exposing them to identity theft or targeted harm. Furthermore, vulnerabilities within complex pharmaceutical supply chains, if exploited, can disrupt operations, particularly for drugs with a single producer or those that are in high demand.

The rapid advancement of AI technology is bringing fundamental changes to all industries, including cybersecurity operations [1]. This powerful technology represents a double-edged sword, as it enables robust defensive capabilities against modern cyberthreats but simultaneously generates new attack vectors for malicious actors. This article examines the complex relationship between AI and cybersecurity by analyzing the new security threats that arise from AI-powered cyberattacks and the security benefits of AI-driven solutions.

AI IN THE PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRY

Global investment in AI and generative AI (GenAI) has surged, with the pharmaceutical and medical device industries actively embracing the trend. IDC's latest release of its "Worldwide AI and Generative AI Spending Guide" reports that the global AI market is currently valued at nearly US\$235 billion, with projections indicating it will exceed US\$631 billion by 2028 [2].

AI is transforming the pharmaceutical and medical device industries. As AI systems become increasingly embedded in regulated pharmaceutical and medical device processes, both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have issued foundational documents to guide their safe and compliant use. However, the development of formal regulations has been slow, with a prevalence of discussion papers—especially regarding GenAI.

The following is a non-exhaustive overview of key publications by the EMA and the US FDA concerning the application of AI in the pharmaceutical and medical device sectors.

Key Publications from the EMA on AI

The EMA's "Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle" [3] covers AI applications across discovery, development, manufacturing, and postmarket activities. It discusses GxP compliance, validation, algorithm transparency, and data governance. It also introduces principles of human oversight, lifecycle management, and AI explainability.

The EMA's "Guideline on Computerised Systems and Electronic Data in Clinical Trials" [4] addresses the use of AI in clinical trial settings, particularly around data integrity, audit trails, and electronic source data.

Key Publications from the US FDA on AI

The discussion paper "Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products" [5] is a foundational document that sets the stage for how the US FDA envisions regulating and encouraging the responsible use of AI/machine learning (ML) across the entire drug development lifecycle.

The guidance "Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together" [6] outlines the detailed, collaborative efforts among US FDA centers to address AI integration across medical product lifecycles.

The "Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device (SaMD)" [7] introduces a framework for regulating AI/ML-based software modifications.

"Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions" [8] is a guidance document providing nonbinding recommendations on the information to include in a predetermined change control plan (PCCP) in a marketing submission for a device that includes one or more AI-enabled device software functions.

"Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" [9] outlines recommendations for managing cybersecurity risks throughout the product life cycle, highlighting the need for robust software development practices to safeguard device integrity and patient safety.

"Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations" [10] provides recommendations on the content of marketing submissions for devices incorporating AI, emphasizing the importance of life cycle management to ensure safety and effectiveness.

"Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" [11] provides recommendations on using AI to support regulatory decision-making for drug and biological products, specifically outlining a risk-based credibility assessment framework that may be used for establishing and evaluating the credibility of an AI model for a particular context of use.

ISPE

The ISPE GAMP® community has begun producing guidance on AI and ML systems, with a particular emphasis on the need for explainability, appropriate validation strategies, and risk-based controls throughout the AI model lifecycle. This aligns with broader industry trends to ensure the trustworthy and auditable use of AI in high-risk contexts [12]. A considerable number of articles have been published in *Pharmaceutical Engineering* over the past few years including "Applying GAMP® Concepts to Machine Learning" [13] published in the January/February 2023 issue of the magazine.

Industry's Next Steps

The pharmaceutical and medical device industries have long faced numerous cybersecurity threats, including data breaches, intellectual property theft, and supply chain vulnerabilities, but AI adoption has transformed both the size and complexity of these threats. Through AI, attackers can automate, personalize, and scale their attacks beyond previous limits. The industry operates with limited AI security expertise while facing slowly developing regulatory requirements. There is an urgent need to update cybersecurity approaches to protect both traditional threats and new AI-based threats if we want—as an industry—to achieve the full potential of AI while keeping patients safe and critical assets secure.

AI-POWERED CYBERATTACKS

Cybercriminals are exploiting AI to develop more sophisticated and scalable attacks. Traditional hacking requires significant technical expertise, but AI is making their operations faster and more effective, lowering the barrier to entry. Attackers can now automate reconnaissance, social engineering, and vulnerability scanning. AI tools can help malicious actors optimize attack vectors, analyze stolen data, and automate fraud at an unprecedented scale. Here's an in-depth look at the worst-case scenarios AI poses to cybersecurity.

Deepfakes and Misinformation Campaigns

AI-generated synthetic media, known as deepfakes, presents a unique and concerning threat to the pharmaceutical and medical device industries. Convincing but fabricated videos or audio

recordings of company representatives or patients can be rapidly created and disseminated, posing a risk of misinformation about pharmaceutical products and medical devices, reputational damage, and public distrust. Although the use of deepfakes for these purposes may be largely theoretical, the potential for financial manipulation, leading to stolen funds and operational disruptions, is a significant concern. For example, a deepfake video of a respected scientist making false claims about a drug's side effects could have devastating consequences for both public health and the company's stability. This combination of misinformation and financial risk poses a significant challenge to maintaining public trust and delivering vital medications.

AI-generated deepfakes have advanced to nearly perfect levels, making it increasingly difficult to distinguish between real and fake content. Cybercriminals use AI-powered voice, video, and image synthesis to execute social engineering attacks and corporate fraud. For example, in 2021, a bank in the UAE was scammed out of \$35 million when criminals used voice cloning, or deepfake audio, to mimic a company director's voice and authorize fraudulent transactions [14]. And in 2025, a network of fraudsters allegedly targeted individuals in the name of Italian Defense Minister Guido Crosetto, demanding large sums of money from wealthy entrepreneurs and professionals to "pay ransoms" for journalists supposedly held captive in the Middle East [15].

Data Poisoning and Prompt Injection

Data is fundamental to innovation in the pharmaceutical and medical device industry. In the GxP context, data is not only vital for making decisions, but also for ensuring compliance with regulatory expectations for data integrity, as outlined in ALCOA+ principles. (ALCOA+ is defined as attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.)

AI-specific information security threats include data poisoning [16], which is the intentional corruption of data sets that train or inform AI systems. This threat is especially insidious in GxP environments because the effects are often subtle, cumulative, and difficult to detect in real time. By introducing small but systematic biases or errors into training or reference data, attackers can:

- Corrupt AI models used for predictive quality monitoring
- Skew clinical data analysis
- Undermine decision-support tools used for batch release, deviation classification, or pharmacovigilance signal detection

Such attacks could lead to flawed scientific conclusions, misinformed regulatory filings, or the release of out-of-specification products without any immediate sign of compromise. However, it's also critical to recognize prompt injection as a distinct threat, where malicious data is introduced to a trained AI model at inference time, potentially manipulating its output and leading to errors in analysis.

AI-powered LLM data poisoning

Frontier large language models (LLMs) face the risk of data poisoning attacks, where adversaries inject malicious data to distort

model behavior. Although the largest frontier model developers are very careful with their training data for models, this risk is more pronounced in the open-source space, internally developed models, or refined models that post-train on frontier models using additional data that may not have been as controlled.

LLMs are already being used in GxP environments to support:

- Regulatory intelligence and response drafting
- Deviation and corrective and preventive action (CAPA) trend analysis
- Automated document generation
- Support tools for quality system management

Compromised LLMs can generate incorrect or manipulated answers, influencing user decisions and, critically, impacting the validity of GxP-related data. Although many applications of these models incorporate a "human in the loop," the danger lies in the inherent risk that humans may not possess the expertise or diligence to properly evaluate the LLM's output. This can lead to a reliance on the LLM's perceived correctness without sufficient inspection and independent validation, potentially resulting in the release of out-of-specification products, compromised medical device operations, or flawed research findings.

Here is how LLM data poisoning works: First, attackers insert adversarial or manipulated content into sources that may be ingested during model training or fine-tuning (e.g., public data, wikis, even internal file repositories). Then the LLM unknowingly "learns" from these poisoned inputs, internalizing incorrect, misleading, or security-compromising patterns. When deployed, the infected model generates flawed outputs that appear valid, influencing decisions or generating documentation that violates regulatory expectations.


To mitigate this risk, careful control over both training and test data is essential, and these data sets must be independently controlled. This independence allows the test data to effectively evaluate model performance and detect potential changes from poisoned training data.

Major cloud service providers (CSPs) typically have robust controls over foundational model training, making poisoning in these contexts particularly challenging. However, this remains a credible risk in situations where organizations use internal third-party data that may not be fully validated. In these cases, even minor poisoning can impact outputs in high-stakes areas such as GxP compliance.

LLM prompt injection

A prompt injection attack is when a user adds hidden instructions for the model, specifically the malicious insertion of prompts or requests into LLM-based interactive systems, resulting in unintended actions or the disclosure of sensitive information. It is similar to an SQL injection attack, where the embedded command appears to be a regular input at the start but has a malicious impact. The injected prompt can deceive the application into executing unauthorized code, exploiting vulnerabilities, and compromising overall security.

Figure 1: Prompt injection attacks on medical images [17]



It is worth noting that many model-serving platforms employ authentication, API security, and input controls. However, we want to highlight those risks that may persist in less mature implementations, such as internal tools, prototypes, or misconfigured interfaces.

Even in authenticated sessions, prompt injection remains a concern when user inputs are integrated into prompts without proper sanitization. Therefore, specific input and output checks should be implemented to evaluate potentially malicious input or inappropriate output from models, especially relevant in healthcare and GxP settings, where outputs may directly impact critical decisions. A recent study [17] provides a real-world example of prompt injection targeting a vision-language model used in oncology.

Numerous scientific and medical applications of LLMs have been proposed, and these could drastically change and improve medicine as we know it. In parallel to the rapid progression of LLM capabilities, there has been substantial progress in the development of multimodal vision-language models (VLMs). VLMs can interpret both images and text, further expanding the applicability of LLMs in medicine. Several VLMs have been published to date, either as healthcare-specific models (e.g., for the interpretation of pathology images or echocardiograms) or as generalist models applicable to multiple domains simultaneously, including healthcare, such as GPT-4o.

Social Engineering and Phishing Attacks

Social engineering and phishing attacks are becoming alarmingly personalized and automated through AI. AI algorithms can analyze social media profiles and publicly available data to craft highly targeted phishing emails. These messages can mimic the language, style, and even the specific concerns of the intended victim, drastically increasing their credibility and the likelihood of success. In this context, we aim to analyze how a popular frontier model can aid in crafting effective social engineering and phishing messages.

Social engineering

This refers to the psychological manipulation of individuals into

performing actions or divulging confidential information. A frontier model's ability to understand context, impressive fluency, and mimic human-like text generation could be leveraged by malicious actors. For example, consider a scenario where an attacker has gained access to a victim's basic personal information, such as their place of employment and job title. The attacker could then use the LLM tool to generate a message that appears to come from a colleague or superior at the victim's workplace. This message, crafted with an understanding of professional tone and language, might request sensitive information for a specific action, such as clicking on a seemingly innocuous link [18].

Phishing

Phishing attacks are a prevalent form of cybercrime wherein attackers pose as trustworthy entities to extract sensitive information from unsuspecting victims. These attackers can potentially exploit frontier LLMs to make their phishing attempts significantly more effective and challenging to detect [19]. Today, a simple frontier model's prompt can instantly produce messages written in the style of your CFO. Maybe now the tipoff is that the email is better written than the ones you get from the CFO [20].

Despite the increased sophistication of phishing attacks due to LLMs, the fundamental security measures required for protection remain unchanged: effective email security and link validation, secure browsers with sandboxing, and regular patching of systems to address known vulnerabilities. LLMs primarily amplify the effectiveness of phishing, but adequate protection should rely on established cybersecurity best practices.

AI-Driven Software Supply Chain Attacks

AI is now being used to identify and exploit weaknesses in software supply chains, targeting trusted vendors to distribute malware on a large scale. Instead of attacking one target at a time, AI automates large-scale compromises across multiple organizations, making mitigation exponentially harder.

Here is how it works: First, attackers use AI-powered reconnaissance tools to map out software dependencies across multiple

companies. The AI then identifies poorly secured third-party libraries, APIs, and dependencies used by high-value targets. From there, attackers inject malicious AI-modified code into open-source repositories or vendor software updates. The compromised software is then deployed across hundreds or thousands of organizations, spreading AI-enhanced malware with minimal suspicion.

The growth and development of AI technology will profoundly impact software development practices, forever altering the software supply chain. Rather than eliminating cyber risks related to software supply chains, AI is more likely to reproduce and possibly displace them. That's because AI adoption is not limited to software developers. It also powers software producers—and, conversely, malicious actors [21].

HOW AI IS STRENGTHENING CYBERSECURITY

AI-powered cyberthreats necessitate the use of AI-powered defensive systems that can match their evolving complexity and scale. The security challenges described in the previous section may exceed the capabilities of conventional security measures. The defensive capabilities presented next show that AI functions effectively as a cybersecurity ally when organizations implement it correctly.

Defending Against Deepfakes and Misinformation

AI-powered deepfake detection systems analyze facial movements, micro-expression abnormalities, and voice pattern irregularities to identify inconsistencies imperceptible to the human eye. There are solutions available on the market that use AI to detect signs of manipulation in video footage. In regulated industries such as pharmaceuticals and medical devices, these tools are highly recommended for authenticating communications from leadership or verifying sensitive public announcements [22].

However, it's equally important to establish tightly controlled processes for all external company communications, ensuring that no single person has the authority to issue them independently. Several other tools offer AI-powered solutions that detect deepfakes by analyzing visual artifacts and inconsistencies in facial movements, enabling organizations to verify the authenticity of media before making critical decisions [23, 24].

In addition to employing these technological tools, it is crucial to establish robust processes for safeguarding critical processes, such as approving financial transactions. To safeguard against fraudulent activities, payment releases should never be authorized by a single individual, regardless of their position. To prevent fraud, it should not be possible for a single deepfake, even one impersonating a CFO, to trigger the release of payments. Implementing simple procedural controls, such as mandatory dual authorization and segregation of duties, can effectively mitigate the risk of deepfakes being used to manipulate financial systems.

Data Poisoning and Prompt Injection

The training of modern AI systems now includes adversarial resilience as a defense mechanism against data poisoning attacks. Organizations test their models through extensive simulation-based

protocols that detect poisoning attacks, thereby improving model capabilities for identifying abnormal training data patterns.

Organizations use AI-powered data validation systems that create normal data pattern baselines to identify potential tampering through anomaly flagging. These systems employ the following techniques.

- AI models receive potential attack patterns through adversarial training techniques during their development phase
- Data provenance tracking systems track the source and complete integrity of training data
- Continuous monitoring systems detect unusual modifications to datasets

In GxP environments, companies are adopting data provenance tools and AI-powered integrity validation systems to monitor regulated data sets. Anomaly detection systems in clinical trials identify subtle changes in data submissions that may indicate attempts at data poisoning or manipulation efforts.

The implementation of AI tools for auditing training datasets by pharmaceutical companies tracks the origins and transformation steps of data to enhance their ALCOA+ compliance.

Hardening LLMs against prompt injection and data poisoning

AI developers implement instruction-following filters, output monitoring, and reinforcement learning from human feedback (RLHF) to build LLMs with built-in safeguards that minimize prompt injection and unintended behavior. Organizations already use next-generation firewalls as intermediary systems to preprocess and sanitize user inputs before they reach the LLM. Real-time natural language understanding solutions filter or rephrase potentially malicious prompts as part of their functionality.

Enterprise-tier frontier models already use multiple layers of behavioral guardrails and content moderation to prevent malicious outputs in compliance-sensitive environments. Companies can implement hybrid AI governance models for safe LLM integration in regulated GxP settings that combine technical validation (e.g., robustness testing, audit trails of model outputs), organizational controls (e.g., restricted usage, dual review processes), and external third-party validation of model behavior on GxP-related tasks.

AI-enhanced auditing tools work in conjunction with these controls to detect model behaviors, such as hallucinations and bias, enabling companies to prevent these issues from impacting regulatory documentation and patient safety decisions.

AI-Driven Phishing and Social Engineering Defense

AI-powered email security platforms use behavioral analytics and natural language processing (NLP) to identify suspicious communications. These tools analyze sender reputation, writing style, timing patterns, and user behavior to flag or block phishing attempts, particularly those created using frontier models. These systems can detect AI-generated phishing attempts by identifying subtle linguistic patterns and contextual inconsistencies that might indicate fraudulent intent.

By continuously learning from new attack patterns, these defenses evolve with threat capabilities, ensuring protection against even AI-generated phishing attempts. AI is revolutionizing cybersecurity, providing sophisticated tools to combat increasingly sophisticated threats [25].

Mitigating Software Supply Chain Attacks with AI

Organizations use AI to protect against AI-assisted software supply chain attacks through the following measures:

- **Automated software composition analysis (SCA):** AI tools examine codebases and dependencies to detect outdated or vulnerable libraries.
- **Anomaly detection in CI/CD pipelines:** Machine learning models track unusual code modifications and deployment activities, often detecting malicious code before it becomes part of the software.
- **Vendor risk profiling:** AI systems perform ongoing digital footprint assessments of suppliers to detect suspicious activities or modifications in security policies.

However, preventive measures are also critical. To further strengthen security, dependency checking and secure code reviews should be integrated into the code development process within integrated development environments (IDEs). Code should not be allowed to be checked into a repository unless it meets a defined quality bar. It is also important to note that AI can assist in code development and is very effective at code analysis, contributing to efficiency and security.

ENCOURAGING TRENDS

To learn how AI is transforming the defensive side of cybersecurity, we checked the predictions presented at the Gartner Security & Risk Management Summit, 18–19 March 2024, in Sydney, Australia [2].


By 2026, enterprises combining generative AI with an integrated platforms-based architecture in security behavior and culture programs (SBCP) will experience 40% fewer employee-driven cybersecurity incidents. Organizations increasingly focus on personalized engagement as an essential component of an effective SBCP.

GenAI has the potential to generate hyperpersonalized content and training materials that take into context an employee's unique attributes. According to Gartner, this will increase the likelihood of employees adopting more secure behaviors in their day-to-day work, resulting in fewer cybersecurity incidents.

By 2028, the adoption of generative AI will collapse the skills gap, removing the need for specialized education from 50% of entry-level cybersecurity positions. Generative AI augments will change how organizations hire and teach cybersecurity workers who are looking for the right aptitude and education.

The CyberEdge 2024 Cyber Defence Report [20] confirms a couple of encouraging trends, where among the top five insights for 2024, we extracted two: confidence is building, and AI is taking center stage.

Figure 2: Percentage of organizations experiencing at least one successful attack (blue) and those experiencing six more (red) [20].



Confidence is Building

Several long-running trends have reversed in the last year or two. Survey data contains multiple indications that security professionals are becoming more confident about their ability to reduce the impact of cyberattacks. The percentage of organizations compromised by cyberattacks fell substantially from the previous survey.


AI is Taking Center Stage

AI technologies are being incorporated into a wide range of security solutions. They promise to increase the power of security professionals to detect and block attacks, respond to incidents, and find and remediate vulnerabilities. Security teams are looking at AI as a force multiplier that will make them more productive and effective. A survey in the CyberEdge 2024 Cyber Defence Report [20] asked “Cybersecurity industry analysts predict that advancements in AI, including ML and generative AI (e.g., ChatGPT), will benefit IT security teams. Which of the following positive outcomes of AI do you predict will impact your organization the most? (Select up to three.)” Figure 3 shows the results of the survey.

CHALLENGES AND CONSIDERATIONS

Although AI offers significant potential for enhancing cybersecurity in the pharmaceutical and medical device industry, its implementation is challenging. Several key areas must be carefully considered to ensure responsible and effective deployment.

Figure 3: Survey results about the positive outcomes for security teams from AI [20].



Ethical Implications of Using AI in Cybersecurity

AI algorithms are trained on data, and if that data reflects existing biases, the AI system may perpetuate or even amplify those biases. The potential for misuse of AI-powered cybersecurity tools is a concern. These tools could be used for surveillance, profiling, or offensive cyber operations. Establishing clear ethical guidelines and developing mechanisms to ensure fairness, transparency, and accountability in the use of AI in cybersecurity is crucial. Going forward, legal executives can take a leading role in strategic decision-making related to any use of generative AI within the enterprise. They are likely to assume responsibilities and accountabilities related to the development of ethical and legal frameworks [27].

Data Privacy and Security Concerns

AI systems require vast data to train and operate effectively. This raises concerns about data privacy and security, particularly within the highly regulated industry. Pharmaceutical and medical device companies must ensure that the data used to train and operate AI systems is collected, stored, and processed in compliance with relevant data privacy regulations, such as GDPR and HIPAA. Furthermore, robust security measures must be in place to protect this data from unauthorized access or breaches. Using anonymization and differential privacy techniques can help mitigate some of these risks. Provisions regarding confidentiality and data privacy are likely to be a key focus of any contractual framework for the provision of generative AI services [27].

Bias and Dataset Quality

The accuracy of cybersecurity AI tools in distinguishing between legitimate and malicious activity depends on the quality of the training data. In pharmaceutical and medical device environments, biased or nonrepresentative data can lead to false positives or

missed detections, potentially exposing critical systems—such as manufacturing execution systems (MES), laboratory information management systems (LIMS), or clinical trial platforms—to undetected threats. It is essential to validate training data sets to ensure reliability across regulated use cases.

Innovation Pressure vs. Cyber Risk Management

Pharmaceutical organizations face substantial pressure to implement advanced AI cybersecurity tools as evolving threats target their intellectual property, clinical trials data, and automated manufacturing systems. Rushed implementation without proper risk analysis, validation, and change control can introduce new vulnerabilities. A risk-based adoption strategy that balances cybersecurity needs with regulatory compliance and system availability requirements is essential.

Regulatory and Ethical Alignment of Security Tools

AI deployment in cybersecurity must meet both IT compliance standards and general AI governance standards, as outlined in the EU AI Act [28]. Pharmaceutical companies must ensure that these tools are effective in mitigating cyber risks and are transparent, auditable, and ethically sound, particularly when they influence decision-making related to incident response or access control.

AI REQUIRES AN INTEGRATED ASSURANCE APPROACH

AI presents significant challenges across key cybersecurity domains and GxP compliance requirements, including data privacy and protection, system security, operational resilience, and risk management, as mandated by regulations and standards in the pharmaceutical and medical device industries. These are essential for driving successful innovation, enhancing managerial decision-making, and gaining a continuous competitive edge. Nevertheless, the rate and scale of the impact are unprecedented.

From an organizational and management perspective, forecasting its development and making a long-term strategy is hardly possible, yet is still necessary and urgent.

Beyond being a legal imperative in many jurisdictions—even with slightly different approaches, whose discrepancies may potentially undermine the overall effectiveness—we face a global issue here: mitigating risks and harnessing the potential of emerging technologies can profit from significant opportunities. Today, most pharmaceutical organizations have a well-established GxP compliance program with varying maturity levels, encompassing procedures, policies, work instructions, and industry best practices. Compliance offices are already burdened by the growing complexity and volume of regulatory requirements they must continuously manage.

Nonetheless, AI compliance is starting to take shape. In the United States, on 30 October 2023, President Biden issued Executive Order 14110, establishing national priorities for AI governance with a focus on safety, security, innovation, and equity [29]. However, upon taking office on 20 January 2025, President Donald Trump revoked this order, citing the need to eliminate policies that could hinder the development of AI innovation [30]. Subsequently, on 23 January 2025, President Trump signed an Executive Order titled “Removing Barriers to American Leadership in Artificial Intelligence,” aiming to foster AI development free from ideological bias and thereby contributing to the United States’ global dominance in AI development [19].

The European Union’s AI Act [28], effective 1 August 2024, aims to introduce a common regulatory framework based on risk categories. In 2023, the European Parliament amended its initial proposal to include generative AI, which must comply with specific transparency requirements. These requirements involve registering the foundation model in a database and developing and retaining technical documentation.

Conversely, we have “ISO world,” the new ISO 42001:2023 [16], the well-established ISO 27001:2022 [31], and ISO 22301:2019 [32]. They share a structured, risk-based approach to governance, resilience, and security. Together, they form a robust foundation for adopting AI in an organization, ensuring trustworthiness, security, and continuity.

Sometimes, it seems we are talking of two worlds apart (regulations vs. standards). But the very aim is and should be the same. The first objective should be to integrate approaches into our organizations. To manage and control processes and technologies, such as AI, which are evolving at a rate never experienced before, we must adopt a more operational, practical, and, above all, interdisciplinary and interdepartmental approach. Organizations should establish a cross-functional governance board to oversee the development and adoption of AI, using a comprehensive framework for responsible AI [33, 34].

It’s sufficient to examine recent developments, such as the EU General-Purpose AI Code of Practice (14 November 2024), which addresses providers of general-purpose AI models and those with systemic risks, including frontier models. Its central themes, for

example, are primarily focused on organizational and IT governance, based first on the evaluation and technical mitigation of risks rather than the other way around.

An integrated approach is necessary, as the obligation for management awareness is rising at all levels. On this point, it is essential to consider the obligations related to AI literacy and awareness. Article 4 of the EU AI Act came into effect on 2 February 2025. It requires both providers and deployers (i.e., users) of AI systems to “take measures to ensure, to the extent possible, a sufficient level of AI literacy among their personnel, as well as any other individuals involved in the operation and use of AI systems on their behalf, taking into account their technical knowledge, experience, education, and training, as well as the context in which AI systems are to be used, and considering the individuals or groups of individuals on whom AI systems are to be applied” [28].

The EU AI Act’s applicability also concerns Title II of the Regulation. Specifically, Article 5 lists the prohibited AI practices [35]. Therefore, it is necessary to conduct a comprehensive review and assessment of the AI systems used within the company to ensure that no unlawful situations exist. This is a draft communication document prepared by the European Commission, intended to provide interpretative guidance on the prohibited AI practices listed in the AI Act (formally adopted as Regulation (EU) 2024/1689). In plain terms, this document is:

- An official set of guidelines (not legally binding, but highly authoritative)
- Designed to help stakeholders, regulators, and companies understand which AI practices are prohibited under the EU’s AI Act
- Focused explicitly on Article 5 of the AI Act, which lists prohibited AI systems considered a clear threat to safety, human rights, or European Union values

Therefore, an integrated assurance approach is the only consistent answer to AI. ISO 42001:2023 can be part of the solution, as it provides guidance to help organizations responsibly perform their role regarding AI systems used for automatic decision-making.

LEVERAGING AI-POWERED TOOLS FOR CYBERSECURITY

Standard infrastructure controls—including identity and access management, encryption, logging and monitoring, and network segmentation—create a solid foundation for cybersecurity. However, AI-powered threat actors use configuration gaps, integration weaknesses, and real-time response shortcomings to attack systems, which demonstrates why AI-driven security tools must complement traditional defenses.

The most significant challenges in modern cyber defense involve collecting and making sense of vast amounts of data. AI excels at addressing these challenges by rapidly identifying patterns in large data sets, summarizing information, and interpreting complex data. Although automation is possible with traditional code, AI offers the ability to take nuanced actions based on data analysis, much like a human analyst, but at a greater

speed. Furthermore, AI facilitates translation between different forms of information, such as converting natural language into programmatic detections, code into threat analysis, and actions into notifications or predicted responses.

Pharmaceutical and medical device companies should adopt a proactive and strategic approach to leverage AI for cybersecurity. First, they should conduct a thorough risk assessment to identify their most critical vulnerabilities and prioritize their cybersecurity investments. Second, they should develop a clear AI strategy aligning with their business objectives and cybersecurity goals. This strategy should include identifying specific use cases for AI in cybersecurity, selecting appropriate AI tools and technologies, and developing a roadmap for implementation. Third, companies should invest in building internal expertise in AI and cybersecurity through training programs, hiring specialized talent, and partnering with external experts. The following sections look at how AI is enhancing cybersecurity capabilities in various areas.

Enhanced Threat Detection and Prevention

The large volume of data generated by pharmaceutical and medical device organizations can make it challenging for human analysts to identify all potential security threats. AI shows a better ability to analyze big data sets and find hidden patterns and anomalies that are not easily seen by humans.

Organizations can use ML algorithms to detect malicious behavior, predict upcoming attacks, and block them before they can cause damage. Companies gain a better security posture by taking a proactive stance in detecting and preventing threats. Companies achieve an enhanced security posture through their proactive approach to threat detection and prevention. AI systems perform network traffic analysis to detect abnormal communication patterns that could signal data exfiltration attempts and simultaneously monitor user activity to identify suspicious logins and unauthorized access attempts.

Detecting advanced threats

AI can detect unknown threats by identifying deviations from standard network or user behavior patterns. It provides adequate protection against zero-day attacks and advanced persistent threats (APTs) because signature-based defenses would otherwise fail to detect these threats.

Identifying indicators of compromise

AI models track behavioral patterns to detect indicators of compromise (IoCs), which include irregular login times, data exfiltration attempts, and unauthorized access to critical systems.

AI-Enhanced Security Tools

Traditional security systems face challenges because they depend on static rules and signatures, yet fail to adapt to these changes. AI-powered security systems demonstrate the ability to learn while adapting to changing threats. Security systems can learn

through ML algorithms, which enable them to detect new attack patterns and identify vulnerabilities before making the necessary security adjustments.

Security systems become more dynamic and resilient through adaptability, which enables them to defend against highly sophisticated attacks. AI-powered intrusion detection systems use behavioral learning to detect new malware types, regardless of modifications made to evade signature-based detection.

The integration of generative AI into cybersecurity platforms enables security professionals to use advanced tools for threat investigation, adversary analysis, and incident response automation.

Cyberthreat investigation

Threat intelligence involves collecting, analyzing, and disseminating information about potential security threats to help organizations improve their security posture and protect against cyberattacks. AI-driven threat intelligence platforms aggregate and analyze global threat data to help security teams understand attack patterns and predict future threats. AI can correlate millions of data points across various attack surfaces in seconds.

For example, a frontier model can help with threat intelligence by processing vast amounts of data to identify potential security threats and generate actionable intelligence. It can also automatically generate threat intelligence reports based on various data sources, including social media, news articles, and other online sources. By processing and analyzing this data, a frontier model can identify potential threats, assess their risk level, and recommend mitigating them [18].

Cyber adversary research

AI provides automated threat-hunting capabilities, allowing analysts to track and profile cybercriminals; understand their tactics, techniques, and procedures (TTPs); and predict their next moves. AI also aids in monitoring the dark web, identifying leaked credentials and discussions related to potential attacks. Frontier models can reduce the workload of security operations center (SOC) analysts by automatically analyzing cybersecurity incidents. LLMs can also help analysts make strategic recommendations to support both instant and long-term defense measures [18].

AI-Powered Vulnerability Management

The complex IT infrastructure of pharmaceutical companies, which includes multiple systems and applications, presents challenges in performing effective vulnerability management. AI technology enables faster and more efficient vulnerability prioritization and remediation. AI algorithms process vulnerability information to determine the risk levels of each vulnerability before determining which remediation efforts should take priority.

Security teams can begin with the most critical vulnerabilities, as this approach reduces their attack surface and decreases the likelihood of exploitation. AI systems perform vulnerability scanning and patching automatically, improving efficiency and shortening

the time needed to fix security weaknesses. AI-powered tools perform vulnerability detection across applications, codebases, and network infrastructure to detect weaknesses before cyber criminals can exploit them.

AI-Powered Security Automation

Security tasks—including vulnerability patching, incident response, and security monitoring—require repetitive work that consumes much time. AI technology enables the automation of these tasks, liberating human staff and enhancing operational efficiency. AI-powered systems use their capabilities to automate incident response functions, enabling fast containment and attack mitigation before threats can expand. AI-powered security monitoring systems track system logs and alerts in real time to identify significant events while decreasing the workload of security analysts. The automation system conserves time and financial resources and decreases the chances of human mistakes, resulting in better security management practices.

Security event monitoring

Real-time analysis of logs through AI-powered security information and event management (SIEM) systems enables the identification of hidden security event correlations that human analysts typically miss. Through its detection capabilities, AI identifies minor signs of malicious activity.

Incident response automation

Security orchestration, automation, and response (SOAR) platforms, driven by AI technology, enable the containment of security incidents through automation, which shortens response times and reduces the impact of damage. AI implements endpoint isolation for compromised systems while revoking user access and applying security patches to prevent threat escalation.

CONCLUSION

The cybersecurity landscape will evolve into an ongoing battle of technological advancements between defensive AI systems that must adapt to new AI-powered threats. Organizations that grasp both AI defensive capabilities and existing threats will succeed in safeguarding their essential assets and operational activities throughout this dynamic environment.

As a “force multiplier” for cybersecurity, AI is not a replacement for human cybersecurity professionals. Instead, it is an enabler that enhances detection capabilities, automates incident response, and strengthens proactive defense strategies. By integrating AI into security operations, organizations can more effectively protect against emerging threats, optimize resource allocation, and equip their security teams with advanced tools and capabilities.

The future of cybersecurity is not human versus machine, but human–AI collaboration against AI-enhanced threats. Furthermore, the concept of autonomous agents will become crucial, with fleets of security agents operating within the infrastructure, performing

tasks in response to other agents, creating complex fabrics of coordinated defense mechanisms.

This article has explored the complex and multifaceted role of AI in the cybersecurity landscape of the pharmaceutical and medical device industries. We have examined how malicious actors can weaponize AI to create more sophisticated cyberattacks, ranging from automated phishing to data poisoning and deepfakes. We have also highlighted the immense potential of AI-driven cybersecurity solutions to enhance threat detection and automate security tasks, thus improving data protection.

Pharmaceutical and medical device companies must invest in AI-driven cybersecurity solutions to protect assets, maintain competitiveness, ensure the safety and quality of their products, and, critically, prevent operational disruptions from attacks on OT and IT systems. Operational attacks leading to ransom requests becoming the norm make this investment essential to secure the future of pharmaceutical innovation, patient care, and the uninterrupted supply of vital medication. 

References

1. Daryanani, M. “AI and Cybersecurity: How Artificial Intelligence Is Revolutionizing the Security Industry.” KPMG Switzerland. Accessed 21 February 2025. <https://kpmg.com/ch/en/insights/cybersecurity-risk/artificial-intelligence-influences.html>
2. Massey, K. “IDC’s Worldwide AI and Generative AI Spending—Industry Outlook.” 21 August 2024. IDC. Accessed 9 February 2025. <https://blogs.idc.com/2024/08/21/idcs-worldwide-ai-and-generative-ai-spending-industry-outlook/>
3. European Medicines Agency. “Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle.” 9 September 2024. www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
4. European Medicines Agency. “Guideline on Computerised Systems and Electronic Data in Clinical Trials.” 9 March 2023. www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf
5. US Food and Drug Administration. “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback.” May 2023. (Revised February 2025). www.fda.gov/media/167973/download
6. US Food and Drug Administration. “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together.” March 2024. (Revised February 2025). www.fda.gov/media/177030/download
7. US Food and Drug Administration. “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD): Discussion Paper and Request for Feedback.” April 2019. www.fda.gov/files/medical%20devices/published/US-FDA-Artificial-Intelligence-and-Machine-Learning-Discussion-Paper.pdf
8. US Food and Drug Administration. “Marketing Submission Recommendations for a Predetermined Change Control for Plan for Artificial Intelligence-Enabled Device Software Functions.” 4 December 2024. www.fda.gov/media/166704/download
9. US Food and Drug Administration. “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions.” 27 September 2023. www.fda.gov/media/119933/download
10. US Food and Drug Administration. “Draft Guidance for Industry. Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.” 7 January 2025. <https://www.fda.gov/media/184856/download>
11. US Food and Drug Administration. “Draft Guidance for Industry. Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.” January 2025. www.fda.gov/media/184830/download

12. International Society for Pharmaceutical Engineering. *GAMP® 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2022. Appendix D11—Artificial Intelligence and Machine Learning (AI/ML).
13. Staib, E., T. G. Williams, and S. Wyn. "Applying GAMP® Concepts to Machine Learning." *Pharmaceutical Engineering*® 43, no. 1 (January/February 2023):14–23. <https://ispe.org/pharmaceutical-engineering/january-february-2023/applying-gamp-concepts-machine-learning>
14. Wodecki, B. "UAE Authorities Request US Help in Tracking Down 'Deep Voice' Scammers." *AI Business*. 19 October 2021. Accessed 28 March 2025. <https://aibusiness.com/verticals/uae-authorities-request-us-help-in-tracking-down-deep-voice-scammers>
15. Reuters. "Italian police freeze cash from AI-voice scam that targeted business leaders." 12 February 2025. <https://www.reuters.com/technology/artificial-intelligence/italian-police-freeze-cash-ai-voice-scam-that-targeted-business-leaders-2025-02-12/>
16. International Electrotechnical Commission. ISO Standard ISO/IEC 42001:2023. "Information Technology—Artificial Intelligence—Management System." December 2023. www.iso.org/obp/ui/en/#iso:std:iso-iec:42001:ed-1:v1:en
17. Clusmann, J., D. Ferber, I. C. Wiest, C. V. Schneider, T. J. Brinker, S. Foersch, D. Truhn, and J. N. Kather. "Prompt Injection Attacks on Vision Language Models in Oncology." *Nature Communications* 16, 1239 (1 February 2025). doi:10.1038/s41467-024-55631-x
18. Gupta, M., C. Akiri, K. Aryal, E. Parker, and L. Praharaj. "From ChatGPT to ThreatGPT: Impact of Generative AI in Cybersecurity and Privacy." *IEEE Access* 11 (4 August 2023): 80218–45. doi:10.1109/ACCESS.2023.3300381
19. Meer, J. E., and J. S. Farmer. "Trump's Executive Order Reshapes US AI Policy; Italian Regulator Blocks DeepSeek's Processing of Personal Data." *The National Law Review*. 4 February 2025. Accessed 28 March 2025. <https://natlawreview.com/article/trumps-executive-order-reshapes-us-ai-policy-italian-regulator-blocks-deepseek>
20. CyberEdge Group, LLC. "2024 Cyberthreat Defense Report." <https://cyberedgegroup.com/cdr/>
21. Reversing Labs. "AI Is the Supply Chain. How the Rise of AI Will Impact Software Supply Chain Security." White Paper. Accessed 15 February 2025. www.reversinglabs.com/ai-is-the-supply-chain-thank-you
22. Intel. "Trusted Media: Real-time FakeCatcher for Deepfake Detection." Accessed 3 April 2025. www.intel.com/content/www/us/en/research/trusted-media-deepfake-detection.html
23. Resemble.AI. "Top 3 Deepfake Detection Tools of 2023." Accessed 3 April 2025. www.resemble.ai/top-deepfake-detection-tools
24. Sensity. Homepage. Accessed 3 April 2025. <https://sensity.ai/>
25. Redress Compliance. "Top 15 Real-Life Use Cases For AI In The Cybersecurity Industry." 4 March 2025. Accessed 3 April 2025. <https://redresscompliance.com/top-15-real-life-use-cases-for-ai-in-the-cybersecurity-industry/>
26. Gartner. 2024. "Gartner Unveils Top Eight Cybersecurity Predictions for 2024." 18 March 2024. Accessed 09 February 2025. www.gartner.com/en/newsroom/press-releases/2024-03-18-gartner-unveils-top-eight-cybersecurity-predictions-for-2024
27. Deloitte AI Institute. 2025. "The legal implications of Generative AI." Considerations for enterprise intellectual property, data protection, and contracts. Accessed 15 February 2025. <https://www2.deloitte.com/us/en/pages/consulting/articles/generative-ai-legal-issues.html>
28. European Parliament and Council. 2024. EU Artificial Intelligence Act (2024/1689) – (Regulation (EU) 2024/1689)
29. US President. Executive Order No. 14110, "Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence." Federal Register, Vol. 88, (210). 1 Nov 2023. <https://bidenwhitehouse.archives.gov/briefing-room/presidential-actions/2023/10/30/executive-order-on-the-safe-secure-and-trustworthy-development-and-use-of-artificial-intelligence/>
30. Reuters. 2025. "Trump revokes Biden executive order on addressing AI risks," Accessed on Feb. 15, 2025 <https://www.reuters.com/technology/artificial-intelligence/trump-revokes-biden-executive-order-addressing-ai-risks-2025-01-21/>
31. International Electrotechnical Commission. ISO Standard ISO/IEC 27001:2022. "Information Security, Cybersecurity and Privacy Protection—Information Security Management Systems—Requirements." 2022. www.iso.org/standard/27001
32. ISO Standard 22301:2019. "Security and resilience—Business Continuity Management Systems—Requirements." 2019. www.iso.org/standard/75106.html
33. Splunk. 2024. "State of Security, The Race to Harness AI," Accessed 22 February 2025. www.splunk.com/en_us/form/state-of-security/thanks.html

34. Mintancian, A., R. Budihandojo J. English, O. Lopez, J. E. Matos, and R. McDowall. "Artificial Intelligence Governance in GxP Environments." *Pharmaceutical Engineering*® (July-August 2024). <https://ispe.org/pharmaceutical-engineering/july-august-2024/artificial-intelligence-governance-gxp-environments>
35. European Union. "Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 Laying Down Harmonised Rules on Artificial Intelligence and Amending Regulations (EC) No 300/2008, (EU) No 167/2013, (EU) No 168/2013, (EU) 2018/858, (EU) 2018/1139 and (EU) 2019/2144 and Directives 2014/90/EU, (EU) 2016/797 and (EU) 2020/1828 (Artificial Intelligence Act)." *Official Journal of the European Union*, L Series L (12 July 2024):1–144. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ:L_202401689

About the authors

Danilo Maruccia is a Principal Consultant at PQE Group. He has over 25 years of experience in information technology, cybersecurity, and computer systems validation within the life sciences industry. He is an experienced professional in medical device cybersecurity and has extensive expertise in regulatory frameworks and standards. He holds certifications as a CompTIA Security Analytics Professional (Security+, CySA+), Cloud Essentials+, and Information System Security Certification Consortium (ISCT) Systems Security Certified Practitioner. He originally joined ISPE in 2001, rejoined in 2007, and has been an active member since 2021.

Gianluca Costa is a PMI-certified Senior Project Manager and Business IT Advisor at PQE Group. He has more than 30 years of experience in information technology. His extensive background spans multiple industries, providing him with a broad perspective on IT solutions. Gianluca's expertise includes GDPR and HIPAA compliance, data security risk management, and incident management. He has consistently supported pharmaceutical companies in addressing the multifaceted challenges of data privacy and security within a regulated environment, enabling them to maintain compliance and pursue their business goals.

MICRONVIEW

EMC Robot Line

Environmental Monitoring & Control
Robot Line



For more information: www.micronview.com
mv@micronview.com

LinkedIn
MicronView LLC

DIGITAL TRANSFORMATION: Developing a Fully Automated Pharma Manufacturing Facility

By André Boyce and Scott Sommer, PE

The move to digital transformation represents a true paradigm shift in manufacturing, enabling organizations to leverage advanced technologies such as the Industrial Internet of Things (IIoT), cloud computing, and artificial intelligence (AI) to ensure compliance and secure a competitive advantage. This article presents a working definition of digital transformation, the components involved in undertaking a transformation initiative, and a phased approach to implementing digital transformation for the pharmaceutical industry.

Digital transformation is helping give pharmaceutical companies the opportunity to develop, manufacture, and deliver life-saving products and treatments to patients more quickly and more sustainably than ever before. Moreover, it does so while improving operational efficiency, cost savings, and flexibility.

The significance of this transformation is underscored by the fact that 90% of all organizations are undergoing some form of digital transformation, whereas the pharmaceutical sector indications are that only 15.1% of survey respondents have not started their digital transformations [1, 2]. For pharmaceutical manufacturers, this shift to digital transformation is particularly critical, because it offers pathways to improved compliance, operational efficiency, and product quality while addressing the need to comply with stringent regulatory requirements.

This article cannot cover or address the depth and breadth of digital transformation for the pharmaceutical industry, but it does layout the high-level steps required for successful implementation. The *ISPE Baseline® Guide: Pharma 4.0™* [3] offers further in-depth guidance, and we recommend discussing this further with a relevant domain expert.

DEFINING DIGITAL TRANSFORMATION

Digital transformation in the pharmaceutical sector involves the strategic integration of operational and information technologies—spanning both manufacturing and business functions—to create a cohesive, data-driven ecosystem. This transformation enables real-time insights that help organizations optimize processes, enhance compliance, and improve product quality. Key principles of digital transformation aligned with business benefits include:

- **Strategic integration:** Aligning each digital initiative with broader organizational goals to ensure coherence and scalability.
- **Data accessibility:** Treating every application, device, and stakeholder as part of a unified information ecosystem to reduce data silos and maximize data utility.
- **Real-time insights:** Using advanced analytics and machine learning to generate actionable intelligence in real time, supporting proactive decision-making.

For pharmaceutical manufacturers, digital transformation also encompasses the development of digital twins and AI-powered drug development. A digital twin can replicate manufacturing processes virtually, allowing pharmaceutical companies to run simulations, predict issues, and ensure product consistency without negatively affecting production. For the pharmaceutical industry as a whole, this transformation is not only about operational efficiency. It is also about the impact on business processes, people and resources, product quality, and patient safety.

There are already some notable successes in life sciences stemming from implementation of digital initiatives. Many pharmaceutical manufacturing companies are members of the World Economic Forum (WEF) Global Lighthouse Network. A recently published WEF white paper indicated the achieved results from two manufacturers' digital transformation initiatives. For one company, their implementations have cut yield variability by 60%, reduced technology transfer time by 50%, and reduced emissions by 31% [4]. Another pharmaceutical manufacturer reportedly upskilled a pool of 3,000 employees. The company

saw a 56% increase in labor productivity while reducing new product development lead times by 67%. More than 50 digital technologies, including machine learning and optimization algorithms, were implemented [4].

The rapid advances in digitization are reflected in recently issued regulatory guidance documents from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In early January 2025, the FDA announced the availability for comment of considerations for compliance with 21 CFR 211.110 Guidance for Industry [5]. Key aspects of the document include support for advanced technologies, real-time quality monitoring, process analytical technologies (PAT), and continuous manufacturing systems to streamline operations and improve efficiency.

Two years earlier, in 2023, the EMA published a reflection paper on the use of AI in the medicinal product lifecycle [6]. The reflection paper provides considerations on the use of AI and machine learning (ML) in the life cycle of medicinal products, including medicinal products development, authorization, and post-authorization.

From Industry 3.0 to Industry 4.0 and Beyond

Depending on how one measures it, digital transformation today is actually a journey that began in the 1970s [7]. That historical context is important in understanding where technology is headed for manufacturing in general and the pharmaceutical industry in particular. According to most historians, Industry 3.0 began with partial automation using memory-programmable controls and computers in manufacturing [8].

Although this era brought significant advancements, it also entrenched inefficiencies such as data silos, linear point-to-point integrations, and the accumulation of dark data—information collected through various computer network operations but not utilized for insights or decision-making.

The negative effects of accumulated dark data, when considering the scope, cannot be underestimated. According to an article in *Forbes* in 2021 [9], from information first reported as early as 2016 by the market research firm Forrester [10]—unused organizational data constitutes approximately 73% of all collected data. For the pharmaceutical industry, this data includes information such as environmental monitoring logs, equipment logs, and machine logs, all often stored in inaccessible formats or on standalone equipment systems.

Such limitations curtailed real-time decision-making and hampered operational flexibility. In pharmaceutical manufacturing, data often flows linearly from field devices to control systems and manufacturing execution systems (MES). In many cases, this movement is executed manually, which poses compliance risks under regulatory frameworks such as 21 CFR Part 11 [11] and EU Annex 11 [12]. Manual data handling increases the potential for data integrity violations, including manipulation and falsification, which can compromise regulatory compliance and product quality.

Additionally, the reliance on point-to-point integrations inflated the costs and time required for solution deployment and

validation. These challenges are often exacerbated when scaling solutions across multiple sites, particularly at the higher levels of the automation hierarchy where MES and enterprise resource planning (ERP) integrations demand specialized expertise and significant financial investment. The ISA-95 model [13] from years past demonstrates the inefficiency of this approach, with data latency often spanning days or weeks, undermining real-time operational insights.

Industry 4.0, which many academics agree began in 2011 [14], introduced cyberphysical systems and a move toward digital integration of business processes. Industry 4.0 emphasizes real-time data exchange, allowing manufacturers to leverage automation, AI, and ML for operational efficiency. It transforms data into actionable intelligence, fostering agility and resilience in manufacturing operations. Most significantly, it can eliminate many common operational technology and information technology barriers, while maintaining the need for human interactivity and collaborations within that framework.

So what may seem like a relatively recent interest in digital transformation for manufacturing is, in fact, a story more than half a century in the making. Notably, the environmental, societal, and cyber-physical dimensions emphasized in Industry 5.0—such as the circular economy, human-centric design, and resilient supply chains—are already integrated within the ISPE Pharma 4.0 operating model

A PRACTICAL FRAMEWORK FOR DIGITAL TRANSFORMATION


In practical application, digital transformation in manufacturing—and particularly in the pharmaceutical sector—is a journey toward real-time integration of production, people, quality, and business processes, creating an organization that can efficiently consume and act on data. Importantly, digital transformation is not only about adopting new technologies. It is also about changing how companies operate by treating each initiative or project as part of a strategic vision, ensuring data is generated, contextualized, and made accessible without assumptions about its use.

In pharmaceutical manufacturing, digital transformation means connecting automation systems (operational technology, or OT) with IT business processes. This includes:

- **Real-time data utilization:** Leveraging manufacturing and business process data in real or near real time for decision-making
- **Strategic integration:** Ensuring seamless connectivity across equipment, systems, and personnel
- **Data ecosystem:** Treating all nodes (equipment, systems, and personnel) as producers and consumers of data

This integration creates a unified, context-rich information ecosystem capable of driving data-informed decision-making in real time. It enables advanced analytics for informed decision-making, and it ensures compliance with stringent regulatory standards. Before deciding on the relevant solution and applications to solve an organization's particular business and manufacturing challenges, however, it is important to understand the framework applicable

Figure 1: Pharma 4.0 Operating Model



to digital transformation. The digital transformation framework is composed of the following elements:

- Identify business goals and objectives
- Conduct a digital maturity assessment
- Develop a foundation architecture design
- Conduct a pilot project/proof of concept
- Move to full-scale implementation
- Strive for continuous evaluation and improvement

Identify Business Goals and Objectives

It may seem obvious, but unless an organization has consensus on the reasons for adopting digital transformation, results will be scattershot and only marginally successful. Before setting out on the path to transformation, every organization needs a well-articulated digital strategy that defines the importance of digital data for supporting business process decision-making. This well-articulated digital strategy serves as a “north star,” providing a clear vision for the organization and aligning efforts across departments. The strategy should define what digital transformation entails for the organization, ensuring that all stakeholders are unified in their understanding and approach.

When developing a digital strategy, organizations must first evaluate and align on their strategic imperatives for digital transformation, and balance those against the risks of inaction. Common objectives include accelerating product development, improving supply chain resilience, and achieving cost efficiencies through process optimization. Failing to adopt digital strategies, despite having such measurable goals, may lead to longer time to market and increased operational costs.

Digital transformation is ultimately an educational journey. Everyone—from shop floor personnel to the C-suite—must share a common understanding of the value of digital data and work to overcome resistance to change. This is also an opportunity to appoint digital transformation champions and form a dedicated team to remove barriers and ensure success.

Organizations can enhance knowledge and training through digital tools such as augmented reality for hands-on learning (e.g., mastering a specific sampling method). These tools should be integrated into the learning management system to ensure compliance, report on training activities, and understand the skills and abilities of all personnel.

Conduct a Digital Maturity Assessment

Conducting a comprehensive digital maturity assessment is essential to understanding whether the organization is ready for digital adoption. This means evaluating technological capabilities, process efficiencies, organizational culture, and leadership alignment. Overall, the key assessment areas include identification of process inefficiencies and pain points, evaluation of cultural readiness for change and potential resistance, and inventory of existing connected systems, data silos, and unconnected devices.

Commonly used and trusted frameworks offer structured methodologies for assessing maturity across many dimensions. These readiness frameworks include the Smart Industry Readiness Index (SIRI) [15], IIoT Digital Transformation Maturity Assessment (DTMA) [16], BioPhorum Digital Plant Maturity Model [17], and ISPE Advancing Pharmaceutical Quality (AQP) maturity assessment tool. For example—and without endorsing any one over the other—the SIRI is an independent digital maturity assessment for manufacturers. It comprises a suite of frameworks and tools to help manufacturers—regardless of size and industry—start, scale, and sustain their manufacturing transformation journeys.

In the pharmaceutical industry, one aspect of digital transformation readiness might include assessing whether batch data from an MES is readily available for real-time analytics, or if manual data review delays decision-making. This assessment would include identifying both good and poor processes and the pain points in the current workflow. The level of cultural readiness could be benchmarked using the AQP St.Gallen Benchmark Questionnaire.

Develop a Foundation Architecture Design

Designing a robust digital architecture is fundamental to ensuring scalable and secure data integration. This includes establishing minimum technical requirements (MTR) that systems must meet to connect to the infrastructure and foster interoperability. This is also the point at which standardized communication protocols may be implemented (such as OPC-UA or MQTT [18]). Many legacy pharma human-machine interface systems actually lack these modern communication protocols and may require gateways to enable standardization.

As in most cases, it is in the foundation architecture design phase that organizational education about digital transformation and digital systems will occur. This education should provide direction to the systems user and future users as to how the transformation will help them in their daily roles and the importance of using data in their day-to-day activities. It enables organizations to plan cultural change management and equipping personnel to adapt to new technologies with confidence.

In this step, the organization may align on a reference Industry 4.0 architecture IIRA [19], RAMI 4.0 [20], SITAM [21], or UNS [22]. For example, an organization may opt for open architecture (not necessarily open technology) that is edge-driven, supports secure data transfer, and complies with global regulatory requirements for data integrity. Importantly, users should not make assumptions about how data is used—if an organization limits the capture of data based on wrong assumptions, it will also limit future insights.

Conduct a Pilot Project/Proof of Concept

You have to walk before you run, and you have to crawl before you walk. It's essential to the success of a digital transformation initiative to not take on more than your organization is prepared to handle at that time. Pilot projects validate the feasibility and effectiveness of proposed solutions. A pilot project or proof of concept is crucial for testing and validation of technology solutions.

To begin, select an area with clear business or manufacturing challenges to validate the solution's effectiveness. In the pharmaceutical context, this could involve a pilot program that integrates equipment data to automatically capture audit logs, alarm records, and event files from process equipment—analyzing the data and feeding relevant information into the electronic batch record. This allows organizations to address tangible challenges while demonstrating value and bringing the organization personnel on-board with the strategy.

For example, a pharmaceutical company implemented a strategy involving system architecture and software integration to successfully pilot a digital transformation in one building within its manufacturing network [23]. The pilot validated that real-time data integration could streamline manufacturing by reducing human intervention and minimizing the risk of data entry errors. Additionally, the project supported the business objective of ongoing process verification (OPV).

Figure 2 illustrates the implemented proof of concept in conceptual view, manufacturing equipment (PLC/HMIs), applications

(SCADA, historian, data analytics), personnel (via the SCADA and HMI) are interconnected via a unified name space reference architecture. Data is available to all subscribed users at the same time as it becomes available at the UNS broker.

The proof of concept is where an opportunity for the organization to validate the effectiveness of the efforts. The learning and validation enable organizations to understand what works for their use cases, and more importantly what will not work. This “fail fast” method minimizes the cost risks to the scale-out phase.

For less mature organizations or those that have not yet started their digital transformation journey, this may very well be a breakthrough Kaikaku step for them and not only continuous improvement. (Taken from the principles of lean manufacturing, this term refers to a period of radical change that necessitates training and cultural adjustment within the organization.)

Move to Full-Scale Implementation

Following a successful pilot, organizations should focus on scaling solutions across the manufacturing network (buildings, sites), ensuring seamless integration across systems. Leveraging insights and learnings from the pilot phase minimizes risks and enhances the efficiency of full-scale deployment. Scaling often involves implementing digital solutions that standardize quality processes, ensuring regulatory alignment across global operations, and standardized data structures across equipment types for consistent manufacturing network deployment. This standardization of structures, systems, and processes provides certainty in a regulatory environment.

Strive for Continuous Evaluation and Improvement


Digital transformation is not a one-time event but an ongoing journey driven by iterative learning. As such, continuous monitoring and evaluation of implemented solutions are essential to sustaining operational excellence. Organizations should leverage continuous improvement frameworks—such as Plan-Do-Check-Act (PDCA) and Define-Measure-Analyze-Improve-Control (DMAIC)—to remain agile and responsive to new challenges and evolving industry requirements.

PHASED EXECUTION IN DIGITAL TRANSFORMATION

As briefly addressed in the preceding section, once a digital transformation initiative has been proven in a pilot project, the next step is to scale the solution across the organization. This involves ensuring that the solution integrates seamlessly across systems, and leverages the knowledge gained during the pilot to avoid pitfalls experienced during the proof of concept.

In the pharmaceutical industry, scaling may involve implementing a digital solution across multiple production sites to achieve consistent quality and compliance. Figure 3 indicates how the company scaled out the proven solution architecture after the proof of concept was validated. Each disparate site became an instance in the architecture that was created during proof of concept. This makes data available to all data users within the organization in a

Figure 2: Proof of concept



consistent manner across similar equipment and processes across sites and countries.


A typical large-scale execution is composed of two phases: phase A, the initial integration (foundational connectivity) and phase B, advanced integrations. These phases can be understood graphically as shown in Figure 4. Phase A contains foundational processes and enablers to phase B. Phase A is where the business governance and prerequisites, mapping process, physical preparation, physical connectivity, data flow, and capture occur. Within this phase, some insights can be found in the data and visualized/presented to users. Phase B is where the organization has established sufficient data volume and fidelity to progress to advanced predictive analytics and intelligence. Further insights and listing suggested steps are stated within the ISPE Baseline® Guide: Pharma 4.0™.

Phase A

Connect intelligence to the network: This applies particularly to connection of standalone machine equipment, sensors or additional sensors to the manufacturing and/or IT networks. Enable devices to communicate through protocols such as Profibus, Modbus, and TCP/IP. Establish device and sensor connectivity using modern communication protocols, where possible. Ensure all equipment has smart, communication-enabled devices to integrate data collection seamlessly.

Collect data: Aggregate data using robust messaging protocols such as MQTT or communication frameworks like OPC-UA, to ensure reliable and scalable data acquisition. Formulate the data structure to be used for integrating the intelligence; this may be

Figure 3: For pharma companies, scaling a digital transformation may involve implementing a solution across multiple production sites, for consistent quality and compliance.



equipment unit-based, such as a centrifuge model or process cell reactor, as well as overheads and packaging lines.

Store and analyze: Use time-series databases, data historians, and data lakes to contextualize data for analytical insights. Implement high-performance data historians to store time-series data.

Analyze this data using dedicated tools to extract insights from the data lake information and to organize it within a data warehouse.

Visualize: Develop user-centric dashboards tailored to stakeholders, such as process engineers, quality managers, shop floor personnel. Present information using relevant platforms for real-time dashboards tailored for the organization's teams (manufacturing, QA, finance, etc.). Data presentation can be done with on-premise, system-specific SCADA, BI tools or a cloud provider platform.

Learn: Assess the information gained to this point, any new knowledge or problem resolutions and if the solution/applications are still "best in class."

Phase B:

Pattern recognition and prediction

Leverage ML algorithms to identify correlations and forecast outcomes based on historical data. Use predictive models for batch yield optimization or equipment maintenance. Develop ML models using contextualized data to detect process anomalies (for example, identifying deviations in media preparation temperature profiles).

Use actionable Insights

Use AI-driven recommendations to optimize process parameters

or identify issues. In pharmaceuticals, these insights must undergo stringent validation to maintain compliance.

Regulatory compliance cannot be understated in the implementation of digital transformation in the pharmaceutical industry. Unlike many other industries, the pharmaceutical sector must adhere to stringent compliance guidelines when applying digital technologies to manufacturing. While predictive analytics and AI can provide valuable recommendations, final decisions about process impacting changes must comply with GxP requirements and be appropriately documented to meet regulatory standards.

For example, recommendations made with AI systems must undergo stringent review and validation before implementation, and must adhere to guidelines such as 21 CFR Part 11 and Annex 11. In fact, any modification to critical process parameters or workflows must be evaluated through formal change control and validation processes. This ensures that modifications align with data integrity principles and meet regulatory expectations.

That said, successful digital transformation not only creates tangible business benefits for the companies in the pharma industry, but it can be an enabler for greater environmental and societal impact (see Figure 1).

Sustainable Digital Transformation

Digital transformation revolutionizes manufacturing, operational efficiency and compliance while playing a critical role in advancing sustainable manufacturing practices. In that way, Pharma 4.0 is not only the industry-specific principles of industry 4.0; it also includes what observers believe will be the hallmark of Industry 5.0: sustainability [8].

Pharmaceutical manufacturing—typically energy-intensive and dependent on complex supply chains—stands to benefit significantly from technologies that reduce environmental impact, optimize resource use, and strengthen supply chain resilience. Digital transformation plays a key role by enabling the development of green factories. These facilities leverage real-time data analytics, machine learning, and the IIoT to improve energy efficiency, minimize waste, and comply with environmental standards such as the EU Green Deal [24] and ISO 50001 Energy Management [25].

There are several direct effects of digital transformation on sustainable manufacturing:


Energy monitoring and optimization

Digital technologies enable real-time monitoring of energy consumption across production lines/buildings. IIoT sensors capture granular data on energy usage, which is analyzed using platforms to identify inefficiencies and recommend energy-saving measures. For example, predictive analytics can optimize heating, ventilation, and cooling (HVAC) and lighting systems, reducing energy costs and emissions.

Circular economy practices

Digital twins can simulate manufacturing processes to minimize waste, enable recycling of by-products, and optimize workflows,

Figure 4: The two phases of full digital transformation



contributing to sustainable operations. These virtual representations allow pharmaceutical companies to reduce material losses, recycle by-products, and implement sustainable waste management systems.

Carbon footprint reduction

Blockchain technology can track the carbon footprint of raw materials and finished products across the supply chain, ensuring transparency and adherence to sustainability goals. Integrated systems also provide automated reporting to comply with regulatory requirements on emissions.

A major pharmaceutical company reduced energy use by 18% over five years by integrating IIoT sensors and AI into its production. This included retrofitting legacy equipment and using AI to optimize batch processing, aligning with sustainability goals.

Supply chain resilience

Pharmaceutical supply chains are uniquely complex, characterized by global sourcing, stringent regulatory requirements, and the need for cold chain logistics. Disruptions caused by geopolitical tensions, pandemics, and climate change amplify the risks, necessitating resilient and adaptive systems.

Digital transformation enhances supply chain resilience through real-time visibility and predictive analytics. Technologies such as blockchain have been adopted for vaccine distribution by pharmaceutical companies to ensure traceability and reduce counterfeit risks. This technology enhances supply chain resilience while meeting stringent compliance requirements.

With predictive analytics, ML models analyze historical and real-time data to forecast supply chain disruptions, such as delays in raw material shipments or changes in demand patterns. This predictive capability allows manufacturers to optimize inventory levels and adjust production schedules accordingly. It also creates a circular supply chain model with which to evaluate supplier practices and prioritize those aligned with sustainability goals.

CONCLUSION

For regulated industries like pharmaceuticals, digital transformation not only helps drive inefficiency out of the process and improve competitiveness, but it also supports enhanced compliance through traceable, automated data flows and minimized manual intervention. This journey, although complex, paves the way for smart, adaptable, and resilient manufacturing ecosystems. The digital transformation journey brings an organization to the ideal digital manufacturing state, where all systems and people are connected in a unified network.

The ultimate vision of digital transformation includes the organization knowing the current state of the business in real time. The organization utilizes predictive analytics through past patterns, current state through ML, and operational adjustment recommendations through AI. With these, stakeholders can better anticipate and adjust to future states proactively. In this ecosystem, manufacturing processes and business layers are seamlessly integrated, and real-time data informs decision-making. The company becomes data-centric because data is integrated, contextualized, and immediately accessible.

Emerging technologies promise further advancements in sustainability and resilience: Quantum computing for optimizing supply chain logistics, AI for developing bio-based materials, and green data centers powered by renewable energy promise to further advance sustainability and resilience in pharmaceutical manufacturing. Blockchain technology will improve end-to-end supply chain traceability and smart contracts, and digital twins will be put to work for predictive maintenance and continuous process improvement. Through digital transformation, pharmaceutical manufacturers can establish themselves as leaders in green manufacturing while building robust, future-ready supply chains that address the challenges of a rapidly changing world. 

References

- McKinsey and Company. "What Is Digital Transformation?" Updated 7 August 2024. Accessed 24 March 2025. www.mckinsey.com/featured-insights/mckinsey-explainers/what-is-digital-transformation
- Minero, T., and Laura Kuger "The 7th ISPE Pharma 4.0™ Survey: Digital Transformation." *Pharmaceutical Engineering*® 44, no. 5 (September/October 2024). Accessed 24 March 2025. <https://ispe.org/pharmaceutical-engineering/september-october-2024/7th-ispe-pharma-40tm-survey-digital>
- International Society for Pharmaceutical Engineering. *ISPE. Baseline® Guide, Vol. 8: Pharma 4.0™, 1st ed*, North Bethesda, MD. 2023.
- World Economic Forum. "World Economic Forum Recognizes Leading Companies Transforming Global Manufacturing with AI Innovation." 8 October 2024. Accessed 17 January 2025/ www.weforum.org/press/2024/10/world-economic-forum-recognizes-leading-companies-transforming-global-manufacturing-with-ai-innovation-bcdb574963
- US Food and Drug Administration. "Guidance for Industry. Considerations for Complying with 21 CFR 211.110." January 2025. Accessed 17 January 2025. www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-complying-21-cfr-211110.
- European Medicines Agency. "Reflection Paper on the Use of Artificial Intelligence in the Lifecycle of Medicines." 19 July 2023. Accessed 3 February 2025. www.ema.europa.eu/en/news/reflection-paper-use-artificial-intelligence-lifecycle-medicines
- Rutgers University School of Engineering. "Industry 4.0 Versus 5.0: What's the Difference?" 4 September 2024. Accessed 17 January 2025. <https://engineeringmastersonline.rutgers.edu/articles/industry-4-0-vs-5-0-whats-the-difference>
- Sharma, A., and B. J. Singh. "Evolution of Industrial Revolutions: A Review." *International Journal of Innovative Technology and Exploring Engineering* 9, no. 11 (September 2020):66–73. doi: 10.35940/ijitee.I7144.0991120
- Scudder, B. "AIoT: The Key to Unlocking Business Value from Industrial Data." *Forbes*. 30 April 2021. www.forbes.com/councils/forbestechcouncil/2021/04/30/aiot-the-key-to-unlocking-business-value-from-industrial-data
- Gualtieri, M. "Hadoop Is Data's Darling for A Reason." 21 January 2016. www.forrester.com/blogs/hadoop-is-datas-darling-for-a-reason
- US Food and Drug Administration. "Guidance for Industry. Part 11, Electronic Records; Electronic Signatures—Scope and Application." August 2003. <https://www.fda.gov/media/75414/download>
- European Commission. "EudraLex, Volume 4: EU Guidelines for GMPs for Medicinal Products for Human and Veterinary Use. Annex 11: Computerised Systems." Published 2011. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/annex11_01-2011_en.pdf
- International Society of Automation. "ISA-95 Standard: Enterprise-Control System Integration." Accessed 17 January 2025. www.isa.org/standards-and-publications/isa-standards/isa-95-standard
- Xun Xu, X., Y. Lu, B. Vogel-Heuser, and L. Wang. "Industry 4.0 and Industry 5.0—Inception, Conception and Perception." *Journal of Manufacturing Systems* 61, (2021):530—5. doi:10.1016/j.jmsy.2021.10.006
- International Centre for Industrial Transformation. "INCIT Smart Industry Readiness Index." Accessed 17 January 2025. <https://incit.org/en/what-we-do/siri/>
- Contentious Ltd. "Digital Maturity 2.0." Accessed 17 January 2025. <https://digitalmaturity.org/>
- BioPhorum. "Digital Plant Maturity Model V3." 3 November 2023. www.biophorum.com/download/digital-plant-maturity-model-3-0 Accessed 17 January 2025.
- OASIS MQTT Technical Committee. "MQTT Specifications." Accessed 17 January 2025. <https://mqtt.org/mqtt-specification>
- Industry IoT Consortium. "The Industrial Internet Reference Architecture: A Common IoT Framework." Accessed 17 January 2025. www.iiconsortium.org/iira/
- "RAMI 4.0 (Reference Architecture Model Industrie 4.0)." Accessed 17 January 2025. <https://www.sci40.com/menu-en-1/thematic-fields/rami4-0/>
- Kassner, L., C. Gröger, J. Königsberger, et al. "The Stuttgart IT Architecture for Manufacturing. An Architecture for the Data-Driven Factory." *Enterprise Information Systems (ICEIS)* 2016. Springer, 2017. Accessed 17 January 2025. www.ipvs.uni-stuttgart.de/departments/as/downloadgallery_as/groegech/Kassner_Stuttgart_IT_Architecture_for_Manufacturing.pdf
- Chen, H. B. "A Universal Namespace Approach to Support Metadata Management and Efficient Data Convergence of HPC and Cloud Scientific Workflows." 2018 IEEE International Conference on Big Data (Big Data), Seattle, WA, USA, 2018, pp. 516–521. doi:10.1109/BigData.2018.8622588. Accessed 17 January 2025. <https://ieeexplore.ieee.org/document/8622588>
- "Case Study of Unified Name Space Deployment to Support Digital Transformation in the Pharmaceutical Industry." 2023 ISPE Europe Annual Conference; <https://virtual.ispe.org/live/120/page/1664?tags=273>; Accessed 24 March 2025.
- "The European Green Deal: Striving to Be the First Climate-Neutral Continent." Accessed 17 January 2025. https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/european-green-deal_en
- International Organization for Standardization. "ISO 50001: Energy Management." Accessed January 17, 2025. <https://www.iso.org/iso-50001-energy-management.html>

About the authors

André Boyce, BSc, CAP, PMP, is the Department Manager and Consultant within Automation at Arcadis. He has 27 years of experience in automation and control systems across the pharmaceutical and biotechnology industries. He has been a contributor to the International Society of Automation (ISA) Automation Project Management Specialist Certificate program and presented at the 2023 ISPE Europe Annual Conference. He is an ISA Certified Automation Professional and a Project Management Institute (PMI) Project Management Professional. He holds a BSc in applied physics and instrumentation from Cork Institute of Technology.

Scott Sommer, PE, CAP, is Department Manager of Instrumentation and Controls at Arcadis. Scott has 43 years of experience in automation, including 25 years in the pharmaceutical and biotechnology industries. He was principal investigator for a NIIMBL data analytics project in 2021 and a lead in a digital transformation project with International Academy of Automation Engineering (IAAE), Manufacturing x Digital (MxD), and the US FDA in 2022. He holds a BS in chemical engineering from the University of Illinois and a MEng in chemical engineering from McNeese State University. He joined ISPE in 2018.

VALGENESIS®

Have You Met VAL?



VAL is your AI Validation Assistant. It can cut your validation costs by up to 30%, accelerate your product launches, and save your budget millions each year. Just like that.

Enter the Age of AI-Powered Validation

- Create validation documents up to 80% faster
- Execute validation up to 20% faster
- Eliminate human errors automatically
- Ensure audit-ready validation



Book a demo to see
AI-Powered validation in action

A PHARMA 4.0™ FUTURE for Brownfield Challenges

By Yvonne Duckworth, PE, and Ryan Thompson

Pharmaceutical companies can use digital maturity assessments to address the challenges of upgrading brownfield facilities and implementing digital transformation improvements. Enabled by stakeholder workshops, these assessments can rapidly produce concrete plans and priorities to guide a facility's development over the next three to five years—delivering business value and laying the foundation for continuous improvement.

THE PHARMA 4.0™ NECESSITY

In just a few short years, Pharma 4.0™ principles have evolved for many companies from 'let's consider planning' to 'why isn't this done yet?' Introducing new technologies and processes to stay competitive often places pressure on multiple areas of pharmaceutical operations. Facilities must not only keep pace with one another but also with partners across the value chain—from drug development to materials and packaging.

Meanwhile, competitors may be acquiring advantages that cannot be ignored. Perhaps now is the time: last year's ISPE Pharma 4.0™ Conference featured multiple case studies highlighting digital transformations [1], and this year's conference, which is in December in Barcelona, Spain, is expected to have even more. Across our industry, leaders are signaling an increased urgency for change [2, 3], as legacy systems lack the flexibility and efficiency to keep up with digitally paced business in 2025. Nowhere is this challenge clearer, and more relevant, than in brownfield facility developments.

This creates the contradiction: the facilities that could benefit most from Pharma 4.0™ may also be the toughest or riskiest to transform. How do you move forward when there are so many interconnected options, each with implications for your products, processes, infrastructure, compliance, and people?

THE BROWNFIELD CONTRADICTION

When planning a new, industry-leading greenfield site, you often have the luxury of embracing multiple aspects of Pharma 4.0™, making cutting-edge innovation a hallmark of the facility. But such opportunities can be rare—more often, development and production must continue at existing sites. Brownfield facilities present unique challenges when it comes to digital transformation [4]. Many were built decades ago and have undergone multiple expansions and ownership changes.

Data is a particular concern. Any facility with a history of more than a few years will have a myriad of equipment, systems, and data management practices—resulting in varying levels of data quality and accessibility. There will be data silos, legacy systems, and manual processes that are all running on aging infrastructure. No matter how much you might want to integrate AI analytics, predictive maintenance, or efficiency mapping, is your data even in a form that could use it? Although a guiding framework like FAIR (Findable, Accessible, Interoperable, and Reusable) can offer end goals and guiding principles [5], they can sometimes feel far removed from the reality of an already constructed and operating brownfield facility.

Implementing digital technologies and launching successful digitalization projects is challenging even under the best of circumstances. Research indicates that most organizations may not achieve their transformation objectives—and those that do often struggle to sustain their successes [6]. Moving forward requires a way to uncover these challenges and a structured approach to addressing them.

DIGITAL MATURITY ASSESSMENTS

Faced with the myriad challenges and potential solutions in a Pharma 4.0™ upgrade effort, the first best step is a digital maturity assessment. This ensures business value for each recommendation, and drives concrete, measurable business decisions to deliver that value. A successful assessment will cover opportunities across the business—from control strategies to quality management down to the foundational process of an interconnected facility.

Technology only succeeds when the people using it are empowered. That's why change management—helping both workers and managers become comfortable with new skills and processes—is vital to a successful digital transition.

Why Do a Digital Maturity Assessment?

A 2021 McKinsey study found that among successful digital transformation projects, one of the three leading indicators of successful value capture was in conducting a thorough, evidence-based assessment of the business to identify opportunities for potential improvement [6].

We've seen more facilities turning to digital maturity assessments not only to get started but also to consistently and successfully drive innovation. A digital maturity assessment can drive decision-making and ensure that progress is made and measured by:

- Preventing business impact from getting lost in technology adoption concerns
- Accelerating the process—assessments only take a few days
- Identifying quick wins and the initiatives that will drive the greatest benefits
- Benchmarking against other manufacturers in the life sciences industry
- Evaluating people and processes alongside technology

Conducting a comprehensive, fact-based assessment of the business can help identify opportunities for improvement. The more thoroughly that an organization uses facts to assess the maximum financial benefit it can achieve from a transformation in the first place, the more confidence leaders will have in setting and pursuing ambitious yet realistic targets that reflect the transformation's full potential. Additionally, non-financial impacts can be evaluated, ensuring strategic transformation is evaluated alongside return on investment.

STANDARDIZED DIGITAL MATURITY ASSESSMENTS

Although assessments can be carried out informally or developed in house, we've found that using standardized third-party assessment tools offers far greater benefits. They cover a wide range of categories, meaning that they can look at what you're doing now, but also what you'll address in the future, making it easier to track progress. These assessments build on the insights of many experts, with valuable considerations built in from other organizations, operations, and industries. They also make it much easier and more valuable to benchmark your organization against competitors and to partner using standardized data. Finally, they offer concrete steps for improvement.

The purpose of this assessment is to understand where digital transformation can deliver business value. Let's look at the three leading digital transformation assessments that we've seen deliver significant value for brownfield pharmaceutical facilities. Although each model has its own slightly different definitions, rating system, and areas of focus, in each assessment you'll find familiar terms

Conducting a comprehensive, fact-based assessment of the business can help identify opportunities for improvement.

that connect with the realities you see today, and the futures you envision for your facility:

- Low maturity: initial, predigital, manual, paper, ad-hoc, top-down
- Medium maturity: developmental, digital silos, semi-automatic, unit-level automation, labor intensive data retrieval, defined, automatic, digital, interoperable, FAIR, empowered teams
- Advanced maturity: managed, predictive, periodic course-correction, simulated, agile, optimized, adaptive, automatically integrated feedback, real-time adjustments

Option 1: ISPE Pharma 4.0™ Maturity Model and Assessment Tool


Built on the knowledge from its 2023 industry survey on the barriers to innovation that limit the development and implementation of innovative technologies, ISPE released its Pharma 4.0™ Maturity Model and Assessment Tool [7] as an attachment to the Baseline Guide. Its goal is to provide practical guidance embedded with regulatory best practices to accelerate Pharma 4.0™ transformations.

The ISPE maturity assessment looks at five key areas (each with five subcategories):

1. Resources
2. Information Systems
3. Culture
4. Organization and Processes
5. Data Integrity by Design

Implementing concepts from Pharma 4.0™ requires coordination of these areas, aligning expectations, communication, analysis, and global pharmaceutical regulations. As a result, the ISPE assessment guidelines recommend that the areas of evaluation should have relatively even scores to achieve optimal business results. Increasing only one dimension could have diminished benefits, and a dramatically lagging area could hold back progress in every other area. Balancing these scores then becomes the first priority for planning but also allows for a sophisticated strategy that accounts for each key area of the business.

The ISPE Digital Maturity Assessment is based on the Pharma 4.0™ Operating Model. Its focus on assessing data integrity, for example, has contributed to the growing popularity of digital maturity assessments small-molecule manufacturing. These

Figure 1: ISPE's Pharma 4.0™ Digital Maturity Assessment chart

The ISPE assessment includes a visual maturity chart that scores not only the five key areas but also each of their five subcategories. This approach is especially useful at quickly identifying relatively undeveloped areas that should be prioritized during planning.

tools allow organizations involved in the pharmaceutical product lifecycle to fully leverage the potential of digitalization—enabling faster therapeutic innovations and improved production processes for the benefit of patients, while also meeting unique regulatory requirements.

In a 2023 report, McKinsey stated, “In many companies, manual data processes persist, making any advanced analytics at scale or speed impossible. Before pharmaceutical companies can achieve digital and analytics transformation, they must embrace data transformation” [8].

We’ve seen the same thing firsthand: data integrity and quality frequently emerge as major inhibitors of digital transformation in the pharmaceutical industry. These challenges often surface during application reviews and are compounded by gaps in harmonized regulations. To address this, ISPE designed the Pharma 4.0™ Assessment as a guided questionnaire to be completed as a group. Having a facilitator present ensures that definitions are aligned between stakeholders and that a shared consensus is developed.

Option 2: BioPhorum Digital Plant Maturity Model (DPMM) Assessment Tool

BioPhorum is an organization that facilitates initiatives across key areas affecting the global biopharmaceutical industry. Its DPMM Assessment Tool [9] provides a structured method for assessing a plant’s digital maturity and setting targets aligned with a company’s digital strategy. It can be used for internal and external benchmarking, building technology and investment roadmaps, and defining dependencies across facility operations. While the DPMM and ISPE assessments share similar goals and scopes, each has its own strengths and organizational structure.

The DPMM multidimensional model has eight business and capability dimensions:

1. Manufacturing execution
2. Process development

3. Quality control labs
4. Quality management systems
5. Manufacturing support
6. Supply chain
7. People
8. Cybersecurity and operations

Scores in each of these dimensions indicate where a facility falls within a five-step digital maturity scale. In the latest version, BioPhorum has increased its own focus on quality control and management systems and has a revised cybersecurity section that focuses on systems that store and transmit digital information. We’ve found this assessment to be especially popular in the biotech sector.

Like the ISPE assessment, the BioPhorum assessment is designed as a questionnaire to be completed as a group. During the assessment, it’s important to ask not only “Where are we at now?” but also “Where do we want to be in the future?” This forward-looking perspective helps gauge the relative importance of each capability and drives prioritization of the gaps to address after the assessment.

Option 3: International Center for Industrial Transformation (INCIT) Smart Industry Readiness Index (SIRI)


The Global SIRI Initiative was developed by the Singapore Economic Development Bank (EDB) and supported by the World Economic Forum [10]. It brings together more than 600 manufacturers, governments, and industry associations across 30 countries to accelerate the adoption of Industry 4.0 benchmarking and transformation [11]. This global effort has resulted in a highly stable standard that draws on cross-industry data to identify the areas with the greatest impact on cost, industry benchmarks, and KPIs selected by the plants.

Figure 2: A BioPhorum Digital Plant Maturity Model (DPMM) blank chart

BioPhorum Digital Plant Maturity Model — Detailed assessment		Company name		Plant name		Select plant type		Select product type	
Dimensions of maturity		Trend	Level 1 Pre-digital plant	Level 2 Digital islands	Level 3 Connected plant	Level 4 Predictive Plant	Level 5 Adaptive plant	Score	
Business capabilities	Manufacturing execution & process automation		0%	0%	0%	0%	0%	0	
	Process development		0%	0%	0%	0%	0%	0	
	Quality control labs		0%	0%	0%	0%	0%	0	
	Quality management systems		0%	0%	0%	0%	0%	0	
	Manufacturing support		0%	0%	0%	0%	0%	0	
	Supply chain		0%	0%	0%	0%	0%	0	
Enabling dimensions	People & culture		0%	0%	0%	0%	0%	0	
	Cybersecurity & operations		0%	0%	0%	0%	0%	0	
Business capabilities			0%	0%	0%	0%	0%	0.0	
Enabling dimensions			0%	0%	0%	0%	0%	0.0	
Total score			0%	0%	0%	0%	0%	0.0	

The BioPhorum Maturity Model scores facilities across eight dimensions to calculate a total maturity score. This score is then mapped to one of five progressively advanced levels: predigital plant, digital silos, connected plant, predictive plant, and the highest level, adaptive plant

Figure 3: Example output from a Smart Industry Readiness Index (SIRI) assessment



This is a generic example of the visual maturity benchmarking chart from a SIRI assessment. The assessed facility's maturity scores are mapped against both the industry median and a Best in Class benchmark across all 16 dimensions.

The SIRI Assessment: Two Key Components

1. **Assessment:** The facility is evaluated across 16 dimensions, categorized by organization, technology, and process. Each of dimension receives a maturity rating from Band 0 (the lowest) to Band 5 (the highest).
2. **Prioritization:** The assessment results are combined with additional company-specific information to generate a formal report. This report helps organizations begin—and sustain—their transformation journeys.

This is a generic example of the visual maturity benchmarking chart from a SIRI assessment. The assessed facility's maturity scores are mapped both to the industry median and a Best in Class standard across all 16 dimensions.

SIRI is fundamentally different from the other two assessments—it doesn't cover crucial pharmaceutical industry-specific topics like regulatory requirements or data integrity. Instead, it provides helpful benchmarks, KPIs, recommended focus dimensions, and potential areas of impact. A SIRI assessment offers a unique opportunity for any manufacturer to understand their progress, competitiveness, and priorities relative to peers through insightful, industry-agnostic approach—and conducted with a SIRI Certified Assessor. When combined with an assessment expressly built for the needs of the biopharmaceutical industry—and the ability to select KPIs that align with your organization's priorities—SIRI becomes an enormously powerful. One of the biggest conversation drivers after an assessment is facility performance against benchmarks.

THE MATURITY ASSESSMENT PROCESS

Once you know the assessment(s) you want to use, it's time to plan the workshop. This is a high-value, low-impact process that can take a few days. Using external facilitators will help set standards across facilities and projects, ensuring a consistent approach that looks similar to the following process:

Pre-Workshop

Prior to the workshop, conduct a questionnaire for all participants.

Workshop

1. Review questionnaire results
1. Define goals and objectives
2. Select business drivers for the facility
3. Identify and discuss pain points
4. Discuss ongoing projects
5. Tour the facility and talk to operations
6. Score according to assessment criteria
7. Review and align based on the maturity assessment

It's important to begin the process by observing participants and understanding their needs. Adopting new technology works is most effective when it applies to specific pain points. Ask: What do we need to solve? What improvements can be implemented? Pharma 4.0™ solutions span many areas—manufacturing, filling, packaging, warehousing, quality, maintenance, and IT. Starting with the solution, rather than the problem, will only distract and lead to diminished value in implementations.

SECRETS TO SUCCESSFUL ASSESSMENTS

Prioritize Workshop Collaboration

Time and again, we've seen that the most important aspect of this entire process is the workshop itself. Every voice is at the table—from production to compliance, and from HR to IT—working through questions, digging into challenges, and discussing what the most successful solution would look like. This one-of-a-kind workshop not only helps everyone understand the project, but also ensures that all participants are aligned and committed to the process. Even if a workshop lasts only a day or two, its impact can extend much further. A data transformation effort may take months, or even years, and the benefits can pay off for decades. One of the most impactful parts of the assessment process is getting everyone with different perspectives in the same room. That's often when the real breakthroughs happen and shared understanding begins to take shape.

SHIFT MINDSETS AND OPERATIONS

It is critical to remember that digital transformation is about more than just adopting new digital technologies—it's a shift in mindset and in how companies operate to deliver value for patients and customers. As shown in initial ISPE research, the "fear of change" is real [12]. Digital transformation requires not only capabilities but also a new adaptable way of thinking.

The standardized, benchmarked point of view that an assessment provides makes conversations with stakeholders and executives much easier. While decision-making around digital transformation initiatives in our industry remains under-researched [13], we've seen firsthand that investing, or not investing, in digital technology projects becomes clearer with the insight and context provided by an assessment.

Document Commitments and Insights

Successful assessments benefit from visible tracking, which ensures clear communication and empowered action, with all parties understanding their shared responsibility for change. This kind of documentation can protect the investment in the whole process. We've seen the best results occur from workshop participants capturing commitments on visual boards, lab leaders tracking communication about progress, and analysts empowered to introduce external data and experiences.

Combine Digital Assessments for Multiple Perspectives

Each maturity model has its own strengths and weaknesses, making it more difficult to determine in advance which one will provide the most insights for your facility—especially if you're just getting started. Since coordinating calendars is often one of the most difficult challenges in conducting an assessment, consider performing multiple assessments simultaneously in the same workshop. In practice, it will only add an incremental amount of work and can deliver more value and even unexpected insights. For example, data integrity insights often align with the vertical integration dimension from the SIRI model, offering a broader and more strategic picture. As you continue to update assessments to track progress, it may not be necessary to carry multiple assessments forward. However, after completing the full process once, you'll likely gain more confidence in the value each model provides.


Even after completing these assessments, the next steps may still be unclear. For example:

- The ISPE assessment may show a relatively low score in Data Integrity by Design.
- The BioPhorum DPMM might indicate a gap between the current and ideal states of manufacturing execution systems.
- The SIRI assessment could recommend focusing on vertical integration, shop floor intelligence, shop floor connectivity, and strategy and governance.

So, what should be the real priority? In this scenario, it's helpful to pause and examine the underlying reasons behind each model's recommendations. Ask: What KPIs are they aligned with? What business capabilities would you gain by advancing this maturity? This will allow you to build internal alignment, allowing your team to acknowledge the most critical gaps and develop a plan to get there.

From there, you can begin identifying the technology and process changes needed to close those gaps and build business cases to support them. This could involve:

Figure 4: Example Pharma 4.0™ roadmap schedule



This example of a Pharma 4.0™ development roadmap shows how insights from a digital transformation maturity assessment can inform planning and resource allocation over a multi-year timeline.

- Exploring solutions already in use within your manufacturing network.
- Conducting external benchmarking using resources like the *ISPE Baseline® Guide Vol 8: Pharma 4.0™* or the World Economic Forum Digital Lighthouses.
- Engaging with solution providers to drive conversations and align on the impacts to your technology and operations landscape.

NEXT STEPS: DRIVING BUSINESS DECISIONS

This is where many organizations falter. Without taking steps to quantify and ensure business value as their project scales, initiatives often become stuck in the pilot stage. Our goal is to equip stakeholders with a practical framework to digitally transform operations—securing a competitive advantage in an industry driven by rapid innovation and regulatory demands.

The initial assessment is followed by several steps to deeply quantify the benefits of proposed changes and develop a detailed digital roadmap. For example, a successful assessment should enable capital expenditures planning for the next 3–5 years.

TECHNOLOGY DEEP DIVES

This process involves mapping improvement opportunities identified during the assessment to current market offerings (if available), developing capital cost profiles, calculating return on investment, and identifying any non-financial benefits aligned with the goals outlined in the initial assessment.

These deep dives are essential to building a business case for a digital transformation project that every stakeholder will understand.

In the previous example, the recommendation to enhance both data integrity and vertical integration requires identifying solutions

that address both aspects. For instance, if paper records pose data integrity risks, this presents an opportunity to enhance vertical integration by ensuring data interoperability across all necessary systems. This approach mitigates data integrity risks associated with manual entry, such as transcription errors, lack of data validation, and delayed error detection. As a bonus, it also generates valuable data that can improve operations and performance in the future.

ROADMAP DEVELOPMENT AND MAINTENANCE

Deep dives into each proposed technological development can inform a sophisticated, multi-stage roadmap to guide your Pharma 4.0™ progress over the next three to five years.

A digital roadmap includes:

- Desired capabilities and technologies
- Key enablers, vendors, and infrastructure
- Business impacts (ROI / NPV, KPI, etc.)
- Pilot opportunities and roll-out strategies

The SIRI Prioritization Matrix helps make this possible by balancing cost, KPIs, and facility assessment matrix scores to bring focus to the efforts that will yield the greatest benefits. There are always areas for improvement with any plan. It's worth identifying these as you go, drill down to fully identify the opportunities, and then adopt the appropriate technologies to solve new problems. We recommend conducting annual assessments to track progress and maintain momentum in your digital transformation efforts.

THE FUTURE: LEADERSHIP AND ADAPTATION

Digital transformation is an exercise in leadership and continual improvement. The humbling power of connected manufacturing

Even though the ceiling of opportunity for digital transformations is very high, the practical reality is that the floor can be quite low.

lies in its ability to highlight weaknesses and reveal opportunities to innovate and improve. As such, consistent reevaluation and openness to changing the ecosystem you've put in place are critical to long-term success.

Even though the ceiling of opportunity for digital transformations is very high, the practical reality is that the floor can be quite low. As we have observed in numerous assessments, digital transformation in pharmaceutical facilities frequently begins with a bold, confident first step from paper to digital records. According to CRB's 2022 Horizons: Life Sciences report, only 27% of respondents prioritized funding specifically for digitizing supply chain information [14] and supply chain is just one component of a much larger picture.

CONCLUSION

Although there are justifiable reasons why our high-stakes, heavily regulated industry has been reluctant to transition to all-digital records, the benefits of doing so are consistently dramatic, positive, and—in 2025—are proven. Organizations that make this leap immediately gain a deeper understanding of their own operations across departments but also unlock new possibilities. Digital information is more flexible and fungible, it can be analyzed and shared in ways that enhance efficiency, reliability, and flexibility.

In our experience, meaningful cross-departmental initiatives like digitization only succeed when everyone is brought into the same room. Time and again, we've seen a maturity assessments act as catalysts for organizational change. In the Horizons: Life Sciences 2022 report by CRB, we found that most of those surveyed considered their companies to be at least at Level 3 of the DPMM, which signifies a connected facility, a high level of automation, and a strong intent to advance further.

This intent represents both an opportunity and a responsibility for leadership. Revisiting progress, celebrating wins, and diagnosing failures keeps teams excited and engaged. Assigning ownership to each technology initiative as its own mini project, can pay dividends in follow-through, accountability, and collaboration. When people

can associate faces with an initiative, they tend to respond more positively, helping sustain momentum over the years required for continuous digital transformation. 

References

1. Wölbeling, C., G. Di Vietri, and I. Garcia Mora. "Pharma 4.0": Case Studies and Lessons Learned." International Society for Pharmaceutical Engineering, iSpeak. 2 December 2024. <https://ispe.org/pharmaceutical-engineering/ispeak/pharma-40tm-case-studies-and-lessons-learned>
2. "This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer." Bioprocess Online. 14 August 2024. www.bioprocessonline.com/doc/this-takeda-official-thinks-pharma-won-t-be-optional-much-longer-0001
3. "How 2025 Can Be a Pivotal Year of Progress for Pharma." World Economic Forum. 16 January 2025. www.weforum.org/stories/2025/01/2025-can-be-a-pivotal-year-of-progress-for-pharma
4. "Modernizing Ageing Factories: The Role of Digital Transformation in Enhancing Brownfield Manufacturing." World Economic Forum. 26 August 2024. www.weforum.org/stories/2024/08/how-digital-transformation-supports-value-creation-in-brownfield-manufacturing/
5. "FAIR Principles." GO FAIR International Support and Coordination Office. Accessed 31 January 2025. www.go-fair.org/fair-principles/
6. "Losing from Day One: Why Even Successful Transformations Fall Short." McKinsey & Company. 7 December 2021. www.mckinsey.com/capabilities/people-and-organizational-performance/our-insights/successful-transformations
7. "Pharma 4.0™." International Society for Pharmaceutical Engineering. Accessed 31 January 2025. <https://ispe.org/topics/pharma-4.0#guidance-documents>
8. "Rewired Pharma Companies Will Win in the Digital Age." McKinsey & Company. 14 June 2023. www.mckinsey.com/industries/life-sciences/our-insights/rewired-pharma-companies-will-win-in-the-digital-age
9. "Digital Plant Maturity Model V3." BioPhorum Operations Group. 3 November 2023. www.biophorum.com/download/digital-plant-maturity-model-3-0/
10. World Economic Forum. "The Global Smart Industry Readiness Index Initiative: Manufacturing Transformation Insights Report 2022." Geneva, Switzerland: World Economic Forum, 2022. www3.weforum.org/docs/WEF_The_Global_Smart_Industry_Readiness_Index_Initiative_2022.pdf
11. "Global Smart Industry Readiness Index Initiative." World Economic Forum. Accessed 31 January 2025. www.weforum.org/projects/global-smart-industry-readiness-index-initiative/
12. International Society for Pharmaceutical Engineering. "Enabling Pharmaceutical Innovation: Delivering for Patients." North Bethesda, MD: International Society for Pharmaceutical Engineering, 2024. <https://ispe.org/sites/default/files/regulatory/2024/Report%20EnabPrmalnov.pdf>
13. Miozza, M., F. Brunetta, and F. P. Appio. "Digital Transformation of the Pharmaceutical Industry: A Future Research Agenda for Management Studies." Technological Forecasting and Social Change 207, (2024). <https://doi.org/10.1016/j.techfore.2024.123580>
14. Horizons: Life Sciences Report. CRB. 26 September 2022. <https://www.crbgroup.com/news/horizons-ls-2022-available>

About the authors

Yvonne Duckworth, MBA, PE, is Fellow of Digital Technology, Associate at CRB. She is a speaker and subject matter expert on Pharma 4.0™, Co-Chair for the ISPE Pharma 4.0™ Community of Practice (CoP), and an active member of ISPE Women in Pharma®, Women in Bio, and the International Society of Automation (ISA). She is a registered automation engineer with 33 years of technical design and project leadership experience within the pharmaceutical and biotech industries. She joined ISPE in 1993.

Ryan Thompson, BASc, is a Senior Specialist, Industry 4.0 at CRB. He has 18 years of experience leading companies through automation and digital transformation initiatives. He leverages technical expertise, leadership, and communication to drive scalable Industry 4.0 strategies. He presented on future-proofing a QC lab at the 2025 ISPE Facilities of the Future Conference and is a member of the Pharma 4.0™ CoP. He has a Bachelor of Applied Science from the University of Toronto. He joined ISPE in 2017.

APPLICATION OF STRATEGIC SKILL MANAGEMENT in Pharma 4.0™

By Yvonne Duckworth, PE, Paige Kane, PhD, Kai Reinhardt, PhD, Linda Wildling, PhD, and Vinzenz Zauner

The complex transformation toward Pharma 4.0™ requires comprehensive skill management. This case study builds on a previously presented framework and follows the fictional company NewCo as it tackles the challenge of developing a future-ready workforce during a plant expansion project. Guided by the framework, NewCo first establishes skill management governance and a cross-functional team. It then identifies and maps current and future skill requirements. A subsequent gap analysis reveals key insights. Leveraging the framework, NewCo systematically addresses critical knowledge gaps using modern virtual reality (VR) and augmented reality (AR) learning methods, which are discussed in detail. Following the project's success, NewCo decides to embed strategic skill management into the broader organizational context.

The concept of Pharma 4.0™ is regarded as an imperative to lasting organizational success in times characterized by volatility, uncertainty, complexity, and ambiguity (VUCA) [1, 2]. This holistic transformation toward digital and artificial intelligence (AI) fundamentally changes the industry. Pharmaceutical organizations face a unique challenge: They must balance rapid technological advancement with skill development of the workforce while continuously ensuring regulatory compliance.

In conventional pharmaceutical organizations, the responsibility for skill development is often fragmented. Traditional


approaches struggle to combine strategic business needs, learning methodology, technical expertise, and operational reality. The described development toward Pharma 4.0™, with its complexity, further increases the demand for a fundamental shift in ownership and a comprehensive approach to skill management.

Analysis of pharmaceutical organizations aiming toward Pharma 4.0™ reveals significant limitations in traditional skill development approaches. These limitations manifest in three critical dimensions that hinder successful digital transformation (see Table 1).

Table 1: Critical dimensions in Pharma 4.0™ skill management

Dimension	What?	Where?	Source
Digital Transformation vs. GxP Compliance	- Technology awareness and foresight - Validation of new digital systems - Implementation of electronic batch records - Data integrity - Continuous process verification	- Strategy - Quality assurance - Validation teams - IT departments - Manufacturing units	[2]
Technical and Process Integration	- Deep process understanding - Digital technology expertise - Cross-functional coordination - Regulatory knowledge	- Manufacturing operations teams - Quality management - Technical services - Process development groups	[3]
Strategic-Operational Alignment	- Incomplete technology adoption - Resistance to change - Inefficient resource allocation - Suboptimal business process integration	- Top management - Shop floor operations - Middle management - Project teams	[4]

Figure 1: Strategic skill management framework [5]



Emerging technologies of Pharma 4.0™ augment the toolset for pharmaceutical operations and skill development alike. Unlocking this potential requires effective integration of the end-to-end skill management process and thoughtful consideration of the critical perspectives: strategic business objectives, operational technical requirements, and learning experience.

Many organizations are aware of these new modalities but struggle to adopt them holistically [2]. This article builds upon a previously proposed strategic skill management framework [5]. It provides a tangible application in the form of a relatable case study based on the authors' collective knowledge as industry leaders. The article aims to support organizations in adopting holistic skill management and therefore ease transformation toward Pharma 4.0™.

CASE STUDY INTRODUCTION

The case study follows the fictitious NewCo and its project to extend production by adding multiple new lines at an established production site. In parallel to engineering, this requires the identification and development of additional skills in the workforce. Here, NewCo takes the holistic approach toward skill management, following a dedicated framework (see Figure 1).

STEP 1: ESTABLISHING A MODEL AND GOVERNANCE

A sound strategic skill management requires strong governance, particularly focusing on the integration of GxP requirements with digital transformation needs. The framework provides a structured way to bring together business leaders, operational managers, and HR professionals to develop a future-ready workforce. In the integrated approach, business leaders orchestrate the convergence of multiple perspectives and capabilities.

In their site expansion, NewCo aims to implement Pharma 4.0™ technologies to fundamentally change how they operate. The 8th thesis of Pharma 4.0™ states: "Pharma 4.0™ is not an IT project" [6].

Although previous digital transformation initiatives focused on technological aspects, NewCo recognizes workforce skills as an equally critical dimension. The company establishes clear and well-communicated governance, characterized by three interconnected core mechanisms that ensure effective implementation: business-led orchestration, cross-functional integration, and compliance-integrated development.

These three mechanisms work synergistically to create a robust implementation approach that bridges the previously identified gaps between strategic intent and operational reality. The business-led orchestration provides direction and accountability, whereas cross-functional integration ensures comprehensive stakeholder engagement. Simultaneously, compliance-integrated development preserves the critical balance between innovation and regulatory requirements, which is essential in pharmaceutical manufacturing.

Business-Led Orchestration

This approach establishes clear leadership accountability for skill development. It ensures direct connection to operational excellence and integrates skill development with business planning cycles. As demonstrated by recent surveys [2], such business leadership proves essential for maintaining momentum in digital transformation while ensuring GxP compliance.

Cross-Functional Integration

This represents the second critical mechanism, characterized by systematic stakeholder involvement across organizational units. This integration comes with clear role definitions and responsibilities, supported by a coordinated implementation approach. Evidence from pharmaceutical manufacturing environments suggests that this systematic integration significantly reduces implementation barriers and enhances adoption rates of new skills [3].

Table 2: Relevant stakeholders for Pharma 4.0™ skill identification

Level	Stakeholders	Focus Areas
Strategic	• CEO/board members • Head of manufacturing • Head of quality • Chief digital officer • Head of compliance	• Digital strategy alignment • Investment priorities • Quality vision • Market requirements
Operational	• Production managers • Quality managers • Validation managers • Technical services leads • Process development heads	• Technical requirements • GxP integration • Process optimization • Validation needs • Operating excellence • Lean Six Sigma
Support	• HR business partners • Training managers • Knowledge management leads • Change management experts	• Development programs • Training documentation • Knowledge transfer • Change readiness • Process optimization and lessons

Compliance-Integrated Development

This addresses the unique requirements of pharmaceutical organizations. By embedding GxP requirements directly into skill development processes and integrating regulatory considerations into skill development pathways, organizations can maintain compliance while driving innovation. This integration extends to quality systems, ensuring that skill development aligns with both regulatory requirements and operational excellence objectives [4].

NewCo's Approach

Aligned with the goals from the second mechanism, NewCo decided to set up a dedicated team for holistic skill management. The site expansion affects core processes rather than peripheral activities. Therefore, the development of new skills must be connected to both technical requirements and business implications. The central learning organization facilitated this by providing the latest learning methods and tools, supported by key team members.

Foresight into skill requirements requires a high level of strategic understanding. Business leaders, with their direct market exposure and organizational oversight, define both the technology strategy and project roadmap. From there, they are best positioned to identify future skill requirements in cooperation with central learning departments.

Technical training content on new digital technologies can typically be fully understood only by the dedicated subject matter experts (SMEs) responsible for the plant's operations. This includes considerations such as data integrity, electronic batch records, and automated quality control systems. At the same time, developing knowledge and training silos per site is to be avoided—for example, by establishing communities of practices and facilitating knowledge management.

Learning governance, methods, and tools are managed by the central learning organization of NewCo. This enables continuous awareness, scalability, and harmonization of effective methods, such as virtual reality (VR) and augmented reality (AR). In addition, an application for skill management is implemented to provide a harmonized setup and base skill model. In such, application-specific roles and skills are defined and accounted for by the respective SMEs.

As a result of the first step, NewCo established a clear governance and team. In addition, a base model to structure skills is available and embedded in a skill management application.

STEPS 2 AND 3: TARGET AND EXISTING SKILLS

Next, NewCo enters the exploratory phase to develop a comprehensive understanding of current skills and future requirements through systematic data collection and analysis. Following established methodological approaches in organizational research [7], the interdisciplinary team conducts semi-structured interviews with stakeholders across organizational levels. Based on extensive implementation experience in pharmaceutical organizations, the interview analysis requires careful consideration of different organizational perspectives and their unique insights into Pharma 4.0™ skill requirements [8].

Strategic leaders provide valuable insights into market dynamics and regulatory trends while being less focused on operational details. Their responses often reveal gaps between strategic vision and implementation reality, particularly regarding digital transformation priorities and compliance requirements.

Operational managers prove most valuable in identifying specific skills needs and practical implementation challenges. Their daily interaction with GxP requirements and digital technologies makes them essential for understanding where skill development is most critical. They can precisely identify where digital transformation initiatives intersect with compliance requirements and where traditional training approaches fall short.

Support function interviews, particularly with the learning department, reveal systemic challenges in skill development and insights on latest learning methods. Their perspective helps understand existing development frameworks and their limitations in addressing Pharma 4.0™ requirements. However, their input must be aligned with operational realities. Table 1 outlines stakeholders, their levels, and their focus areas in more depth.

The analysis focusses on identifying patterns across these perspectives. Common themes emerge around the following:

- Compliance-innovation balance
- Technical skill gaps
- Process integration challenges
- Documentation requirements
- Change management needs
- New ways of learning

The key is synthesizing these different perspectives into actionable insights while maintaining GxP compliance. Experience shows that successful analysis requires particular attention to areas where

strategic vision and operational reality diverge, as these often represent critical implementation challenges. Achieving tangible results is ensured by transparent definition of required roles; their associated skill sets and underlining skills. Extracting and documenting this information in a skill management application unlocks the required transparency and contributes toward general commitment.

With steps 2 and 3, New Co identified and documented its current roles and skills. Furthermore, a harmonized understanding of the upcoming required roles and skills for the site expansion and technological upgrade toward Pharma 4.0™ is established and documented.

STEP 4: SKILL GAP ANALYSIS

The established data foundation from the definition of current and target skills allows NewCo a data-driven skill gap analysis. Data is held in an application allowing for direct quantitative analytics. This includes the number of people and the “width” of the skill gap. In combination with available training formats, this leads to the training effort. The impact of a skill gap derives from its criticality and possibility to be mitigated, e.g., by temporarily relying on external talent or partners. In a portfolio approach, an impact–effort matrix is setup for different skill areas (Figure 2).

The gained insights are augmented with expert judgements and additional sources, such as analysis from manufacturing deviations/incidents and continual improvement. Existing formats of knowledge management bring insights from other plants and on future training opportunities. With that, NewCo systematically identifies several action areas for targeted skill development and hiring of new talents. For NewCo, the analysis shows a critical skill gap around aseptic manufacturing. The workforce should receive their base training and gain their qualification during line training prior to production. However, a delay in engineering reduces the time window for on-site qualification. The stakes are high, as this might become a bottleneck in the overall project timeline.

As a result from step 4, gaps are identified and evaluated. The skill development demand is clearly communicated to the involved business leaders and ambitions are high to solve the challenge around the critical skill gap in aseptic manufacturing.

STEP 5: DEVELOPING A ROADMAP


The sound gap analysis in step 4 allows NewCo to develop specific actions to secure the project timeline. The critical knowledge gap around aseptic manufacturing is tackled by the cross-functional team. As the on-site facilities are not available for training, the learning organization—with its expertise in modern training methods—proposes to leverage VR and AR. After consolidation with experts from Takeda, they present the concepts and best practices.

Leveraging Pharmaceutical Manufacturing Training with VR

Enhancing learning through immersion and safety

VR is transforming pharmaceutical manufacturing training by

Figure 2: Impact–effort matrix on identified skill gaps and development areas. The red circle marks a high-impact, high-effort skill gap in aseptic manufacturing.



providing an immersive, interactive learning environment. With advanced VR headsets and hand controllers, users can engage with digital simulations, experiencing complex cleanroom procedures in a risk-free setting.

A major advantage of VR in cleanroom operator training is its ability to make the invisible visible, transforming complex processes into clear, tangible experiences. Trainees gain a deeper understanding of cleanroom protocols, equipment handling, and operational procedures through realistic, interactive simulations. By offering hands-on experience in a controlled digital space, VR reduces the risks and stress associated with real-world training, ensuring that employees are well-prepared before entering a real cleanroom.

Anytime, anywhere training with real-time feedback

The flexibility of VR training enables trainees to access learning modules at any time, accommodating different time zones and work shifts. This 24/7 availability ensures continuous learning without disrupting critical cleanroom operations. Additionally, VR provides real-time feedback on performance, instantly identifying errors and guiding trainees to correct their mistakes. This enhances knowledge retention while reinforcing proper protocol adherence.

Standardized, Scalable, and validated VR training

The Takeda VR program establishes a globally standardized and scalable training framework across all sites, ensuring that cleanroom operators receive consistent, high-quality training aligned with industry's best practices and regulatory standards.

A key aspect of the program is platform validation, which ensures compliance with Good Manufacturing Practices (GMP) and other regulatory requirements. This includes meeting regulatory

compliance with the US FDA, EudraLex, and US Pharmacopeia (USP) standards, seamlessly integrating with the Takeda learning management system (LMS) for tracking training records, and maintaining compliance documentation.

LMS integration ensures training consistency and effectiveness by automating training records, supporting Sharable Content Object Reference Model (SCORM)-compliant learning paths, and enabling centralized monitoring for large-scale deployment across multiple sites.

Additionally, content validation is crucial to maintaining training accuracy and regulatory compliance. Training modules follow a structured framework that defines learning objectives, maps out interactive step-by-step training procedures, and incorporates both correct and incorrect scenarios to reinforce error prevention. By embedding validation mechanisms, content validation ensures that VR-based cleanroom training remains effective, scalable, and aligned with the highest industry and regulatory standards.

The future of training in pharmaceutical manufacturing

By integrating VR technology into cleanroom training, the pharmaceutical industry is embracing a new era of education that is immersive, flexible, and highly effective. VR not only enhances learning outcomes, but it also improves compliance, minimizes human errors, and boosts operational efficiency. As this technology continues to evolve, its role in workforce training and development will become increasingly indispensable, setting new standards for excellence in pharmaceutical manufacturing.

AR: Transforming Digital Instruction, Remote Assistance, and Training

Enhancing digital instruction with AR

AR is revolutionizing digital instruction by providing real-time, interactive guidance that improves how complex procedures are followed. Traditional standard operating procedures (SOPs) often rely on static manuals or written documentation, which can be difficult to interpret and are prone to human error. AR changes this by overlaying digital information directly onto the physical environment, making instructions more intuitive and accessible.

Takeda has a fully GxP-validated version of AR using Microsoft HoloLens, with a validated platform to deploy digital instructions in full compliance with GxP standards. This solution is part of a comprehensive global program, ensuring seamless deployment and adherence to industry regulations.

With AR-enabled devices, employees can receive step-by-step visual guidance while performing their tasks, eliminating the need to pause and referring to printed instructions. This hands-free approach ensures smoother workflow execution and reduces the likelihood of errors. Updates to procedures can be made instantly in AR systems, ensuring that employees always have access to the latest instructions. By making digital instruction more interactive and engaging, AR significantly improves compliance, efficiency, and accuracy in pharmaceutical productions, where precision is critical.

Augmented reality significantly improves compliance, efficiency, and accuracy in pharmaceutical productions, where precision is critical.

Revolutionizing remote assistance with AR

One of the most impactful applications of augmented reality (AR) is in remote troubleshooting and technical assistance. Traditional troubleshooting methods often require experts to be physically present on-site, leading to delays and increased costs. AR changes this dynamic by enabling real-time, remote collaboration, where specialists can guide field workers through repairs and maintenance from anywhere in the world.

Through “see-what-I-see” technology, remote experts can view exactly what the on-site worker sees and provide real-time visual instructions. AR overlays can highlight specific parts, provide animated guidance, or display relevant data to help resolve issues more efficiently. This reduces downtime and increases productivity, as problems can be diagnosed and fixed faster without waiting for a technician to arrive in person. Using remote assistance in our productions can maintain high operational efficiency while reducing service interruptions.

Immersive training for workforce development

AR is revolutionizing employee training by providing immersive, hands-on learning experiences. Traditional methods often focus on theory, making it difficult for employees to apply knowledge in real-world scenarios. AR allows employees to practice complex procedures in simulated environments before executing them in real life, improving confidence and competence. Interactive AR modules enhance understanding of workflows and equipment, ensuring better knowledge retention. The benefit from AR is the ability to reduce errors and enhance safety.

AR as a strategic asset

The integration of augmented reality into digital instruction, remote troubleshooting, and workforce training is reshaping industry operations by increasing efficiency, minimizing downtime, and improving workforce capabilities. By embracing AR technology, organizations are not only improving operational processes but also setting a new standard for workforce development and innovation.

NewCo's Use of VR and AR

At NewCo, the cross-functional team received the AR and VR input well and completed it with further sources and case studies [8]. The cross-functional team is tasked with developing optimal training formats for key users (Table 3). The learning organization provides knowledge on VR and AR technology. The on-site SMEs specify the targeted training content, and the business leadership ensures strategic alignment and budget commitment.

In step 5, NewCo developed a solid roadmap for addressing identified skill gaps. Applying modern learning technologies is quickly established and facilitated by systematic argumentation and the cross-functional team setup.

STEP 6: SKILL SOURCING AND DEVELOPMENT

As developed in the roadmap in step 5, applying advanced Pharma 4.0™ learning technologies such as VR and AR support efficiently closing the identified skill gaps. The skill development portfolio is systematically addressed. With a combination of internal and external support, the workforce is successfully qualified in time with facility construction.

STEP 7: ONGOING EVALUATION AND LEARNING ORGANIZATION

Driven by project demands, NewCo adopted a systematic approach to skill management and explored VR and AR technologies. To ensure lasting impact, NewCo integrated the gained insights in their programs on knowledge management (KM) and organizational change management (OCM). KM is an area of practice that encompasses the capture, curation, and dissemination of information and knowledge (not data) that can then be turned into action (learning or a task). This is key when considering identification and strategic implementation of skills management in the Pharma 4.0™ environment. The practice of KM—in the spirit of information and knowledge findability and availability—also can be supported by large language models (LLMs) and AI to better enable search and create insights. The practice of KM is typically very human centric and has strong ties to OCM, communication, and culture [9].

OCM and KM lay the foundation for mindsets and culture. Key considerations for a mindset and culture of adaptability include continuous learning, adaptability, and reskilling and upskilling. Continuous learning requires embracing continuous learning to keep pace with rapid technological advancements. Adaptability must be developed so teams and processes can adjust to changing roles and responsibilities in the Pharma 4.0™ landscape. Reskilling and upskilling both encourage proactively seeking opportunities for training to stay relevant in the evolving job market.

KM, digital communication and collaboration tools, and skills development are closely interconnected. Examples include:

- Digital platforms: Gaining proficiency in tools that support digital communication and collaboration in connected environments.
- Remote collaboration: Developing skills for remote collaboration across distributed manufacturing sites.
- Information sharing: Using digital tools to share information and knowledge efficiently across the manufacturing ecosystem

Table 3: Virtual reality and augmented reality training formats, users, and limitations

Training Aspect	Virtual Reality	Augmented Reality
Best Training Formats	Guided on-the-job training: Real-world overlays for step-by-step guidance	Cleanroom and machinery simulations: Immersive sterile environment training with virtual replicas of equipment for practice
	Real-time troubleshooting and maintenance: Hands-free visual instructions for equipment servicing, with potential guidance by remote experts	Emergency response and hazard training: Simulated chemical spills, airflow disruptions, etc.
Best-Suited Users	Line operators and technicians: Hands-free access to procedural steps	New employees and trainees: Safe, immersive learning environment
	Maintenance and engineering teams: Faster troubleshooting with digital overlays	Cleanroom operators: Virtual gowning and contamination control practice
		Emergency response teams: High-risk scenario training
Limitations	Less effective for theoretical training: Not ideal for GMP principles or compliance courses	Not ideal for on-the-job training: Disconnected from real-world machines
	Lacks physical dexterity training: Limited tactile feedback for manual skills	Setup time and motion sickness risks: VR sessions require preparation and adaptation
	Limited use in controlled environments: AR headsets may not be allowed in sterile zones	Impractical for quick refreshers: Setting up VR is time intensive for short sessions

After successful plant completion, NewCo integrates strategic skill management at the corporate level. Further projects will apply similar concepts, and the skill management application is planned to be rolled out across the organization. Skill management is then integrated into the OCM and KM concepts of the organization to enable systematic and data-driven management of current and future skills.

CONCLUSION

The article describes how NewCo applies strategic skill management to enable timely skill development within a project, utilizing modern AR and VR learning methods. It demonstrates how an interdisciplinary team and an integrated, holistic approach to skill management facilitate the adoption of new learning technologies and data-driven decision-making. Organizations can leverage these approaches to address the complexities of Pharma 4.0™ transformation while appropriately considering workforce needs. 

Acknowledgments

The authors thank Takeda for sharing insights on their VR and AR activities.

References

1. Baumgartner, G. "This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer." Bioprocess Online. 14 August 2024. www.bioprocessonline.com/doc/this-takeda-official-thinks-pharma-won-t-be-optional-much-longer-0001
2. Minero T., and L. Kuger. "The 7th ISPE Pharma 4.0™ Survey: Digital Transformation." *Pharmaceutical Engineering®* (September/October 2024). <https://ispe.org/pharmaceutical-engineering/september-october-2024/7th-ispe-pharma-40tm-survey-digital>
3. Baines, D., L. S. Nørgaard, Z.-U.-D. Babar, and C. Rossing. "The Fourth Industrial Revolution: Will It Change Pharmacy Practice?" *Research in Social and Administrative Pharmacy* 16, no. 9 (2021):1279–81. doi:10.1016/j.sapharm.2019.04.003
4. Reinhardt, K. *Digital Transformation of the Organization: Fundamentals, Practices, and Case Studies of Digital Business Development*. Springer Gabler, 2020. doi:10.1007/978-3-658-28630-9
5. Zauner V., K. Reinhardt, Y. Duckworth, and P. Kane. "A Skill Management Framework for a Pharma 4.0™ Workforce." *Pharmaceutical Engineering®* (February/March 2025). <https://ispe.org/pharmaceutical-engineering/march-april-2025/skill-management-framework-pharma-40tm-workforce>
6. International Society for Pharmaceutical Engineering. "Pharma 4.0™." ISPE.org. <https://ispe.org/initiatives/pharma-4.0>
7. Kaltenrieder, B., M. K. Peter, and K. Reinhardt. *Digital Competitive Advantages in Practice: How to Successfully Plan, Implement, and Anchor Digital Strategies*. Stuttgart: Schäffer-Poeschel. 2024. doi:10.34156/978-3-7910-6062-0
8. International Society for Pharmaceutical Engineering. *ISPE Baseline Guide Vol. 8: Pharma 4.0*, 1st ed. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2023.
9. International Society for Pharmaceutical Engineering. *Knowledge Management in the Pharmaceutical Industry*, 1st ed., International Society for Pharmaceutical Engineering, 2021.

About the authors

Vinzenz Zauner, MSc, is a Consultant focused on digital transformation and business process management. He gained experience in bioprocess analytical technology with stations at Knick Elektronische Messgeräte GmbH & Co. KG, Joint Lab Bioelectronics at TU Berlin, and the Research Group for Bioprocess Technology at TU Vienna. He holds an MSc in biotechnology and an MSc in innovation management, entrepreneurship, and sustainability. Vinzenz has served on numerous ISPE committees. He joined ISPE in 2019.

Kai Reinhardt, PhD, is a Professor of Business Administration at HTW Berlin. He specializes in digital transformation, strategic human resources, and competence management. His research includes collaborations with leading corporations. Kai's extensive background in strategic roles at top firms like eBay, Vodafone, and Jenoptik enriches his academic contributions. He directs the master's program in labor and personnel management at HTW Berlin and has authored influential books, including *Digital Transformation of Organizations* and *Competence Management in Practice*.

Yvonne Duckworth, PE, MBA, is a Fellow in Digital Technology at CRB, where she provides automation and digitalization strategic consulting, identifying clients' facility pain points, and determining how digital technologies can address them. She is a registered automation engineer with 33 years of technical design and project leadership experience within the pharmaceutical and biotechnology industries. Yvonne is a world-renowned speaker and subject matter expert on Pharma 4.0™. She serves on multiple ISPE committees and task teams. She joined ISPE in 1993.

Paige Kane, PhD, MSD, CPIP, is an industry leader with over 30 years of experience, including with the Genetics Institute, Wyeth, Pfizer, Merck, and the US government. She has led quality systems groups focusing on automation compliance, data integrity, computer validation, and change control during startup and operations for biologics facilities in the US and Ireland. She frequently contributes to ISPE Guidance Documents, is an industry author and presenter, and continues her research as a member of the TU Dublin Pharmaceutical Regulatory Sciences Team. She joined ISPE in 2000.

Linda Wildling, PhD, is Head of Intelligent Automation and Quality Engineering at Takeda, where she leads digital transformation, including Takeda's VR cleanroom operator training program. Since 2011, she has held various roles at Takeda in quality, production, and digital. Her work integrates emerging technologies like extended reality, AI, and Industry 4.0 to advance manufacturing, compliance, and quality in the pharmaceutical industry. She completed postdoctoral research in biophysics at Johannes Kepler University Linz.



LEARN MORE SAVE MORE

Buy one Online Live or In-Person training course and get the second **50% off** with code **TRBOGO2025**.

Restrictions apply

ENROLL NOW



APPLYING PROCESS DATA MAPPING METHODOLOGY

for Systematic and Sustainable Transformation Toward Pharma 4.0™

By Emmie Heeren, Frank Krüger, PhD, Venkateshwar Rao Nalluri, PhD, Sebastian Niederhauser, Alexandros Papadopoulos, Dirk Wollaert, and Vinzenz Zauner

Pharma 4.0™ is a reference framework tailored to the pharmaceutical industry, guiding its digital transformation. Although many of today's processes generate sufficient data to enable advanced use cases, structured guidance for transformation is often lacking. To address this, the ISPE Pharma 4.0™ Subcommittee on Process Data Maps and Critical Thinking has introduced an approach to help organizations develop a holistic perspective on transformation.

This article presents a case study that explores the application of this framework, highlighting key aspects that support the adoption of the methodology and accelerate industry-wide transformation.

The case study outlines the steps involved in process mapping, creating process data maps, applying critical thinking, and optimizing data flow. By offering a tangible example, it demonstrates how organizations can shift from a process-oriented to a data-centric perspective. This shift supports multiple Pharma 4.0™ principles, including enhanced data integrity and governance, and lays a stronger foundation for quality by design, risk-based approaches, control strategies, and ultimately, validation.

SYNOPSIS

This article presents a practical case study demonstrating the application of the process data mapping framework for structured

transformation. It illustrates the shift from a process-oriented to a data-centric approach to support Pharma 4.0™ principles and enhance data integrity and governance.

BACKGROUND

Pharma 4.0™ is a reference framework designed to guide the pharmaceutical industry through digital transformation. Since its introduction in 2015, Pharma 4.0™ has seen growing adoption, with key industry leaders describing it as an imperative rather than a competitive advantage [1–3]. Digital maturity and data integrity by design are the two key enablers of the Pharma 4.0™ operating model (see Figure 1) [4, 5].

Pharmaceutical industry stakeholders need to digitalize their processes to leverage Pharma 4.0™ benefits such as increased agility, efficiency, flexibility, and quality of their production processes. Although many of today's processes provide sufficient data to enable advanced use cases, structured guidance for transformation is often missing. The current industrial stage traditionally centers around

Figure 1: Pharma 4.0™ operating model [6]





Figure 2: ISA-95 model [8]



the ISA-95 model for digital systems with processes-centricity at its core [7] (see Figure 2).

With individual, predefined use cases in mind, data flows have been tailored so that generated data is fed through a series of defined connections up to the business solution level. In comparison, Pharma 4.0™ envisions a data-centric architecture of tightly entangled processes and supporting systems where digitalization empowers better decision-making through promoting concepts such as original data, which is used as a single source of truth [9]. To implement Pharma 4.0™ to its full extent, data itself needs to be understood as an asset. Changing to this data-centric viewpoint has not only been linked to substantial improvements in data governance and data integrity, but it also serves as a sustainable basis for next-generation operating models [10, 11].

PURPOSE

ISPE's Pharma 4.0™ Community of Practice (CoP) Process Data Maps and Critical Thinking subcommittee previously published how Reference Architecture Model Industry 4.0 (RAMI 4.0), process maps, data flows, and critical thinking can be leveraged for structured transformation [12]. A four-step approach was presented to let organizations develop a perspective on holistic transformation toward Pharma 4.0™. First, the current process-oriented state is documented. Second, it is transformed into a data-centric view. Third, the data-centric view enables critical thinking, which helps envision a target state. In the fourth and final step, the target state is implemented.

While the general concept of the approach was given in a previous article, this publication focuses on providing a tangible case study. Important aspects during application of the framework are discussed. The aim is to provide relatable guidance to ease adoption of the methodology and therefore accelerate the industry transformation towards Pharma 4.0™.

This case study dives into how companies manage access—think cleanrooms or digital systems—using structured workflows. It's all about mapping out each step clearly, from request to approval, to stay compliant and efficient. These process maps are the first building blocks for smart digital transformation.

MAIN PART: CASE STUDY FOR STRUCTURED TRANSFORMATION

Step 1: Process Maps

In this case study, an access request process is reviewed. This or similar processes have become standard in the industry to manage access permissions to regulated information or environments such as user groups in digital systems, role changes within the company, or key-card access to restricted areas like cleanrooms in production. Process users typically follow a standard workflow, starting with submitting the request for access, adapting the training plan (i.e., training on relevant SOPs), implementing the requested permissions in the target system, verifying permissions

The case study analyzes the process for two key Pharma 4.0™ concepts: single source of truth and data as a strategic asset.

with a second person, and, finally, informing the required personnel of the request's outcome (see Figure 3).

For compliant operation in GxP-relevant systems, workflows such as these must be clearly defined in related SOPs. Beyond compliance, efficient operations are driven by such harmonized workflows. The systemic documentation of business processes is foundational to the application of the presented methodology and might already be present within an organization. Only a few companies will have their current process maps on the level of detail that is required for digital transformation.

Companies can start from their individual level and go into detailing selected processes in scope of their digital transformation initiative. Detailed documentation may also result as a byproduct from root cause analysis after findings from internal or external reviewers. It is important to systematically channel information in an overarching process management documentation governance. Detailed literature and insights on process identification, types of notations, and management can be found under the term business process management (BPM).

To begin the systematic Pharma 4.0™ transformation, the process map is complemented by the occurring data sets. Here, a data set is defined as a conceptual view of a data record, independent of its form [9]. Data sets are needed as input for a process step or decision, and as output to record the outcome.

Figure 4 shows the outcome of the data mapping. Four different data sets are identified in the process: change request, training plan, user application access, and screen capture. At each step, the specific data life cycle stage is assessed. The GAMP® structure of the data life cycle is used as a basis, which consists of five different phases: creation, processing, review, reporting and use, retention and retrieval, and destruction [13]. Each identified data set is placed in its appropriate lane of the data life cycle. If a data set is created, it is placed in the creation lane. If a data set is processed in a subsequent step, it is placed in the processing lane, and so on until all process steps have been analyzed.

Specifying processes and mapping data sets according to their data life cycle concludes the first step in the four-step approach. It serves as the foundation for describing the operational details and is potentially already available to some extent.

Step 2: Process Data Maps

The result of the first step yields the existing data sets within one process. If the viewpoint is limited to this one process, one could already start suggesting improvements. However, the identified data sets are likely also used in other processes within the organization. Focusing on the training plan data set, human resources (HR) processes, such as onboarding, offboarding, and periodic reviews, also interact with this data set. After all interacting processes are identified, a holistic overview of the interactions of the training plan is achieved.

To adequately transform a business process of an organization, it is unavoidable to holistically identify each data set and connect it to its process steps in every process. By doing so, an individual process transformation often requires inspecting multiple processes from the data set's point of view. Various software solutions offer building such connected landscapes and inventories. More information on application and data management can be found under the term enterprise architecture management (EAM).

Figure 5 shows the completed mapping for the data set training plan. The connection between the processes through the data set is shown, including the respective data life cycle stages. For the upcoming transformation, it is required to identify where, and in which format, the data set is stored. This is done with reference to the related computerized system or other types of storage.

Next, the process steps are rearranged from a process-oriented to data-oriented view along the data life cycle. This visualizes where data is created, processed, reviewed, reported, used, retained, retrieved, and destroyed. Figure 6 shows this view on the data set training plan.

This holistic data-oriented view along the data life cycle phases concludes the second step in the four-step approach. With this step, the data set is put in the focus and reveals its usage across multiple processes. This perspective is often novel to an organization. The sorting across the data life cycle provides the foundation to identify optimization potentials.

Step 3: Critical Thinking

The *ISPE GAMP® Guide: Records and Data Integrity* defines critical thinking as “a systematic, rational, and disciplined process of evaluating information from a variety of perspectives to yield a balanced and well-reasoned answer” [13].

During critical review of the process, multiple questions arise naturally, such as, why is the training plan created twice within the onboarding, once in paper form training plan form and once in digital form in the learning management system? And when following the life cycle phases, how do the paper-based training plan forms get destroyed when no destruction process is defined? During the critical thinking step, each phase is analyzed to determine if the activity occurs in the appropriate process step, the right storage is used, and there is no redundancy.

A more in-depth insight into critical thinking is given in *ISPE GAMP® 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)* [14]. It should be noted that the business

process review (BPR) should not be limited to the current way of working. Instead of incremental optimizations, the process data map should provide a basis from which a strategic objective could be derived and how the process might look in the near or distant future. Depending on the level of complexity, it can prove useful to include internal and external subject matter experts and to analyze related processes in different industries.

During the critical thinking step, it is imperative to not limit creativity. It is important to stress that the details of this long-term objective do not need to be clear yet. In fact, omitting details facilitates the process. Potential solutions might be discovered outside the scope of currently considered technical solutions. As one example, today's artificial intelligence (AI)-powered virtual assistants seemed far-fetched in 2009.

In the case study, the focus is set on analyzing the process for two key concepts of Pharma 4.0™: single source of truth and data as an asset. Application of the first concept concludes in removing redundancies and avoiding the training data being created in both a paper-based format and an electronic format. To achieve the usage of data as an asset itself, the current process's data sets are mapped on the RAMI architecture (see Figure 7).

The RAMI model was developed as a general design tool for Industry 4.0 processes. The four-step approach applies it as an analysis tool to assess the level of integration of data sets [12]. In this representation, a classification on the asset layer means that the availability of the data is limited to the asset itself where it was generated with no automatic integrations to other systems. An entry on the integration layer on the other hand signifies that a digital representation of the data is available. By such integration, physical assets are made available to the other layers in the form of an administrative shell.

The communication layer represents the method of communication at the underlying use cases, services or any other function or data models. Communication methods can include physical systems like wired connections, data links (wireless connections), networks (like internet protocols), or applications. Including the communication layer onto every data set exceeds practicality. A detailed description of each layer in context of the four-step approach is provided in, "Methodology to Define a Pharma 4.0™ Roadmap" by Heeren et al. (*Pharmaceutical Engineering*, May/June 2023) [12]. Critical thinking and holistic identification of transformation potentials with the support of RAMI concludes the third step in the four-step approach. This step is the core for digital transformation of the processes in perspective of the data life cycle.

Step 4: Optimized Data Flow

In the final step of the four-step approach, the identified solutions are implemented to enhance data flow. This transformation project requires following clear regulatory documentation requirements, especially if GxP-relevant processes are impacted. ISPE guidelines are available for further information on effective project management [15]. To optimize the training plan data set, the outdated training plan form storage is eliminated and directly integrated

Pharma 4.0™ isn't a sprint— it's smart, steady, data-driven evolution.

into the learning management system for creating, reviewing, and approving training plans, as well as for recording the training outcome. This not only enhances the integrity of the data set and thus improves regulatory compliance, but also simplifies the process for the user by not having to deal with more than one record.

Transferring the creation and approval of training plans from the access request process to an HR-specific process further streamlines operations. This simplifies maintenance and designates a single function for this critical aspect. The strategic redesign results in a more consistent data life cycle for the training plan. It is now elevated to the information layer, serving as a single source of truth without relying on system-specific interfaces (Figure 8). The integration of this data set and the resulting data availability allow for further improvements of the overall access management process. Further data sets and transformation can be addressed by the next iteration of the four-step approach. The data-centric optimization concludes the fourth and final step in the four-step approach.

CONCLUSION

As the pharmaceutical industry continues to evolve, adopting Pharma 4.0™ principles will not only enhance data governance and integrity but also position companies for success. Optimizing processes toward Pharma 4.0™ is an iterative and continuous endeavor. The journey toward optimized data flows requires commitment, adaptability, innovation, and holistic contemplation. As organizations embrace change, they position themselves for sustained success in an environment where data is a strategic asset, and its seamless integration is key to achieving business goals.

Transformation necessitates a reevaluation of both process and data flows. Here, using the RAMI model as an analysis tool ensures alignment with industry standards, fostering a seamless flow of data across different layers. It facilitates a bottom-up approach to transformation, moving from the asset layer toward the business layer. The RAMI representation aims to create an administrative shell that facilitates seamless communication with integrated systems, databases, and applications. Once all processes align with the "single source of truth" principle, the business layer is examined from a bidirectional view. This defines how layers integrate to achieve overarching business objectives.

In the presented case study, the applied four-step approach revealed inefficiencies and redundant data storage and facilitated

critical thinking. This case study provides a systematic framework to map, analyze, and optimize processes and serves as the bridge between current practices and long-term objectives, steering organizations toward a future-ready state. 

Acknowledgments

This article is a joint effort from multiple members of ISPE's Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee. In addition, we want to acknowledge and thank Volker Röder for his engagement in the development of the framework and chairing subcommittee.

References

1. Baumgartner, G. (Interviewee). "This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer." 14 August 2024. www.biosimilardevelopment.com/doc/this-takeda-official-thinks-pharma-won-t-be-optional-much-longer-0001
2. Canzoneri, M., J. Trapl, W. Winter, C. Woelbeling, and T. Zimmer. Pharma's Digital Transformation. "Lessons Learned from ISPE's Pharma 4.0™ Baseline® Guide." 11 September 2024. <https://ispe.org/news/lessons-learned-ispe-pharma-40tm-baseline-guide>
3. Minero, T., and L. Kuger. "The 7th ISPE Pharma 4.0™ Survey: Digital Transformation." *Pharmaceutical Engineering* 44, no. 5 (September/October 2024):. <https://ispe.org/pharmaceutical-engineering/september-october-2024/7th-ispe-pharma-40tm-survey-digital>
4. International Society for Pharmaceutical Engineering. "Pharma 4.0™." 2015. <https://ispe.org/initiatives/pharma-4.0>
5. Arden, N. S., A. C. Fisher, K. Tyner, L. X. Yu, S. L. Lee, and M. Kopcha. "Industry 4.0 for Pharmaceutical Manufacturing: Preparing for the Smart Factories of the Future." *International Journal of Pharmaceutics* 602 (June 2021). doi:10.1016/j.ijpharm.2021.120554
6. International Society for Pharmaceutical Engineering. "Pharma 4.0™." 11 October 2024. <https://ispe.org/initiatives/pharma-4.0>

7. ISO Standard IEC 62264-1:2013. "Enterprise-Control System Integration." May 2013. www.iso.org/standard/57308.html
8. International Society of Automation. "ISA-95 Series of Standards: Enterprise-Control System Integration." www.isa.org/standards-and-publications/isa-standards/isa-95-standard
9. International Society for Pharmaceutical Engineering. *ISPE Baseline® Guide Vol 8: Pharma 4.0™, 1st ed.* North Bethesda, MD: International Society for Pharmaceutical Engineering, 2023.
10. McKinsey and Company. "A New Operating Model for Pharma: How the Pandemic Has Influenced Priorities." 21 December 2021. www.mckinsey.com/industries/life-sciences/our-insights/a-new-operating-model-for-pharma-how-the-pandemic-has-influenced-priorities
11. Alosert, H., J. Savery, J. Rheume, M. Cheeks, R. Turner, C. Spencer, et al. "Data Integrity Within the Biopharmaceutical Sector in the Era of Industry 4.0." *Biotechnology Journal* (2022). doi:10.1016/j.coche.2021.100758.
12. Heeren, E., A. J. Wassink, V. R. Nalluri, and S. Niederhauser, "Methodology to Define a Pharma 4.0™ Roadmap." *Pharmaceutical Engineering* (May/June 2023). <https://ispe.org/pharmaceutical-engineering/may-june-2023/methodology-define-pharma-40tm-roadmap>
13. International Society for Pharmaceutical Engineering. *ISPE GAMP® Guide: Records and Data Integrity*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2017.
14. International Society for Pharmaceutical Engineering. *ISPE GAMP® 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2022.
15. International Society for Pharmaceutical Engineering. *ISPE Good Practice Guide: Project Management for the Pharmaceutical Industry*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2011.

About the author

Emmie Heeren is a Senior Manager with Kite Pharma, a company connecting business goals with advanced technology, and she has been involved in international digitalization processes for most of her career. For many years she chaired the Pharma 4.0™ CoP Data Integrity by Design subcommittee. Recently she was involved as co-founder of the local Dutch ISPE Pharma 4.0™ CoP. She joined ISPE in 2020.

Frank Krüger, PhD, is Senior Digital Business Process Specialist in the CMC development of the Healthcare Business of Merck KGaA, Darmstadt, Germany. He holds a PhD in information science from the University Saarbrücken and has more than 25 years of experience in computerized system validation and data integrity at both pharmaceutical manufacturers and suppliers. He is a founding member of the ISPE Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee. He joined ISPE in 2009.

Venkateshwar Rao Nalluri, PhD, is Senior Scientist at Janssen Cilag AG in Schaffhausen, Switzerland. He has 14 years of experience in the pharmaceutical industry in biologics manufacturing. He received his BPharm from BITS-Pilani, India, and his PhD from University of Basel, Switzerland. He is an active contributor to the Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee. He has been an ISPE member since 2017.

Sebastian Niederhauser is the Branch Manager and Authorized Officer at cts GmbH in Vienna. He has more than 20 years of experience in the pharmaceutical industry. His main focus is in process automation, ranging from field instrumentation up to DCS, batch, and historian systems. He holds a degree in electrical engineering. He joined the ISPE Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee in 2018.

Alexandros Papadopoulos is the Operational Technology Manager at Viralgen in San Sebastián, Spain. He is focused on optimizing operations through a holistic, systems-driven approach. He joined the Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee in 2022 to further contribute to the field. He holds a master's degree in biochemical engineering from the Karlsruhe Institute of Technology in Germany. He has been an active member of ISPE since 2017.

Dirk Wollaert is a member of the Siemens competent center for pharma and life sciences. He is a board member for the ISPE Belgium Affiliate, co-authored the ISPE Baseline® Guide: Pharma 4.0™, and is an active contributor to the Pharma 4.0™ CoP Process Data Mapping and Critical Thinking subcommittee. He has a master's degree in computer science and a graduate degree in business management. He joined ISPE in 2021.

Vinzenz Zauner is a Consultant focused on systematic digital transformation with business process management and enterprise architecture management. He has served as the Emerging Leaders Chair of the ISPE Pharma 4.0™ CoP Steering Committee since 2022 and as an Emerging Leader Representative for conferences and hackathons. He is a member of the editorial board for Pharmaceutical Engineering. He holds an MSc in biotechnology and an MSc in innovation management, entrepreneurship, and sustainability. He joined ISPE in 2019.

THANK YOU TO OUR CORPORATE PARTNERS



Through the ISPE Corporate Partnership program, these companies have committed to supporting and contributing to ISPE's mission within the pharmaceutical industry.

PLATINUM

Kneat **SteelcoBelimed**

GOLD



SILVER



[ISPE.org/Corporate-Partners](https://ispe.org/Corporate-Partners)

ADOPTION AND IMPLEMENTATION of Innovative Technologies in CMC

By Robert Dream, CPIP


The often-overlooked function of chemistry, manufacturing, and controls (CMC) holds tremendous potential to reshape the landscape of drug development. By embracing innovation and rethinking traditional approaches, CMC has the rare opportunity to drive transformative changes that could significantly accelerate the journey from initial concept to a fully realized therapy. This offers the possibility of faster drug availability, lower costs, and more efficient development pathways.

CMC is a critical multidisciplinary function in the biopharmaceutical industry. It plays an indispensable role in the successful development of every drug by establishing the

processes and methods required to produce safe, effective, and high-quality medicines. Although it often operates in the background, CMC's impact on drug development cannot be overstated. It is responsible for several key advances in the field, including the development of new biopharmaceutical technologies, optimizing drug delivery systems, managing costs, increasing patient adherence, and ensuring broader access to treatment, particularly for underserved populations.

Despite its importance, CMC has historically been overshadowed by clinical development, which tends to dominate the focus of drug development teams and funding. However, recent trends show a shift, with CMC leaders beginning to recognize the power of innovative technologies like advanced analytics, data science, digitalization, and automation. These advancements hold the promise of significant improvements in the efficiency and effectiveness of CMC operations. Yet, although there has been progress, the function has a long way to go before fully embracing these modern tools and systems.

Figure 1: Module 3 of an IND application describes CMC.



Legacy processes, siloed data, unstructured information, and a lack of standardized systems continue to impede the full realization of CMC's potential.

The challenge is particularly evident when attempting to integrate novel equipment, systems, and data management solutions needed for research and development and preclinical and clinical production. Meeting the rigorous data requirements for CMC, Investigational New Drug (IND) applications, and clinical lot production (see Figure 1) often demands advanced capabilities that many organizations are still striving to implement effectively.

DEMANDS FOR ADVANCED CAPABILITIES IN CMC FOR BIOLOGICS

The development and commercialization of biologic drugs involve intricate and specialized processes that demand a high level of expertise, precision, and consistency. The CMC phase of biologic drug development is a critical component that ensures the safety, quality, and efficacy of biologics. As the biologics landscape continues to evolve, the need for advanced capabilities in CMC has become more pronounced. These advancements are necessary to address the growing complexity of biologic therapies, streamline manufacturing processes, and meet rigorous regulatory standards.

COMPLEXITY OF BIOLOGIC PRODUCTS

Biologic drugs, such as monoclonal antibodies, gene therapies, and recombinant proteins, are large, complex molecules derived from living organisms. Unlike small molecule drugs, biologics are subject to considerable variability due to differences in production processes, the cells used for manufacturing, and the inherent complexity of their structures. This complexity introduces several challenges:

- **Product heterogeneity:** Biologics are often heterogeneous, meaning they can exist in multiple forms with slightly different molecular profiles. Ensuring uniformity across batches is a key challenge.
- **Manufacturing variability:** Biologics are typically produced in living cells, and variations in cell culture conditions, expression systems, and downstream processing can impact the final product's quality.
- **Regulatory complexity:** Regulatory authorities require extensive documentation and data to ensure biologics' quality, consistency, and safety. This requires robust systems for tracking every stage of development and manufacturing.

As a result, biologic drug development requires advanced capabilities to address these complexities and ensure that the product is both safe and effective.

ADVANCED CAPABILITIES IN CMC FOR BIOLOGICS

To meet the demands of biologic drug development, the CMC phase must incorporate a range of advanced capabilities, including innovative technologies, innovative processes, and a deep understanding of biologic behavior.

Improved Analytical Techniques

The need for sophisticated analytical methods to characterize biologics is critical during the CMC phase. Advanced capabilities in analytical technologies are essential for ensuring product quality and consistency across production batches. Key analytical techniques include mass spectrometry (MS), chromatography, and cryo-electron microscopy (cryo-EM).

Advanced MS techniques, such as high-resolution MS and ion mobility spectrometry, allow for detailed characterization of biologics, including the identification of post-translational modifications, glycosylation patterns, and higher-order structure. High-performance liquid chromatography (HPLC) and other chromatographic techniques are integral for the separation and purification of biologics, ensuring product purity and identifying isoforms or impurities that might affect therapeutic efficacy. Cryo-EM enables the direct visualization of biologic molecules at high resolution, providing detailed insights into their structural integrity and functionality.

Cell Line Development and Optimization

The cell line used for the production of biologics is one of the most critical factors in ensuring a consistent and high-quality product. Advances in cell line development and optimization are necessary to improve yields and reduce variability. Techniques include Chinese hamster ovary (CHO) cell line engineering and genome editing technologies (e.g., CRISPR-Cas9).

CHO cells are commonly used for the production of therapeutic proteins. Optimizing these cells through genetic engineering and culture condition optimization can lead to improved product yields and quality. Genome editing enables the creation of stable cell lines with enhanced productivity and improved quality attributes, making the process more efficient and scalable.

Advanced Bioreactor Design and Control Systems

Bioreactors are essential for growing cells at a large scale and producing biologics. Advanced bioreactor technologies enable more precise control of the culture environment, leading to higher yields and better product quality. These advancements include single-use bioreactors and real-time process monitoring. Single-use bioreactors have gained popularity due to their flexibility, reduced risk of cross-contamination, and ease of scalability. They are particularly useful for smaller-scale production and for clinical trials. For process monitoring, modern control systems with real-time monitoring capabilities allow for better control over variables such as pH, temperature, and dissolved oxygen, helping optimize cell growth and product quality.

Process Analytical Technology (PAT)

PAT is a critical approach for monitoring and controlling the manufacturing process of biologics in real time. By integrating advanced sensors, data analytics, and automation, PAT enables real-time quality control and increased process understanding. PAT allows for continuous monitoring of critical quality attributes

(CQAs) and process parameters, ensuring that the biologic product remains within desired specifications throughout production. And by collecting and analyzing large datasets, PAT helps deepen the understanding of the manufacturing process, allowing for better predictions and process optimizations.

Quality by Design (QbD) Approach

The QbD approach emphasizes the proactive design of a manufacturing process to ensure product quality from the start. This approach incorporates several advanced capabilities. Risk-based analysis identifies potential risks early in the process, allowing for better management of variables that could affect product quality. Process optimization uses data-driven approaches, such as design of experiments (DOE), to optimize the production process and ensure consistent quality. Implementing robust control strategies helps mitigate risks and maintain product consistency during scale-up and commercial manufacturing.

Supply Chain and Logistics Innovations

The global nature of biologic drug development requires highly efficient and reliable supply chain and logistics capabilities. New developments in the supply chain include:

- **Cold Chain Management:** Biologics often require stringent temperature controls to maintain their stability. Advances in cold chain logistics, such as real-time temperature monitoring and advanced packaging solutions, ensure that biologics remain viable throughout transportation and storage.
- **Supply Chain Digitization:** Digital platforms and blockchain technology can be used to track and trace biologic products throughout the supply chain, improving transparency, reducing errors, and ensuring compliance with regulatory requirements.

Regulatory Demands and Compliance

The increasing complexity of biologic products has led to more stringent regulatory demands in the CMC phase. Regulatory bodies, such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), require comprehensive documentation and data to ensure that biologics meet safety, efficacy, and quality standards. Meeting these demands requires advanced CMC capabilities in:

- **Data integrity and documentation:** With increasing regulatory scrutiny, it is vital to maintain rigorous documentation and ensure data integrity at every stage of the CMC process.
- **Adaptive manufacturing processes:** Regulatory agencies are increasingly open to more flexible, adaptive manufacturing processes, provided that the product quality is maintained. This requires the implementation of real-time monitoring, predictive modeling, and robust quality control systems.
- **Global harmonization:** Regulatory requirements vary across regions, and biologic manufacturers must navigate these differences to ensure international market access. Advanced regulatory knowledge and the ability to design processes that can meet multiple regulatory standards are essential.

ENHANCING ANALYTICAL METHODS IN BIOLOGICS

The development and commercialization of biologic drugs have revolutionized modern medicine, offering treatments for a wide range of diseases, including cancer, autoimmune disorders, and rare genetic conditions. However, the complexity of biologics—biopharmaceutical products such as monoclonal antibodies, gene therapies, and recombinant proteins—presents significant challenges in their characterization, quality control, and regulatory approval. Therefore, enhancing analytical methods used to assess biologics is crucial to ensuring their safety, efficacy, and consistency.

Current Challenges in Biologic Drug Development

Biologics differ from small molecule drugs in that they are large, complex molecules derived from living cells. Their structure, post-translational modifications, and function can be highly variable, making their analysis more challenging. The current challenges in biologic drug development include the following. Because biologics often exhibit variability due to the production process, differences in cell lines, and the nature of post-translational modifications, heterogeneity is a challenge. Stability is a concern because biologics can degrade over time. Stability is influenced by factors such as temperature, pH, and agitation. Immunogenicity must be considered because biologics may induce immune responses, potentially leading to adverse effects or loss of efficacy. Finally, regulatory compliance always is a consideration to ensure consistency across production batches and compliance with regulatory standards, which is critical for market approval.

Innovative Analytical Methods

To address these challenges, the following innovative analytical methods are being explored and implemented in the biologics field.

Advanced MS

MS has become a cornerstone technique for the characterization of biologics. Recent advancements in MS technology, such as high-resolution MS and ion mobility spectrometry, provide enhanced sensitivity and the ability to analyze complex biologic samples with greater accuracy. These methods allow for:

- **Detailed characterization:** MS is capable of determining the primary structure, post-translational modifications, and sequence of proteins, which is essential for understanding biologic activity.
- **Quantitative analysis:** MS can be used to quantify protein levels with high precision, ensuring the consistency of drug formulations.
- **Glycan profiling:** MS plays a critical role in analyzing glycosylation patterns, which are key to the functional activity and immunogenicity of biologics.

Chromatographic techniques

Chromatographic methods, such as HPLC and affinity chromatography, remain essential for the analysis and purification of biologics. Recent improvements in chromatographic technologies, like multidimensional chromatography, provide better resolution

and efficiency in separating complex biologic samples. These advancements aid in:

- **Purity assessment:** Ensuring the purity of biologics is vital for their safety and effectiveness.
- **Isoform characterization:** Differentiating between product variants that might influence efficacy and immunogenicity.
- **Accelerated development:** The application of modern chromatography techniques enables faster and more reliable screening of biologic candidates during development.

Structural biology and cryo-EM

Cryo-EM has emerged as a groundbreaking technique for visualizing the three-dimensional structures of large biomolecules, such as antibodies and viral particles, without the need for crystallization. This technique has significantly enhanced our ability to:

- **Visualize molecular structures:** Detailed three-dimensional images of biologics provide insights into their structural integrity, which is critical for understanding their function and mechanism of action.
- **Monitor conformational changes:** Cryo-EM allows researchers to study conformational changes in biologic molecules that can impact their activity and stability.

Cell-based assays and bioanalytics

Cell-based assays and bioanalytical techniques are crucial for assessing the biological activity of therapeutics. Innovations in this area have led to more predictive, high-throughput assays that provide information on the potency, mechanism of action, and pharmacodynamics of biologics. The advancements include:

- **Cellular imaging:** Using advanced imaging technologies to study cellular interactions with biologic drugs in real time.
- **Reporter gene assays:** These assays can help in assessing the immunogenicity and potency of biologics by detecting specific responses in cells.
- **Biosensors:** New biosensor technologies can continuously monitor real-time biological responses, improving the accuracy and speed of testing.

Regulatory Implications and Standardization

As analytical methods evolve, regulatory agencies such as the FDA and EMA must adapt their standards to ensure biologics are rigorously evaluated for safety and efficacy. The following areas are crucial for enhancing regulatory processes:

- **Harmonization of analytical standards:** Collaborating internationally to standardize analytical methods and quality control protocols will streamline the approval process for biologics across markets.
- **Risk-based approaches:** Regulatory bodies are increasingly adopting risk-based approaches to ensure that new biologics meet safety and quality standards without overburdening development timelines.
- **Real-time monitoring:** Regulatory agencies are beginning to explore real-time monitoring technologies, which will allow for more flexible and adaptive quality control during manufacturing.

Future Directions

The future of biologic drug development lies in integrating new technologies and improving the efficiency of analytical methods. Some promising developments include:

- **Artificial Intelligence (AI) and machine learning (ML):** These technologies can help in data interpretation, predictive modeling, and identifying new biomarkers, thereby accelerating the development process.
- **Microfluidics and lab-on-a-chip technologies:** These innovations enable high-throughput and miniaturized testing systems that could revolutionize biologic drug development by providing more efficient, cost-effective analyses.
- **Advanced high-throughput screening:** More rapid and reliable screening platforms will help in identifying potential biologics with higher efficacy and fewer side effects.

Accelerating Time to Market

In an increasingly competitive biopharmaceutical landscape, accelerating time to market is not just a priority—it's a necessity. To remain relevant and maintain market share, companies must find ways to speed up the development process without compromising quality. Several strategies can be implemented to achieve this goal:

- **Optimize workflows:** Streamlining processes across the entire product life cycle—from design and development through production—can help identify and eliminate bottlenecks that slow progress.
- **Adopt agile methodologies:** Using agile development practices allows for iterative progress, making it easier to adapt to changes quickly, incorporate feedback, and speed up product delivery.
- **Leverage advanced technologies:** The integration of AI, ML, and automation into CMC operations can significantly reduce decision-making time, improve predictive capabilities, and help streamline development cycles.

By optimizing workflows, adopting agile strategies, and embracing cutting-edge technologies, companies can dramatically improve CMC efficiency. This, in turn, enhances competitiveness and enables organizations to meet market demands faster and more effectively.

Together, these innovations not only enhance CMC's overall performance but also reshape how the entire drug development process unfolds. By reimagining the role of CMC and leveraging advanced tools, the pharmaceutical industry can achieve faster, more efficient development cycles, delivering life-saving therapies to patients.

SETTING SPECIFICATIONS FOR BIOPHARMACEUTICALS

Setting specifications is a vital part of a comprehensive control strategy for ensuring the quality and consistency of biopharmaceutical products. Although specifications are fundamental for confirming product quality, they are just one piece of the larger strategy. Other components of this strategy include thorough product characterization during development, adherence to

GMPs, validated manufacturing processes, raw material testing, in-process testing, and stability assessments.

For specifications, therefore, it is important to focus primarily on key molecular and biological characteristics that are critical for ensuring the safety, efficacy, and overall quality of the drug product. However, specifications are not designed to fully characterize the product but to confirm that it aligns with required relevant and phase-appropriate standards at various stages of production and throughout its life cycle.

PHYSICOCHEMICAL PROPERTIES

Physicochemical characterization is an essential aspect of the product development process. This typically involves a thorough assessment of the composition, physical properties, and primary structure of the intended product. For many biologics, particularly proteins, understanding their higher-order structures is also important, as these structures are often directly linked to their biological activity.

A characteristic feature of biopharmaceutical products, particularly proteins, is their inherent structural heterogeneity. This heterogeneity arises due to the complexity of biological production processes, which often result in a mix of post-translationally modified forms, such as different glycoforms. These variations may be biologically active and, in many cases, do not negatively impact the safety or efficacy of the product. It is critical for manufacturers to define the acceptable pattern of this heterogeneity and demonstrate its consistency with the product used in preclinical and clinical trials.

If this pattern remains consistent across different production batches, it may not be necessary to evaluate each variant individually for its activity, safety, or immunogenicity. However, when process changes or degradation during storage introduce unexpected variations in the heterogeneity, these changes should be carefully evaluated for potential effects on the product's quality [8].

BIOLOGICAL ACTIVITY

The assessment of biological activity is crucial for confirming that a drug product performs as intended within the biological system. Biological activity refers to the product's specific ability to elicit a defined biological response, and it is typically quantified through biological assays. The manufacturer should select and validate appropriate assays, which can include:

- Animal-based assays, which measure the biological response in an organism exposed to the product
- Cell culture-based assays, which value biochemical or physiological changes at the cellular level
- Biochemical assays, which quantify biological activity through enzymatic reactions or immunological interactions

Potency, which quantifies biological activity in units, is distinct from the measurement of quantity, which is typically expressed in mass (e.g., protein content). In many cases, biological assays are essential to measure potency, especially for complex biological molecules. It is important to establish a correlation between the biological

activity observed in assays and the expected clinical response, either through pharmacodynamic studies or clinical trials.

Biological assays should ideally be calibrated against an international or national reference standard. If no such standard exists, the manufacturer must establish an in-house reference material. Although physicochemical methods can provide valuable information, they may not always fully confirm the higher-order structure. In such cases, a biological assay with acceptable confidence limits may be used, supplemented by physicochemical data for a more comprehensive evaluation [8].

PURITY

Determining the purity of a biopharmaceutical product is a complex task, as it involves distinguishing the active drug from various molecular entities or variants that may be present due to the biosynthetic processes used to produce the product. Purity assessments are performed using a combination of analytical methods to differentiate between the desired product and product-related substances or impurities.

When these molecular variants arise from anticipated post-translational modifications, they are considered part of the desired product and not impurities. However, when variants result from changes in the manufacturing process or degradation during storage, they must be carefully evaluated for their impact on the product's overall quality. The acceptance criteria for product-related substances should be based on their biological activity, safety, and efficacy profiles.

The challenge of purity testing is amplified by the unique nature of biotechnologically derived products. For instance, proteins produced in living systems may exhibit different forms (such as glycoforms or phosphorylated variants), which may still meet the required therapeutic standards. Establishing the level of acceptable purity involves assessing these variations and ensuring they do not adversely affect the therapeutic properties [8].

IMPURITIES

In addition to assessing the purity of the drug product, manufacturers must consider the presence of impurities. Impurities may be process-related (derived from the manufacturing process, such as host cell proteins or residual DNA) or product-related (e.g., degradation products or incomplete post-translational modifications). These impurities must be evaluated for their potential impact on product quality.

Impurities can be classified into known, partially characterized, or unidentified substances. Whenever possible, manufacturers should characterize these impurities and assess their potential biological activity. Acceptance criteria for impurities are typically based on data from preclinical and clinical studies, as well as manufacturing consistency lots.

Under certain circumstances, the need for specific impurity acceptance criteria may be waived, depending on the impurity's nature and its demonstrated lack of impact on product safety and efficacy [8].

CONTAMINANTS

Contaminants, which include adventitiously introduced substances like microbial species or chemical contaminants (such as microbial proteases), pose a significant risk to product safety. Contaminants must be strictly controlled and eliminated from the manufacturing process. In the case of adventitious viral or mycoplasma contamination, it is essential to follow specialized guidelines to evaluate and control these risks, as action limits are not applicable. Manufacturers should refer to ICH Harmonised Tripartite Guidelines to manage viral safety and contamination risks effectively [8].

QUANTITY

The quantity of active ingredients in a biopharmaceutical product is typically measured as protein content, which is critical for ensuring therapeutic efficacy. This quantity is usually determined using physicochemical assays. In some cases, a correlation may exist between the quantity and biological activity, allowing for the measurement of protein quantity rather than conducting full biological assays. This correlation may be particularly relevant during the production process, including steps such as filling and lot release [8].

IMMUNOCHEMICAL PROPERTIES

For biologic products such as monoclonal antibodies, immunochemical characterization is essential for establishing product identity, homogeneity, and purity. The binding affinity and specificity of the antibody for its target antigen should be thoroughly evaluated using binding assays. These assays can assess the affinity, avidity, and immunoreactivity, including potential cross-reactivity with other molecules [8].

For some products, immunochemical methods like enzyme-linked immunosorbent assay (ELISA) or Western blotting are used to identify and quantify specific epitopes or determine homogeneity. Immunochemical testing can also serve to ensure that the product meets release criteria for identity and purity. When immunochemical properties are part of lot release specifications, manufacturers must provide comprehensive data on the antibody's behavior and characteristics [8].

GAP ANALYSIS IN CMC

For decades, the structure of CMC organizations has remained relatively stable, with specialized groups managing laboratories and systems that focused on clearly defined small molecule and biologics platforms. This traditional model has served the industry well in the past, ensuring consistent quality and predictable timelines. However, in recent years, several industry trends have exposed limitations in this approach, highlighting the need for significant change.

THE NEED FOR CHANGE IN CMC

Several key factors are driving the evolution of the CMC operating model.

Faster Pace of Pharmaceutical Development

The increasing speed of pharmaceutical development is placing more pressure on CMC teams. With drug development cycles shrinking due to innovations in trial designs, optimized clinical operations, and expedited regulatory pathways, CMC departments are under pressure to adapt their timelines and workflows accordingly. This shift means that CMC processes, traditionally slower and more methodical, now need to move at a faster pace, making them a more critical component in the overall development timeline.

Increasing Complexity of Product Development

The biopharmaceutical landscape is becoming more complex as the industry diversifies into new modalities. These innovations include biologics, cell and gene therapies, and RNA-based therapeutics. Alongside this complexity, manufacturing processes are becoming more intricate, and product specifications are broadening, incorporating components such as medical devices and software. CMC must evolve to handle these complex products and processes, ensuring quality while navigating new regulatory and technological landscapes.

Advancements in Technology


The rapid introduction of new technologies is another major driver of change. Innovations in automation, digitalization, production systems, and testing methods are reshaping how CMC functions. These advancements require the recruitment of specialized talent, the development of new skills, and the formation of strategic partnerships to stay at the forefront of innovation. Additionally, data from equipment, prediction models, and external partners is growing exponentially, necessitating a stronger focus on data governance and knowledge management to ensure efficiency and compliance in product development.

CREATING A PARADIGM SHIFT IN CMC

The challenge of accelerating the development and supply of new medicinal products requires a shift in the way CMC organizations approach product development and manufacturing. Industry stakeholders, including regulators, have already begun addressing these needs through collaborative efforts. Key insights have emerged from various forums and publications aimed at defining a new path forward:

- In 2016, a joint industry and FDA group published a report, "Examining Manufacturing Readiness for Breakthrough Drug Development," outlining principles to accelerate the development of breakthrough therapies [2]
- The European Federation of Pharmaceutical Industries and Associations (EFPIA) further refined these principles in a 2017 proposal, emphasizing risk-based and science-driven approaches to developing high-quality medicines [3]
- In 2018, the EMA and FDA conducted a PRIME/Breakthrough Quality Workshop, which expanded on these principles with real-world case studies from the evolving biopharmaceutical landscape [4, 5]

Figure 2: Lifecycle of an ETP [1]



- Most recently, in 2020, the EFPIA's paper on COVID-19 pandemic medicines further refined these principles to facilitate rapid development in response to urgent global health needs [6]
- In 2021, the EMA also released a draft CMC acceleration toolbox, based on insights gathered during previous workshops and consultations, providing concrete strategies to speed up the regulatory approval processes for new therapies [7]

ADVANCED MANUFACTURING TECHNOLOGIES

A critical aspect of the paradigm shift in CMC is the adoption of advanced manufacturing technologies. These technologies enable more efficient production, ensure higher product quality, and facilitate faster time to market. Key advanced manufacturing innovations include the following.

Continuous Manufacturing (CM)

Traditional drug manufacturing processes, typically batch or fed batch, involve halting production between stages. Continuous manufacturing, on the other hand, integrates all production steps into a continuous flow, allowing for ongoing production without interruptions. This method helps improve efficiency, reduce costs, and improve the consistency of product quality.

3D Printing (Additive Manufacturing)

In biopharmaceuticals, 3D printing enables the creation of personalized medicines, allowing for the precise customization of dosages and drug delivery systems tailored to individual patient needs. This technology can also improve the efficiency of drug production, particularly for complex therapies that require highly specific formulations.

PAT

PAT involves the use of sensors and digital analytics to monitor the CQAs of a product during production. With real-time data collection and analysis, PAT ensures that products meet regulatory standards without the need for post-production batch testing, streamlining the manufacturing process and improving quality control.

Automation and Robotics

The use of automation and robotics in the manufacturing process

ensures the precise handling of materials, consistent measurement of ingredients, and control of environmental conditions. Artificial intelligence (AI) and machine learning (ML) can also be integrated into these systems to optimize production schedules and predict potential issues, further enhancing the efficiency and scalability of manufacturing processes. These advanced manufacturing technologies offer significant opportunities to reduce variability, improve scalability, and meet the growing demand for personalized and complex therapeutics.

REGULATORY EMERGING TECHNOLOGY PROGRAM (ETP)

To address challenges from rapidly evolving biopharmaceutical manufacturing technologies, the FDA launched the Emerging Technology Program (ETP) in 2014 to support and accelerate the adoption of advanced manufacturing techniques.

The ETP provides a collaborative platform where industry stakeholders can engage with the FDA's Emerging Technology Team (ETT) to discuss potential regulatory and technical issues associated with novel technologies. This program aims to address concerns about delays caused by unfamiliar technologies and regulatory frameworks. By facilitating early dialogue, the ETP helps industry representatives identify and resolve potential roadblocks before regulatory submissions, ensuring smoother approval processes.

The ETP includes representatives from the FDA's Office of Pharmaceutical Quality (OPQ), Office of Compliance (OC), and the Office of Regulatory Affairs (ORA). By engaging with these regulatory experts, companies can gain a better understanding of how to align their technologies with existing regulatory standards and accelerate the development and approval of innovative therapies (Figure 2).

EMERGING TECHNOLOGIES

As the pharmaceutical landscape rapidly evolves, emerging technologies are transforming both small molecule and biologic drug manufacturing processes. These innovative technologies are being integrated across all stages of drug development to improve product quality, reduce manufacturing costs, and accelerate time to market. Here, we explore the latest advancements in small molecule and biologic drug production, as well as the systems designed to enhance the overall manufacturing ecosystem.

Emerging Equipment and Systems Technologies

Continuous manufacturing of drug substance

Traditional drug substance manufacturing often involves batch processing, where production occurs in distinct stages. Continuous manufacturing integrates all production steps into a continuous, uninterrupted process. This approach enhances efficiency by reducing downtime between stages, improving product consistency, and providing real-time monitoring and control over critical process parameters.

Continuous manufacturing of drug product

Similar to the continuous manufacturing of drug substances, continuous manufacturing of drug products involves a seamless, integrated process for product formulation and finishing. By maintaining a continuous production flow, this method can improve scalability, reduce production costs, and enhance supply chain flexibility, particularly for high-demand or personalized medicines.

Model-based control strategy for continuous manufacturing

As continuous manufacturing becomes more widespread, model-based control strategies are being developed to optimize the manufacturing process. These strategies use mathematical models to predict and control CQAs in real time, ensuring product quality and reducing the need for extensive post-production testing.

Continuous aseptic spray drying

Spray drying is an important technique for producing dry powders for inhalation or oral solid dosage forms. Aseptic spray drying ensures the sterility of the drug substance while maintaining high manufacturing efficiency. The continuous nature of the process improves scalability and consistency, whereas the aseptic environment ensures that the drug remains free from contamination.

3D printing manufacturing

3D printing (additive manufacturing) offers the possibility of personalized dosing, allowing for precise customization of drug formulations to meet individual patient needs. In drug manufacturing and production, 3D printing can facilitate the creation of complex dosage forms that are difficult to achieve through traditional manufacturing methods. It also holds potential for enhancing the development of combination products involving drugs and medical devices.

Ultra-long-acting oral formulation

Traditional oral formulations often require frequent dosing. Ultra-long-acting oral formulations aim to extend the duration of action of drugs, reducing the frequency of administration. This can significantly improve patient adherence and convenience. Technologies such as controlled-release and sustained-release formulations, alongside advanced drug delivery systems, are being explored to develop these long-acting therapies.

Emerging Technologies for Biological Molecules

Controlled ice nucleation for lyophilization processes

Lyophilization (freeze-drying) is a critical process for stabilizing biologics, such as proteins and vaccines, by removing water while maintaining product integrity. Controlled ice nucleation improves the uniformity and efficiency of the lyophilization process, ensuring better preservation of the biologic's structure and activity.

Advanced process control (APC)

Predictive modeling and closed-loop bioreactor control are reshaping the way biologics are manufactured. APC systems use real-time data and ML algorithms to predict outcomes, monitor critical process parameters, and adjust in real time to maintain product quality throughout the production process. This approach reduces variability and enhances the efficiency of biologic manufacturing.

Multi-attribute method (MAM)

MAM is an advanced analytical approach that allows for the simultaneous measurement of multiple attributes of a biologic product, such as purity, potency, and stability. This holistic method provides a more comprehensive understanding of the product's quality and can replace traditional batch testing, enabling more efficient release testing and process monitoring.

Next-generation sequencing (NGS)

NGS is revolutionizing the development of biologics by enabling comprehensive, high-throughput genomic analysis. This technology allows researchers to quickly sequence genes, genomes, and transcriptomes, accelerating the discovery of novel biologic drugs and improving the characterization of biologic products, such as monoclonal antibodies and gene therapies.

Continuous manufacturing for downstream processes

Traditionally, downstream processing in biologic production (e.g., purification and formulation) has been performed in discrete, batch-based stages. Continuous manufacturing for downstream processes integrates purification and product recovery into a continuous workflow, increasing efficiency, reducing waste, and improving the scalability of biologic production.

Pharmacy on demand


The concept of pharmacy on demand refers to a compact, on-site manufacturing platform for biologic products that allows for the continuous production of therapies in a controlled, decentralized environment. This technology could enable faster delivery of personalized treatments, reduce transportation costs, and provide localized solutions for remote or underserved populations.

Emerging Technologies for Multiple Products

Closed aseptic filling system

A closed aseptic filling system ensures that products, particularly injectable biologics, are filled into containers in a sterile environment without exposure to contaminants. This system maintains sterility

Figure 3: Interaction with CBER/OTP



CATT: CBER Advanced Technology Team; BLA: biologics license application, PAS: postapproval study, IND: Investigational New Drug, BT: breakthrough therapy, RMAT: designation and regenerative medicine advanced therapy, EOP: end of phase

throughout the filling process, reducing the risk of contamination and improving product quality.

Isolator and robotic arm for aseptic filling

The integration of isolators and robotic arms in aseptic filling processes ensures precision and minimizes human intervention, further reducing the risk of contamination. These automated systems enhance the efficiency of filling, while improving reproducibility and compliance with stringent regulatory standards.

NOVEL CONTAINER AND CLOSURE SYSTEMS FOR INJECTABLES

The development of novel container and closure systems is essential for enhancing the stability, sterility, and shelf-life of injectable products. Innovations in packaging materials, such as prefilled syringes, polymeric vials, and wearable injectors, are improving patient convenience, ease of administration, and overall product performance.

INTERACTIONS WITH THE OFFICE OF THERAPEUTIC PRODUCTS

The OTP, part of the FDA's Center for Biologics Evaluation and Research (CBER), is responsible for regulatory oversight of biologic products. The OTP plays a critical role in ensuring that biologic therapies, including cellular and gene therapies, meet rigorous safety and efficacy standards.

The OTP oversees a diverse range of advanced therapies, including recombinant proteins, gene therapies, cell therapies, therapeutic vaccines, and xenotransplantation products. (Xenotransplantation involves transplanting cells, tissues, or organs from nonhuman animals into human recipients and presents unique regulatory challenges.) Developers of advanced therapies

By embracing these technological advancements, the biologic drug development process becomes more adaptable, enabling faster time to market and enhanced product quality.

regulated by the OTP have multiple opportunities to engage with the office through both informal and formal meetings. Formal meetings follow established processes for requesting, scheduling, preparing, conducting, and documenting the interactions. These meetings provide sponsors with the opportunity to clarify regulatory requirements, discuss data submissions, and address any concerns about product development.

In the context of biologics and advanced therapies, the sponsor is typically the entity responsible for initiating clinical investigations and regulatory applications, such as IND applications. Sponsors may be pharmaceutical companies, academic institutions, or government agencies that seek regulatory guidance and support for their product development. By fostering close interactions between the FDA and industry sponsors, the OTP ensures that innovative therapies are developed in compliance with regulatory standards, enabling faster access to safe and effective treatments for patients (see Figure 3).

CONCLUSION

The integration of emerging technologies in biologic drug development is paving the way for faster, more efficient, and cost-effective manufacturing processes. Innovations such as continuous manufacturing, advanced process controls, and personalized drug delivery systems are reshaping the biopharmaceutical industry, whereas regulatory frameworks like those provided by the OTP help ensure that these technologies align with safety and efficacy standards. As the industry continues to evolve, these technological advancements promise to drive the next generation of therapies, improving patient outcomes and transforming healthcare.

The adoption and implementation of innovative technologies in the CMC phase is pivotal to the advancement of biologics development. As biologics become increasingly complex, these technologies provide the tools needed to address the challenges of product consistency, regulatory compliance, and manufacturing scalability. Innovations such as advanced analytical methods, real-time process monitoring, automation, and data-driven decision-making empower manufacturers to produce high-quality biologic therapies with greater efficiency and precision.

By embracing these technological advancements, the biologic drug development process becomes more adaptable, enabling faster time to market and enhanced product quality. Furthermore, the integration of cutting-edge technologies in CMC not only improves

the robustness and reliability of biologic products, but also fosters the flexibility needed to meet the dynamic regulatory demands and global market expectations. Ultimately, the continued evolution of CMC through the adoption of these innovations will lead to safer, more effective biologic therapies, benefiting patients and the broader healthcare landscape.

The strategic adoption and seamless implementation of innovative technologies in CMC are essential for maintaining the high standards required in biologic drug development, ensuring that these complex therapies can meet the growing demands of modern medicine. 

References

1. US Food and Drug Administration. "Emerging Technology Program (ETP)." Updated 24 February 2025. www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program-etp
2. Dye, E., A. Sturgess, G. Maheshwari, K. May, C. Ruegger, U. Ramesh, et al. "Examining Manufacturing Readiness for Breakthrough Drug Development." *AAPS PharmSciTech* 17, no. 3 (2016): 529–38. doi:10.1208/s12249-015-0455-1.
3. European Federation of Pharmaceutical Industries and Associations. "EFPIA-EBE White Paper on Expedited CMC Development: Accelerated Access for Medicines of Unmet Medical Need—CMC Challenges and Opportunities (Final Version - December 2017)." December 2017. www.efpia.eu/media/288657/efpia-ebe-white-paper-expedited-cmc-development-accelerated-access-for-medicines-of-unmet-medical-need-december-2017.pdf
4. European Medicines Agency. "Meeting Report: Workshop with Stakeholders on Support to Quality Development in Early Access Approaches (i.e. PRIME, Breakthrough Therapies)." Presented at the EMA Stakeholder Workshop on Support to Quality Development in Early Access Approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, 23 November 2017. www.ema.europa.eu/documents/report/report-workshop-stakeholders-support-quality-development-early-access-approaches-ie-prime_en.pdf. Accessed 29 March 2022.
5. European Medicines Agency. "Meeting Report: Joint BWP/QWP Workshop with Stakeholders in Relation to Prior Knowledge and its Use in Regulatory Applications." Presented at the Joint BWP/QWP Workshop with Stakeholders in Relation to Prior Knowledge and its Use in Regulatory Applications, European Medicines Agency, London, 26 November 2018. www.ema.europa.eu/en/documents/report/meeting-report-joint-biologics-working-party/quality-working-party-workshop-stakeholders-relation-prior-knowledge-its-use-regulatory-applications_en.pdf
6. European Federation of Pharmaceutical Industries and Associations. EFPIA White Paper on CMC Development, Manufacture and Supply of Pandemic COVID-19 Therapies and Vaccines." 8 June 2020. www.efpia.eu/media/554681/cmc-development-manufacture-and-supply-of-covid-19-therapies-and-vaccines.pdf. Accessed 29 March 2022.
7. European Medicines Agency. "Draft Toolbox Guidance on Scientific Elements and Regulatory Tools to Support Quality Data Packages for PRIME Marketing Authorization Applications." 2 February 2021. www.ema.europa.eu/en/documents/scientific-guideline/draft-toolbox-guidance-scientific-elements-regulatory-tools-support-quality-data-packages-prime_en.pdf.
8. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. "ICH Harmonised Tripartite Guideline. ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for New Biotechnological/Biological Products." Published March 1999. https://database.ich.org/sites/default/files/Q6B_Guideline.pdf

About the author

Robert Dream, CPIP, is the Principal Consultant and Strategic Advisor for HDR Company LLC. He brings over 34 years of experience in the biopharmaceutical industry, having held leadership positions at several companies. His expertise lies in the manufacturing of biotechnological and biological products, including continuous biomanufacturing and advanced therapy medicinal products (ATMPs). Throughout his career, Dream has been at the forefront of manufacturing, regulatory compliance, facility design and qualification, process development and validation, and strategic planning. He serves as the Co-Chair of the ISPE Continuous Manufacturing Biotechnology Products GPG Task Team. Dream joined ISPE in 1990.

COMING SUMMER 2025

ISPE GAMP® GUIDE: Artificial Intelligence



The Guide will explore how to build, implement, and maintain AI systems in GxP areas—maximizing tech benefits while addressing real-world challenges



Scan to
explore Guides



KEY INSIGHTS FROM A JOURNEY THROUGH THE PHARMA 4.0™ BASELINE® GUIDE

Pharma 4.0™ Guide Charts Bold New Course for Digital Transformation

By Alfred Penfold

The ISPE Baseline® Guide Vol 8: Pharma 4.0™ was published in December 2023 to help accelerate the adoption of digital transformation. In quoting the opening narration of the original 1960s *Star Trek* television series, Christian Wölbeling, Founder and Chair of the ISPE Pharma 4.0™ Community of Practice, likes to say, “To boldly go where no one has gone before.”

BACKGROUND

The concept of Pharma 4.0™ was partially developed from Industry 4.0 [1], which refers to the intelligent networking of machines and processes in industry through information and communication technology. The journey began in 2004 with the formation of an ISPE Special Interest Group (SIG) for Process Analytic Technology (PAT) in the Germany–Austria–Switzerland (DACH) region. The PAT SIG eventually led to the formation of a much broader Community of Practice (CoP) for Pharma 4.0™ in 2017. Such is the level of interest in Pharma 4.0™ that today the CoP is fast approaching 3,000 members.

I first met Christian in April 2022 at the ISPE Europe Annual Conference in Madrid, Spain, just as ISPE was resuming its conferences after the COVID-19 pandemic. Given how long Pharma 4.0™ had been established within the pharmaceutical industry, I was curious as to why it had taken so long to begin developing a Baseline® Guide. The answer: the industry simply wasn't ready at that time. Relevant use cases didn't begin to emerge until 2022. As a result, work on the Pharma 4.0™ Baseline® Guide began in July 2022, ultimately incorporating 35 use cases.

With the proliferation of emerging technologies—among them machine learning and artificial intelligence—the industry is clearly poised to apply Pharma 4.0™ principles and begin realizing their many benefits.

The four main objectives of Pharma 4.0™ are:

1. To understand the interdependencies among technologies, processes, people, and regulations necessary for a successful digital business transformation—based on global principles from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [2]—starting with an operating model, followed by maturity assessments for all elements and enablers.
2. To explain the principle of a holistic view and transformation specific to the pharmaceutical industry.
3. To orchestrate the interdisciplinary ISPE knowledge spaces, such as GAMP [3], Product Quality Lifecycle Implementation (PQLI) [4], Advancing Pharmaceutical Quality (APQ) [5], and Pharma 4.0™.
4. To develop the necessary organizational culture for success, as outlined in the *ISPE APQ Guide: Cultural Excellence* [6].

The new Baseline® Guide is intended to help shape the digital transformation of the pharmaceutical industry. It will require a high level of management awareness and a clearly defined stakeholder structure. The principles and process-based approach are outlined in the ISPE Pharma 4.0™ Operating Model (see Figure 1). A roadmap is essential, with clearly identified benefits supported by use cases.

Furthermore, as the Baseline® Guide has the character of a textbook, it represents a second generation of Good Practice Guides in development—akin to a ‘cookbook’—providing more detailed guidance on how to implement a successful digital transformation. Use cases will also illustrate the roadmaps for implementation.

UNDERSTANDING PHARMA 4.0™

Explaining the purpose of digital transformation is essential, as it supports a more holistic approach and enables the generation of usable data to inform decision-making and drive improvements in operations, cost efficiency, and regulatory compliance. Enhancements in regulatory compliance are achieved by bridging

Figure 1: Pharma 4.0™ Operating Model




Image courtesy of ISPE Baseline® Guide Vol 8: Pharma 4.0™.

automation with regulations and ICH Quality Guidelines [2]. This can only be accomplished through clearly defined roles and responsibilities for digitalization, along with a shared understanding between industry and regulators when adopting innovative technologies.

In many organizations, parts of the operation remain isolated—or siloed. One of the key objectives of Pharma 4.0™ is to break down silos and foster a common understanding across departments. For example, Pharma 4.0™ can link departments such as product development, commercial manufacturing, engineering, automation, information technology (IT), and supply chain stakeholders. This integration facilitates innovation, technology transfer, and the maintenance of equipment and systems.

Similarly, in the context of stakeholder management, Pharma 4.0™ can connect regulators—such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national competent authorities—with industry and healthcare providers. Strengthening these connections can lead to further benefits, including the adoption of innovative technologies, enhanced patient protection, and improved product delivery.

In 2017, the Pharma 4.0™ Community of Practice (CoP) summarized its key objective as follows: “We provide practical guidance, embedding regulatory best practices, to accelerate Pharma 4.0™ transformations. Our objective is to enable organizations involved in the product life cycle to leverage the full potential of digitalization to provide faster innovations for the benefit of the patients.”

The *ISPE Baseline® Guide Vol. 8: Pharma 4.0™* outlines the foundational principles of Pharma 4.0™ and its potential for holistic transformation. Authored by 30 qualified industry professionals, the guide spans 250 pages and includes 35 use cases. Figure 2 illustrates the guide structure.

Figure 2: This figure presents the structure outlined in the *ISPE Baseline® Guide Vol 8: Pharma 4.0™*.

Image courtesy of ISPE Baseline® Guide Vol 8: Pharma 4.0™.

At the core of Pharma 4.0™, there is strong alignment with Industry 4.0. For example, Industry 5.0 [7] emphasizes the promotion of talent, diversity, and empowerment. Within Pharma 4.0™, this is reflected in the concept of cultural excellence, as described in the *ISPE APQ Guide: Process Performance and Product Quality Monitoring System (PPQMS)* [5], as well as in the ISPE Engage program. Figure 3 illustrates how Pharma 4.0™ incorporates pharmaceutical industry-specific elements to the broader principles of Industry 4.0 and 5.0.

Holistic Control Strategy

Implementing a holistic control strategy for the end-to-end management of manufacturing supply chains is key to realizing the benefits of Pharma 4.0™. All manufacturing steps—from the supply of raw materials to the storage and distribution of products to patients—must be mapped and integrated into an overarching quality framework. This framework can then be evaluated and enhanced through the application of Pharma 4.0™ principles.

Figure 3: Pharma 4.0™ pharmaceutical industry specifics with reference to Industry 4.0 and 5.0 principles




Image courtesy of ISPE Baseline® Guide Vol 8: Pharma 4.0™.

It is important to assess the current level of digitalization and define the desired level by creating a roadmap for implementation. Identifying pain points during the mapping of the end-to-end manufacturing supply chain is also a critical step.

The transition to Pharma 4.0™ is unlikely to occur without incremental steps. It begins with conducting maturity assessments across all elements and enablers of the Operating Model. The ISPE Quality Management Maturity Program [5] and ICH Q10 [2] are useful references for conducting these assessments and benchmarking efforts, in addition to the maturity grids shown in the Guide's attachments. These assessments, based on the Operating Model, take a holistic approach to evaluating digital business maturity and can be further detailed as follows:

- **Resources:** Team organization; digital skills/Workforce 4.0; resource management; automation and technical capabilities; engineering and construction
- **Organization and Processes:** Business strategy; quality management; performance management; control strategy; knowledge management
- **Information Systems:** IT strategy; IT operational governance; IT components; architecture integration; cybersecurity
- **Culture:** Value-based mission and vision; patient orientation; sense of urgency; activation and empowerment; relationships with authorities

A quality management maturity rating from 1 to 5 has been defined by the FDA [6]. The overall Pharma 4.0™ Digital Maturity Score would be an average of these ratings and includes an assessment of data integrity.

Maturity Level 5: Optimized (Best in Class)

- Policies, standards, processes, and procedures are clearly defined and integrated across the supply chain.
- Feedback loops are implemented for continual improvement.
- A high degree of data-based decisions are established.

Maturity Level 4: Managed

- Policies, standards, processes, and procedures are aligned with current industry standards.
- Quantitative goals for processes and products are well-defined and measured.
- Full global integration is achieved.
- Data are interoperable and contextualized.

Maturity Level 3: Defined (Enhanced Pharmaceutical Quality System)

- Policies, standards, technical and business processes, and procedures (SOPs) are defined on a global level.
- A high level of global (i.e., organization-wide) integration is achieved.
- Data management is clearly defined across all functions and organizational levels.

Maturity Level 2: Developmental (Enhanced Pharmaceutical Quality System)

- Policies, standards, and written procedures (SOPs) are at least defined at the local level.
- There is little to no integration between different entities.
- A master data management framework is available.

Maturity Level 1: Initial (Minimally Compliant)

- Regulatory requirements are fulfilled.
- Only minimal compliance is achieved.
- Operations are highly dependent on individuals; knowledge is lost when individuals are unavailable.
- Processes exhibit high variability and rely on reactive control.
- Numerous deviations and corrective and preventive actions are required.
- Data management exists without a structured framework.

Data Integrity

Once the required level of quality management maturity is established, the next step is to begin digitization by focusing on data integrity by design and achieving a level of digital maturity that enables the principles of Pharma 4.0™. These principles are based on the Operating Model shown in Figure 1, which incorporates a holistic control strategy that drives both digital transformation and a digitalization strategy. Only then can the full benefits and value of Pharma 4.0™ be realized.

The Pharma 4.0™ journey is expected to push the boundaries of innovative technologies and in doing so, it is important to maintain a strong connection with the regulatory authorities. In the United States, this can be achieved through programs such as the FDA Emerging Technologies Program (ETP) [8] and the FDA Digital Health Advisory Committee [9]. In Europe, similar support may be obtained through the EMA Quality Innovation Group (QIG) [10]. I have found the FDA ETP and the EMA QIG to be particularly effective when applied to innovations.

Regulatory Guidance That May Apply

EMA

- EudraLex, Volume 4: Good Manufacturing Practice (GMP) Guidelines [11]
- EudraLex, Volume 4, Part 1: Basic Requirements for Medicinal Products, Chapter 4, Documentation [12]
- EudraLex, Volume 4, Annex 11: Computerized Systems (currently under revision) [13]
- European Commission's Digital Services Act (DSA) [14]

US FDA

- Code of Federal Register (CFR) [15]
- CFR, Title 21, § 211.68 Automatic, Mechanical and Electronic Equipment [16]
- CFR Title 21, Part 11, Electronic Records, Electronic Signatures, Scope and Application [17]
- CFR Title 21, Data Integrity and Compliance with Drug cGMP Questions and Answers Guidance for Industry [18]

WHO

- Annex 5: Guidance on Good Data and Record Management Practices [19]

PIC/S

- PIC/S Guidance: Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments [20]

Figure 4: Key benefits of implementing the Pharma 4.0™ Operating Model




Image courtesy of ISPE Baseline® Guide Vol 8: Pharma 4.0™.

CONCLUSION

The Pharma 4.0™ journey requires a clearly defined set of business goals and a comprehensive business strategy. Business processes, corresponding process data flows, and data lifecycle must all be clearly outlined. Achieving this vision will require the formation of interdisciplinary teams tasked with enabling the necessary level of quality management maturity—for example, APQ Level 3 [5].

The final prerequisite is to establish infrastructure connectivity that supports interconnectivity and plug-and-produce integration, based on the International Society of Automation's ISA-95 Model [21] and the Industry 4.0 Structured Network Model [1].

When developing business strategies, it is imperative to highlight the many benefits of applying the Pharma 4.0 Operating Model. Some of the key benefits are listed in Figure 4.

The many opportunities presented by digitization include the transition from paper-based or analog records to digital formats. Once digitized, processes can be further integrated through digitalization and enhanced by data analysis. Transitioning from manual to more robust, automated steps—such as those enabled by robotics—will support the modernization of existing operations. A key challenge is to become more proactive, responsive, and efficient through digitalization, IT applications, and infrastructure, especially when compared to traditional approaches to validation and other asset life cycle activities.

Digital transformation is a strategic business initiative—not merely an IT project. It can only be executed by management, who must take full responsibility for the transformation, as outlined in the “ICH Q10 Pharmaceutical Quality System [2].” The *ISPE Pharma 4.0™ Baseline® Guide* introduces the basic concepts and principles of Pharma 4.0™, aiming to establish a shared understanding among all stakeholders. Additional practical guidance will be provided in future ISPE guidance documents.

Exactly two years after meeting Christian Wölbeling, I saw him again in April 2024 at the ISPE Europe Annual Conference in Lisbon, Portugal. By that time, the *ISPE Pharma 4.0™ Baseline® Guide* had

I'm not sure if the industry fully realizes the extent of the transformation we are about to experience. What I do know is that now is the time to embrace Pharma 4.0™

been published, and I had already read it. I found it compelling in terms of the opportunities it presented. Given the many emerging technologies and the drive toward digitization, it seemed clear that the industry was ready for Pharma 4.0™.

We appear to be on the cusp of a new era—a paradigm shift that could transform the pharmaceutical industry in ways that are difficult to fully imagine. When I shared my thoughts with Christian, he responded, “Yes, we will be spending the next 20 years implementing Pharma 4.0™.”

I'm not sure the industry fully realizes the extent of the transformation we are about to experience. What I do know is that now is the time to embrace Pharma 4.0™—and the best place to start is by reading the *ISPE Pharma 4.0™ Baseline® Guide*. After reading it, I can guarantee that the phrase “To boldly go where no one has gone before” will take on a whole new meaning 🚀

References

1. Federal Ministry for Economic Affairs and Climate Action. Federal Ministry of Education and Research. “Industrie 4.0 - What Is It?” 25 February 2019. www.plattform-i40.de/IP/Navigation/EN/Industrie40/WhatIsIndustrie40/what-is-industrie40.html
2. International Council for Harmonisation. “ICH Q10 Pharmaceutical Quality System.” April 2009. <https://www.fda.gov/media/71553/download>
3. International Society for Pharmaceutical Engineering. *ISPE GAMP® Good Practice Guides*. <https://ispe.org/product-types/gamp-good-practice-guides>
4. International Society for Pharmaceutical Engineering. *ISPE Product Quality Lifecycle Implementation (PQLI)*. <https://ispe.org/initiatives/pqli>
5. International Society for Pharmaceutical Engineering. *ISPE Advancing Pharmaceutical Quality Guide: Process Performance and Product Quality Monitoring System*. International Society for Pharmaceutical Engineering (ISPE), North Bethesda, MD: International Society for Pharmaceutical Engineering, 2022.
6. International Society for Pharmaceutical Engineering. *ISPE APQ Guide: Cultural Excellence*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2022.
7. European Commission. “Industry 5.0, A Transformative Vision for Europe.” Published 10 January 2022. https://research-and-innovation.ec.europa.eu/knowledge-publications-tools-and-data/publications/all-publications/industry-50-transformative-vision-europe_en
8. US Food and Drug Administration. “Emerging Technology Program.” www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program-etp
9. US Food and Drug Administration. “FDA Digital Health Advisory Committee.” www.fda.gov/medical-devices/digital-health-center-excellence/fda-digital-health-advisory-committee
10. European Medicines Agency. “Quality Innovation Group.” www.ema.europa.eu
11. European Commission. “EudraLex, Volume 4: EU Guidelines for GMPs for Medicinal Products for Human and Veterinary Use. Part 4: EU Guidelines for Good Manufacturing Practice (GMP) Specific to Advanced Therapy Medicinal Products.” November 2017. https://health.ec.europa.eu/document/download/ad33d9dd-03f0-4bef-af53-21308ce2187d_en
12. European Commission. “EudraLex, Volume 4: EU Guidance for Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use. Part I: Basic Requirements for Medicinal Products.” Published 2003. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en#part-i---basic-requirements-for-medicinal-products
13. European Commission. “EudraLex, Volume 4: Guidelines for GMPs for Medicinal Products for Human and Veterinary Use. Annex 11: Computerised Systems.” Published 2011. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm
14. European Commission. “The Digital Services Act.” https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/europe-fit-digital-age/digital-services-act_en
15. US Food and Drug Administration. “CFR - Code of Federal Regulations Title 21, Annex 11.” March 1997. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11
16. US Food and Drug Administration. “CFR - Code of Federal Regulations Title 21, Part 211.68, Automatic, Mechanical, and Electronic Equipment.” September 1978. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=211.68
17. US Food and Drug Administration. “CFR - Code of Federal Regulations Title 21, Part 11, Electronic records; Electronic Signatures.” March 1997. <https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11>
18. US Food and Drug Administration. “Guidance for Industry: Data Integrity and Compliance with cGMP Questions and Answers.” December 2018. www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
19. World Health Organization. “Annex 5: Guidance on Good Data and Record Management Practices.” Published 2016. <https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/trs966-annex05-fr-who-record-management-practices.pdf>
20. Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-Operation Scheme. “PIC/S Guidance: Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments.” Published 1 July 2021. <https://picscheme.org/docview/4234>
21. International Society of Automation. “ISA-95 Standard: Enterprise-Control System Integration.” www.isa.org/standards-and-publications/isa-standards/isa-95-standard

About the author

Alfred Penfold, MBA, CEng, MIET, is Technical Director for PM Group and focused on current GMPs and regulatory compliance. He has more than 35 years of experience in the pharmaceutical and biotech industry working for GSK, Catalent, and Pfizer. He is recognized internationally as a subject matter expert in serialization and has advised the US FDA. Penfold is a member of the ISPE Europe Leadership Team, ISPE Regulatory Quality Harmonisation Steering Committee for Europe-Middle East-Africa Regional Focus Group, and an elected member of the PHSS Management Committee. He joined ISPE in 1999.

ADVANCED APPLICATIONS for Digital Twins in Pharma

By Antonello Finucci and Stefan R. Kappeler, PhD

With the help of Digital Twins, companies can achieve greater certainty and precision in making informed decisions at various stages of the product lifecycle, driven by a deep understanding of underlying Critical Business Parameters (CBPs).

We present a novel, holistic approach to utilizing Digital Twins (DTs) and AI Agents throughout the pharmaceutical product lifecycle by focusing on CBPs that influence both product and company performance. Our approach involves the development and operation of multiple Digital Twins, each targeting a specific parameter and collectively forming a network of interconnected models—referred to as a federated Digital Twin, herein called "Twin of Twins."

We also explore the role of AI Agents as assistants throughout the DT lifecycle, including conception, development, validation, operation, and maintenance. Additionally, we propose a modular approach that simplifies complex process flows and cost models into standardized building blocks, enabling the creation of efficient and scalable Digital Twins. Considerations around cost, validation, and ethical implications are also addressed.

INTRODUCTION: WHAT ARE DIGITAL TWINS?

Decisions often must be made without fully knowing the outcomes. The use of "safe spaces" to test scenarios, understand potential effects, and make informed decisions is therefore nothing new. Throughout history, architects and engineers have used scale models and mock-ups to visualize and test structures and concepts before implementation, thus mitigating construction errors and operational risks. Similarly, mathematical models that simulate

real-world aspects have been used for decades in engineering and finance to improve decision-making and predict outcomes prior to implementation.

Key differentiators of current approaches include the integration of connected devices, the Industrial Internet of Things (IIoT), High-Performance Computing (HPC), and advances in artificial intelligence (AI). Together, these digital innovations enable the simultaneous inclusion of numerous adjustable variables in simulation models, providing a more comprehensive understanding of real-world events and enabling real-time simulations.

At the forefront of this transformation is the concept of DTs, which are defined as precise digital replicas of physical systems [1]. By leveraging the aforementioned digital enablers, DTs are continuously updated with real-time data from the physical world, enabling highly accurate simulations and predictive insights. This empowers organizations to test, optimize, and accelerate data-driven decisions, all while minimizing risk and enhancing operational efficiency.

DIGITAL TWINS IN THE PHARMACEUTICAL INDUSTRY

The pharmaceutical industry is expected to provide society with a reliable supply of safe, effective, and affordable medicines of high quality that reflect the current state of science and technology. These and other Critical Business Aspects (CBAs) must be considered throughout the pharmaceutical product lifecycle [4]. DTs can be used to assess these interacting CBAs and are increasingly becoming important tools for accelerating decision-making and minimizing business risks [5]. They are particularly useful when evaluating change projects that may impact CBPs—the specific metrics and factors used to measure and control the respective CBAs.

For example, a CBP such as annual output depends on numerous other factors, including the supply chain, production scale, process flexibility, product yield, plant utilization, external and operational

Figure 1: Example of a ToT to with CBPs, CBAs, and DTs




Table 1: Directly applicable use cases for DTs in the pharmaceutical sector, some of which have already been implemented

Use Case	Description
Drug Discovery and Development	DTs can accelerate drug discovery and reduce research and development (R&D) costs in the company's innovation pipeline (the CBA, in this case) by simulating experimental systems, thereby optimizing resources, accelerating timelines, and improving success rates of R&D efforts [8, 9].
Clinical Studies	As a critical aspect of clinical trial management, DTs simulate patient responses in order to measurably optimize study design, ensure protocol compliance, limit the number of subjects required, and ultimately ensure data quality [10, 11].
Facility Design and Modification	With facility management as the CBA, the DTs evaluate the intended design changes in terms of their impact on process performance, product quality, assets and equipment, space utilization, and environmental control [12].
Environmental Impact Reduction	DTs optimize manufacturing processes and logistics to reduce waste, energy consumption, and environmental impact, supporting the critical aspect of environmental sustainability. Important metrics include energy consumption, waste volume, resource consumption, environmental impact, maturity of sustainable development, and ecological footprint in an industrial comparison [13, 14].
Manufacturing and Supply Chain	For DT management, the same as the CBA, the overall process is to identify bottlenecks, optimize efficiency, and ensure availability and quality [15, 16].
Predictive Maintenance of Equipment	DTs driven by sensors and IIoT reduce downtime and safeguard product quality, ensuring the CBA of equipment availability. Key metrics are asset health, maintenance schedules, performance efficiency, downtime reduction, and quality impact [17, 18].
Training and Education	DTs allow staff to be safely trained on new equipment and for new processes, guaranteeing product quality and patient safety while ensuring the CBA of staff development. Key CBPs are progress in learning, risk reduction, competence, and performance improvement [19].
Continuous Improvement	Under the critical aspect of optimized processes, DTs assess and refine changes to operational workflows and measurably improve their impact, performance, efficiency, cost, and quality [20].
Regulatory Compliance and Reporting	This is an emerging application where DTs maintain real-time records of drug development and manufacturing, facilitate regulatory compliance, prepare for audits and inspections, and ensure the critical aspect of inspection readiness. Key metrics include compliance status, documentation quality, inspection performance, risk assessment, and reporting efficiency [19].
Collaboration and Data Sharing	Under the critical aspect of knowledge management, DTs improve the collaboration between researchers, industrial companies, and healthcare institutions by providing standardized real-time data. The key metrics are the efficiency of collaboration, data sharing, quality of communication, access control, and level of integration [21, 22].
Personalized Medicine	Another goal of DTs is to simulate patient behavior and predict individual drug responses, enabling personalized treatment plans and tailor-made medicine that improves the patient's well-being, viewing it as a critical aspect, with optimized treatment success and minimum risks and side effects [10, 23–25].
Treatment Adherence	Another pioneering project is when DTs are based on synthetic patient data that provides insights into treatment adherence, enables timely intervention, and improves the critical aspect of treatment compliance. Important CBPs here are treatment adherence, treatment response, patient behavior, timing of intervention, and outcome assessment [26, 27].

constraints [1], and market demand. ADT capable of simulating such relationships with a high degree of accuracy enables informed and rapid decision-making, thereby reducing both operational costs and business risks.

With the help of high-performance computing (HPC) and modularization, DTs gain the ability to interconnect and simulate multiple CBPs simultaneously. DTs are now overcoming past limitations to become powerful tools that provide direct, unbiased,

Table 2: Non-exhaustive list of CBAs

CBA	Important Metrics
Regulatory Compliance	Regulatory approvals, adherence to regulations, and post-market surveillance (pharmacovigilance)
Quality Control (QC) and Quality Assurance (QA)	Product quality, stability testing, documentation, and traceability
Supply Chain Management	Global supply chain, supply chain resilience, risk management, and inventory management
R&D	Innovation and discovery, clinical trials, pipeline management, intellectual property (IP), process optimization, and scaling up
Financial Performance	Revenue and revenue growth, cost control, and financial sustainability
Sales and Marketing	Market access, product differentiation, pricing strategy, and brand management
Risk Management	Compliance risks, product liability, and financial risks
Patient Safety and Ethical Considerations	Patient safety, drug accessibility, ethical conduct, and social responsibility

Table 3: Non-exhaustive list of CBPs

CBP	Important Metrics
Production Capacity	Yield and throughput
Quality Metrics	Batch failure rate, out-of-specification (OOS) results, and deviation rate
Cost Metrics	Cost per batch, cost of goods sold (COGS), and inventory turnover rate
Production Time and Efficiency	Cycle time, overall equipment effectiveness (OEE), and manufacturing capacity
Supply Chain Metrics	Lead time, supplier reliability, and quality
Compliance and Regulatory	Regulatory approval timelines, regulatory compliance costs, audit findings, training compliance rate, documentation accuracy, and completeness
R&D and Innovation	Program pipeline, pipeline depth, pipeline value, time to market, R&D cost efficiency, clinical trial success rate, regulatory approval rate, patent strength, and expiry
Commercial Performance	Market share, sales growth, profit margins, and product revenue mix
Sales and Financial Performance	Revenue per batch or unit, profit margin, cash flow, return on investment (ROI), market share, and demand forecasting
Patient Safety and Efficacy	Adverse event rates, product recalls, and patient satisfaction

real-time information on CBAs and the likely impact of planned changes—supporting engineers, scientists, and decision-makers across product development, production, and management. CBAs and CBPs will be discussed in more detail later.

Given the diversity of activities involved, it is clear that different types of DTs must be applied across disciplines to achieve relevant results. Some are based on multiphysics, others on tangible relationships, and still others on intangible processes, systems, and workflow dynamics. Connecting these various DTs to generate high-level insights requires a modularly connected network of DTs—referred to as a "Twin of Twins" (ToT)—where each DT specializes in a specific task [6].

Some applications of DTs in the pharmaceutical industry, where multiple CBPs must be managed simultaneously to assess associated CBAs, are illustrated in Figure 1. To create a digital ToT, a digital maturity level of 5—according to the BioPhorum Digital Plant Maturity Model (DPMM) [7]—is required for the business processes involved. This level pertains to autonomous, self-optimizing, plug-and-play facilities.

POTENTIAL USE CASES FOR DTs

In addition to the envisaged control of interdependent CBAs via ToTs, a growing number of directly applicable and partially realized use cases should also be considered, as shown in Table 1.

KEY CHALLENGES

Key challenges include protecting data privacy and security due to the large amount of information shared, integrating DTs into commonly used legacy systems, and the high initial implementation costs, which, however, are outweighed by substantial advantages in the long term.

CBAs AND CBPs

Tables 2 and 3 outline non-exhaustive lists of the CBAs and CBPs, respectively, of business-critical disciplines such as process control, production and supply chain management, quality control, and finance. CBAs help pharmaceutical companies drive innovation, improve patient outcomes, and achieve long-term success. Each of these aspects requires detailed planning, monitoring, and

Figure 2: An example of a decision sequence in an autonomous system consisting of DTs and AI agents. Simplified core equations of the steps have been added [29, 30].





Figure 3: Diagram of how the planner agent orchestrates other AI agents with different capabilities. The green box is more useful in the creation of a DT, while the orange box is more useful in the subsequent operational phase.



resources to ensure that pharmaceutical manufacturing operations are successful, sustainable, and in compliance with regulatory standards. CBPs enable pharmaceutical manufacturers to measure and control quality, efficiency, and profitability while staying compliant and competitive. Monitoring these metrics closely can help identify opportunities for process improvements and cost savings, while maintaining rigorous quality and regulatory standards.

AGENTIC AI-POWERED TOT ENVIRONMENTS

Agentic AI refers to AI systems designed to operate autonomously, make decisions, and execute requests with minimal human intervention [28]. A large language model (LLM) is used to understand a request and then executes the needed tasks with software-defined tools. This is a shift from passive AI that, for example, informs the user that stock is low, to an active AI that also asks the user to reorder the material if necessary.


Fields of application in the pharmaceutical industry are diverse, especially when used together with DTs, which can be considered advanced tools for such agents. Figure 2 shows an example of a

decision sequence in an autonomous system consisting of DTs and AI agents. The signals received from the real system are processed in the DT and lead to a decision that is then executed by the AI agent. The result is finally reported back to the DT and helps improve the system parameters.

AI agents are also expected to be a valuable support both in the creation of DTs—by having agents with the different capabilities to create the different components of a DT—and in later operations, where other agents use the DT as a tool. Figure 3 illustrates how a planner agent orchestrates other AI agents with different capabilities. Its role is to receive information, make decisions, and provide feedback, but ultimately the human in the loop is still responsible for making the final decisions and taking overall responsibility.

A specific type, termed a ReAct agent (Figure 4), is designed to perceive the environment, reason, plan, and act autonomously to achieve specific goals, thereby bridging the gap between logic and action and enabling sophisticated problem-solving in the real world [31]. ReAct agents operate in a loop: receiving input, processing it with the LLM to generate a plan, executing the plan through tool

Figure 4: Diagram of how a ReAct agent (yellow box) operates



interactions (e.g., internet searches, code execution, 3D modeling, database access, DT simulations), receiving feedback, and using that feedback to improve future performance [32].

ReAct agents can leverage DT environments to safely train and experiment with virtual representations of real-world systems. Using built-in memory systems, they learn continuously from past experiences while generating synthetic data for future applications. These agents can create, validate, and optimize simulations of complex business processes, enabling thorough testing of strategies before real-world implementation. In this way, they can understand and predict CBPs and their impact on CBAs.

MODULAR ARCHITECTURE OF DTS FOR TOT ASSEMBLY

Given the different types of DTs that need to communicate and collaborate with each other to enable accurate and comprehensive simulations of business processes, standardized interfaces and reusable building blocks are necessary to ensure consistency in the development, validation, and maintenance of DTs and their associated data flows. With the Digital Twin System Interoperability Framework [33] introduced by the Digital Twin Consortium (DTC), a modular approach has been developed to achieve interoperability between complex systems on a large scale. Seven key concepts have been defined for this purpose. These include:

1. System-centric design for cross-domain collaboration
2. Model-based standardization for reusable applications
3. Holistic information flow for comprehensive decision-making
4. State-based interactions capturing system attributes
5. Federated repositories for distributed information access
6. Actionable information beyond raw data
7. Scalable mechanisms for handling simple to complex system interactions

This standardization aims to simplify DT integration, allowing system integrators to focus on application development rather than integration work and to unify service ecosystems to enable seamless interactions when maintaining an interconnected ToTs system.

VALIDATION OF DTS AND AI AGENTS

The development, deployment, and operation of DTs and AI agents in the pharmaceutical industry present new challenges.

The accuracy and safety of these systems cannot be verified using proven CSV methods and new questions arise regarding ethical aspects of accountability, bias, and safety of learning and autonomously acting systems. The challenges arise from both the inherent complexity of AI models and the stringent regulatory requirements (e.g., cGxP) to ensure patient safety and product quality.

According to ISO Standard 23247 [34], a DT should support information continuity throughout the product life cycle including design, planning, manufacturing, and maintenance. This information should be reliable, which means that the tracking of the replicated objects and the creation of updated DT models must be validated. A rational basis for the validation of AI systems for use in GxP applications has been outlined by the ISPE GAMP D/A/CH Working Group on AI Validation, which employs a maturity model to guide validation practices [35].

In addition, the US Food and Drug Administration (FDA) recently published a draft guidance document on the use of AI models in drug and biological product submissions [36], underscoring the growing importance of clear regulatory pathways. The risk-based credibility assessment described in this draft defines the risk of an AI model as a combination of the influence the model has on an outcome and the impact of the decision resulting from it. The extent to which the AI models are evaluated should then be proportionate to the model risk. This concept of “model influence” and “decision consequence” can likewise be applied equally to the risk-based validation of DTs.

COST CONSIDERATIONS

A quantitative analysis of the costs for the development of DTs and ToTs is not yet possible, as no standardized application solutions are yet available on the market in the current state of development. Some of the most important cost drivers are presented in Table 4. Essential components, AI agents, and elements that can potentially be shared in the development and maintenance of DTs and thus have a potential to reduce overall costs are listed. The estimated cost contribution is based on our experience and is only a very indicative estimate.

The initial costs for setting up a DT will strongly depend on the digital maturity level [7] of the processes to be mapped. In addition, the costs incurred by inactivity, e.g., less predictable downtimes, should be considered as well and compared to the investment costs [37]. It should also be considered that DTs are currently at an early stage of development for industrially viable applications. The more they are standardized, modularized, and commoditized, the more significant cost reductions can be expected.

CONCLUSION

DTs—empowered by connected devices, IIoT, HPC, and advances in AI—offer the potential for unparalleled accuracy in simulating complex interactions, enabling informed decision-making, and mitigating risks of the real twin. Here we have illustrated their potential in combination with agentic AI to transform the

Table 4: Critical cost drivers for building up a DT of a process system are illustrated for pharmaceutical manufacturing applications

Cost Drivers	Essential Components	AI Agents	Shared Elements	Estimated Contribution
Process DT Core	• Critical process sensors • Real-time monitoring systems • Process control interfaces • Quality monitoring equipment	• Process optimization AI • Real-time anomaly detection • Predictive maintenance • Quality prediction	• Process knowledge base • Historical data • Model libraries	20%–25% of total cost
Regulatory Compliance	• Compliance monitoring systems • Electronic batch records • Audit trail systems • Documentation tools	• Compliance verification AI • Regulatory impact analysis • Documentation generators • Validation management	• Compliance frameworks • Validation protocols • Standard procedures	15%–20% of total cost
Predictive Analytics	• HPC • Machine learning infrastructure • Model development tools • Validation environments	• Predictive modeling AI • Pattern recognition • Optimization engines • What-if analysis	• Analytics platforms • Model repositories • Training datasets	10%–15% of total cost
Data Integration and Quality	• Enterprise data lake infrastructure • Master data management systems • Data validation tools • Integration middleware	• Data quality AI • Master data governance • Real-time data synchronization • Data lineage tracking	• Data standards • Integration frameworks • Validation protocols	25%–30% of total cost
Enterprise Integration	• API management platform • Integration servers • Security infrastructure • Cross-functional dashboards	• Enterprise orchestration • Decision support systems • Cross-process optimization • Risk management	• Internal procedures • Master data • Security protocols	10%–15% of total cost

pharmaceutical industry by optimizing production and general business processes, thereby improving decision-making and product life cycle management.

One of the key innovations presented is the development of interconnected ToTs. These allow for comprehensive, modular simulations across disciplines such as process control, production, quality assurance, and regulatory compliance. A modular, standardized architecture is required for seamless integration, making DTs scalable and adaptable to a variety of relevant use cases, from drug discovery and clinical studies to predictive maintenance and supply chain management.

The integration of agentic AI extends the capabilities of DTs by enabling autonomous decision-making and active learning. AI agents that create, review, optimize, and continuously improve simulations through feedback loops can simplify operations, improve prediction of outcomes and failures, and ensure compliance with stringent regulatory requirements. Despite the immense potential, challenges such as data protection, the integration of legacy systems, and the high initial costs of DT implementation are key barriers. We believe, however, that the long-term benefits, such as increased operational efficiency, reduced downtime, and cost savings, outweigh these initial

hurdles. Increasing standardization of DT technologies and AI validation frameworks, such as those proposed by the FDA and ISPE, will further facilitate adoption while ensuring safety, compliance, and ethical accountability.

DTs and agent-based AI represent a paradigm shift in the pharmaceutical industry, improving patient treatment results, driving continuous improvement, and facilitating more sustainable operations. A successful adoption of these technologies will require close collaboration between all stakeholders in the supply chain and product life cycle, continuous regulatory adaptation and investment in modular and scalable solutions. The transition to fully integrated ToTs has the potential to provide pharmaceutical manufacturers with greater control over the interacting CBPs and CBAs, leading to improved operational excellence, faster drug development, and further improvements in the quality and compliance of pharmaceutical supply to the public. 

References

1. International Society for Pharmaceutical Engineering. *ISPE Baseline® Guide Vol. 8: Pharma 4.0 (First Edition)*. North Bethesda, MD, US. 2023. <https://ispe.org/publications/guidance-documents/baseline-guide-vol-8-pharma-40-1st-edition>

2. Iliuță, M.-E., M.-A., Moisescu, E. Pop, A.-D. Ionita, S.-I. Caramihai, and T.-C. Mitulescu. "Digital Twin—A Review of the Evolution from Concept to Technology and Its Analytical Perspectives on Applications in Various Fields." *Applied Sciences* 14, no. 13(2024):5454. <https://www.mdpi.com/2076-3417/14/13/5454>
3. Rasheed, A., O. San, and T. Kvamsdal. "Digital Twin: Values, Challenges and Enablers From a Modeling Perspective." *IEEE Internet of Things Magazine* 8 (2020):21980–2012. <https://ieeexplore.ieee.org/document/8972429>
4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. "ICH Harmonised Tripartite Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, Guidance for Industry." November 2019. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.
5. Chen, Y., O. Yang, C. Sampat, P. Bhalode, R. Ramachandran, and M. Ierapetritou. "Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review." *Processes* 8, no. 9 (2020). doi:10.3390/pr8091088
6. Vergara, C., R. Bahsoon, G. Theodoropoulos, W. Yanez, and N. Tziritis. "Federated Digital Twin." *IEEE/ACM 27th International Symposium on Distributed Simulation and Real Time Applications (DS-RT)*, pp. 115–16, 2023. doi:10.1109/DS-RT58998.2023.00027
7. "Digital Plant Maturity Model V3." BioPhorum. 3 November 2023. www.biophorum.com/download/digital-plant-maturity-model-3-0/
8. Terranova, N., D. Renard, M. H. Shahin, et al. "Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices." *Clinical Pharmacology & Therapeutics* 115, no. 4 (2024):658–72. doi:10.1002/cpt.3053
9. Mariam, Z., S. K. Niazi, and M. Magoola. "Unlocking the Future of Drug Development: Generative AI, Digital Twins, and Beyond." *BioMedInformatics* 4, no. 2 (2024):1441–56. doi:10.3390/biomedinformatics4020079
10. Vallée, A. "Envisioning the Future of Personalized Medicine: Role and Realities of Digital Twins." *Journal of Medical Internet Research* 26, 2024. doi:10.2196/50204
11. Wang, H., T. Arulraj, A. Ippolito, and A. S. Popel. "From Virtual Patients to Digital Twins in Immuno-oncology: Lessons Learned from Mechanistic Quantitative Systems Pharmacology Modeling." *npj Digital Medicine* 7, no. 189 (2024). doi:10.1038/s41746-024-01188-4
12. Zhang, H., and F. Pei. "Environmental Space Design Based on Digital Twin Technology." Presented at the 2024 IEEE 4th International Conference on Electronic Communications, Internet of Things and Big Data, Taipei, Taiwan, 19–21 April 2024. <https://www.proceedings.com/content/075/075473webtoc.pdf>
13. Hongliang, L., H. C. Pangborn, and I. Kovalenko. "A System-Level Energy-Efficient Digital Twin Framework for Runtime Control of Batch Manufacturing Processes." Presented at the IEEE International Conference on Automation Science and Engineering, Auckland, New Zealand, 26–30 August. doi:10.1109/CASE56687.2023.10260642
14. Ladislav, R., J. Fabianová, M. Lokšík, and N. Mikušová. "Utilising Digital Twins to Bolster the Sustainability of Logistics Processes in Industry 4.0." *Sustainability* 16, no. 6 (2024):2575. doi:10.3390/su16062575
15. Canzoneri, M., M. Horner, and P. Banerjee. "Digital Twins in Biomanufacturing." *Bioconvergence Revolution* (2024): 59–81. doi:10.1007/978-3-031-61593-1_4
16. Martin, M., E. Blum, D. Wöllstein, and G. Lanza. "Mastering the Future of Production: A Training Concept for Digital Twins." *Lecture Notes in Networks and Systems* 1059 (2024):121–28. doi:10.1007/978-3-031-65411-4_15
17. van Dinter, R., C. Catal, O. Arends, S., et al. "Reference Architecture for IoT-Based Predictive Maintenance Systems Using Digital Twins." *SSRN*. 9 November 2024. doi:10.2139/ssrn.5014879
18. Ma, S., K. A. Flanigan, and M. Bergés. "State-of-the-Art Review: The Use of Digital Twins to Support Artificial Intelligence-Guided Predictive Maintenance." *arXiv* 2406.13117, June 2024. doi:10.48550/arXiv.2406.13117
19. Hazrat, M. H., N. M. S. Hassan, A. A. Chowdhury, M. G. Rasul, and B. A. Taylor. "Developing a Skilled Workforce for Future Industry Demand: The Potential of Digital Twin-Based Teaching and Learning Practices in Engineering Education." *Sustainability* 15, no. 23 (2023):16433. doi:10.3390/su152316433
20. Yin, Y., L. Wang, D. T. Hoang, W. Wang, and D. Niyato. "Sparse Attention-Driven Quality Prediction for Production Process Optimization in Digital Twins." *arXiv* 2405.11895v1 [cs.LG] 20 May 2024 <https://arxiv.org/html/2405.11895v1>
21. HaBe, H., H. van der Valk, F. Möller, and B. Otto. "Design Principles for Shared Digital Twins in Distributed Systems." *Business and Information Systems Engineering* 64 (December 2022):2022:751–72. doi:10.1007/s12599-022-00751-1
22. Conde, J., A. Munoz-Arcenales, A. Alonso, G. Huecas, and J. Salvachua. "Collaboration of Digital Twins Through Linked Open Data: Architecture With FIWARE as Enabling Technology." *IT Professional* 24, no. 6 (2023):41–6. doi:10.1109/MITP.2022.3224826
23. Fischer, R.-P., A. Volpert, P. Antonino, and T. D. Ahrens. "Digital Patient Twins for Personalized Therapeutics and Pharmaceutical Manufacturing." *Frontiers in Digital Health* 5, 2024, 1302338. doi:10.3389/fdgth.2023.1302338
24. Łukaniszyn, M., Ł. Majka, B. Grochowicz, D. Mikołajewski, and A. Kawala-Sterniuk. "Digital Twins Generated by Artificial Intelligence in Personalized Healthcare." *Applied Sciences* 14, no. 20 (2024):9404. doi:10.3390/app14209404
25. Björnsson, B., C. Borrebaeck, N. Elander, T. Gasslander, D. R. Gawel, M. Gustafsson, et al. "Digital Twins to Personalize Medicine." *Genome Medicine* 12, no. 1 (2020):1–4. doi:10.1186/s13073-019-0701-3
26. Mikołajewska, E., J. Masiak, and D. Mikołajewski. "Applications of Artificial Intelligence-Based Patient Digital Twins in Decision Support in Rehabilitation and Physical Therapy." *Electronics* 13, no. 24 (2024):4994. doi:10.3390/electronics13244994
27. Sai, S., A. Gaur, V. Hassija, and V. Chamola. "Artificial Intelligence Empowered Digital Twin and NFT-Based Patient Monitoring and Assisting Framework for Chronic Disease Patients." *IEEE Internet of Things Magazine* 7, no. 2 (2024):101–6. doi:10.1109/IOTM.001.2300138
28. Bousetouane, F. "Agentic Systems: A Guide to Transforming Industries with Vertical AI Agents." *arXiv*, no. arXiv:2501.00881. 2025. <https://arxiv.org/pdf/2501.00881>
29. Goodfellow, I., Y. Bengio, and A. Courville. "Deep Learning." MIT Press. 2016. www.deeplearningbook.org
30. Volodymyr, M., K. Kavukcuoglu, D. Silver, A. A. Rusu, J. Veness, M. G. Bellemare, et al. "Human-Level Control Through Deep Reinforcement Learning." *Nature* 518 (2015):529–33. www.nature.com/articles/nature14236
31. Yao, S., J. Zhao, D. Yu, N. Du, I. Shafraan, K. Narasimhan, et al. "ReAct: Synergizing Reasoning and Acting in Language Models." *arXiv preprint arXiv:2210.03629*, 2022. arxiv.org/abs/2210.03629
32. Hoang, M. "Maximizing the Power of LLM by Using ReAct Agent." *Medium*. 28 Aug 2024. <https://shorturl.at/iFpM5>
33. Budiardjo, A., and D. Migliori. "Digital Twin System Interoperability Framework." Digital Twin Consortium Whitepaper. December 2021. www.digitaltwinconsortium.org/pdf/Digital-Twin-System-Interoperability-Framework-12072021.pdf
34. "Automation Systems and Integration — Digital Twin Framework for Manufacturing. Part 1: Overview and General Principles." ISO. October 2021. www.iso.org/standard/75066.html
35. Erdmann, N., R. Blumenthal, I. Baumann, and M. Kaufmann. "AI Maturity Model for GxP Application: A Foundation for AI Validation." *Pharmaceutical Engineering* 42, no. 2 (March/April 2022):18–24. <https://ispe.org/pharmaceutical-engineering/march-april-2022>
36. US Food and Drug Administration. "Draft Guidance on Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, Draft Guidance for Industry and Other Interested Parties." January 2025. <https://shorturl.at/f6DGk>
37. Rubini, R., R. Cassandro, C. Semeraro, Z. S. Li, and M. Dassiti. "Cost-Benefit Evaluation of Digital Twin Implementation for Pharmaceutical Lyophilization Plant." *Innovative Intelligent Industrial Production and Logistics* (2023):398–407. https://doi.org/10.1007/978-3-031-49339-3_25

About the authors

Antonello Finucci, EMBA, is a seasoned engineer with over 20 years of experience. He specializes in Digital Twins and AI-driven innovation and in enhancing efficiency and safety across industries. A recognized leader in the field, he has spearheaded transformative projects that bridge technology and operational excellence. His work continues to drive advancements in smart systems and intelligent automation. He has academic credentials from the University of Pisa, Mannheim, and Johns Hopkins.

Stefan R. Kappeler, PhD, is Senior Director of Biopharma and Regulatory at Exyte and has over 30 years of experience in the life sciences industry. He has completed a variety of projects in research, clinical development, early and late process development, technology transfer, upstream and downstream biological drug manufacturing, quality control and assurance, facility design, engineering, commissioning, and qualification. He received his PhD in molecular biotechnology from the Swiss Federal Institute of Technology in Zurich.

REIMAGINING INFORMED CONSENT

AI Avatars in the Era of Complex Clinical Trials

By Ina Burgstaller, Martin Heitmann, LaToya Hinton, and Brandi Stockton

Informed consent aims to provide clinical trial participants with transparent education about the trial's objectives, potential risks and benefits, and procedural requirements. As clinical trial designs evolve to include decentralized and adaptive elements, the informed consent process becomes increasingly complex. In response, this article explores the potential application of AI-powered synthetic avatars as an informational tool to support participants during clinical trials.

HOW AI CAN HELP IMPROVE INFORMED CONSENT

In recent years, efforts to improve the efficiency and effectiveness of informed consent in clinical trials have been sought, propelled by the needs created by the COVID-19 pandemic. Although technological platforms have facilitated efficient ways to collect consent, participant comprehension remains a challenge. As clinical trial designs become more complex by incorporating adaptive protocols or decentralized elements, studies demonstrate that fundamental information is often not well understood by participants [1]. For example, a trial participant and attorney shared how the lengthy and complex language of current consent forms led her to overlook important information, despite her legal expertise [2].

This anecdote underscores a proposed mandate of the US Food and Drug Administration (FDA) that Informed Consent Forms (ICFs) should start with key information—the essential details that help potential participants decide to join a study [3]. Clearly, there is a need to simplify consent language, but there is also potential for modern technologies to support equitable education of participants. In particular, synthetic avatars powered by artificial intelligence (AI) may support participants' true understanding of trial aspects. This article describes how an AI-based synthetic avatar can assist site operators and clinical research organizations (CROs) during the recruitment and informed consent process in providing a multimodal experience via video and audio.

Leveraging *ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)* and its Appendix D11 [4], the *ISPE GAMP® Good Practice Guide: Validation and Compliance of Computerized GCP Systems and Data—Good eClinical Practice (Second Edition)* [5], and the FDA's recent draft guidance [6] on enhancing informed consent in clinical research, we aim for safe and effective use of an AI-based solution. We also discuss recurring challenges, ethical considerations, and the benefits to various stakeholders—including patients, Contract Research Organizations (CRO)s, sites, and sponsors.

INFORMED CONSENT PURPOSE AND ELEMENTS

An ICF serves two main purposes: First, it explains aspects of clinical trials to the patient, and second, allows the patient the option to agree to its conditions. Hence, it should provide the relevant information to make this decision in a fair, unbiased, and informative manner, suitable for the typical knowledge level of a patient [7].

Typical elements of an ICF include:

- **Purpose of the trial:** Explains the goal of the research, including details about the investigational product.
- **Details of the trial:** Covers aspects such as the trial's duration, the role of alternative therapies or placebos, and any procedures involved.
- **Potential benefits:** Describes possible benefits for the participant, while fairly acknowledging associated uncertainties.
- **Rights:** Outlines legal considerations, including data privacy, regulatory inspections, and the participant's right to withdraw at any time
- **Risk and discomforts:** Lists potential side effects or adverse events that may occur, presented clearly and in an informative manner based on current evidence.

With fair treatment and effective communication as key objectives, patient-centered and culturally sensitive approaches are of high relevance. Consent forms should be tailored to the diverse needs of study participants, fostering an inclusive environment in which all participants are truly informed about trial procedures.

These considerations are even more important when aiming for a high degree of diversity in trials in the realms of rare diseases and

personalized medicine, where trials tend to be smaller and more specialized [8]. Although decentralized clinical trials offer a partial solution by reducing the need for travel and potentially increasing trust through more personalized engagement, establishing trust through effective patient information also needs to be considered, especially when decentralized layouts lack direct human interaction.

TECHNOLOGY ADVANCEMENTS

Supporting ideas presented in this article, two important technological advancements are considered with both potential in Good Clinical Practice (GCP) and other guidelines and regulations (GxP and non-GxP) of the pharmaceutical, biotech, and life sciences industries. These include electronic informed consent (eConsent) platforms and AI-based synthetic avatars.

eConsent Platforms

eConsent platforms [9] (see also FDA guidance) allow for more dynamic and interactive consent processes [10]. Through these platforms, informed consent processes may adapt according to the user's comprehension and feedback, addressing individual needs and enhancing understanding. In this context, further regulation and guidance such as the European Union's General Data Protection Regulation (GDPR) [11] or changes to the US Common Rule [12] should be considered regarding data protection and privacy, as well as ethical aspects.

AI-Based Synthetic Avatars

AI-based synthetic avatars are digital constructs that represent humans, characters, or entities in virtual environments. These are typically created using a combination of 3D modeling, animation, and AI technologies. After designing the avatar's visual human-like appearance, dynamic behavior and movement are enabled by modeling a skeletal system close to real-world behavior. Programmers and animators ensure that the avatar can display a range of motions and expressions.

Synthetic avatars can be further augmented to enable interactive behavior, responding to input in real time. For instance, AI components process inputs from users or the environment and respond in a way that mimics human reactions. In more advanced applications, such as customer service bots or virtual assistants, avatars engage in conversations with humans. Synthetic avatars are currently evolving, enhancing their realism and responsiveness. Avatar synthesis is available as a software-as-a-service, for utilization in various contexts of use. Such use requires careful consideration of GxP requirements in areas like clinical trials, as demonstrated throughout the article.

MANAGING INFORMED CONSENT: KEY CHALLENGES

Challenges in managing informed consent in clinical trials affect participant understanding and ethical considerations. Primary challenges in informed consent include poor understanding, growing complexity, and lack of respect for autonomy. Addressing these challenges through a combination

of educational enhancements, technological integration, and clear communication strategies holds great potential for fairer and more inclusive clinical trials.

Biesecker et al. have demonstrated this potential in a study [13], evaluating the effectiveness of an interactive computer-based informed consent process compared to traditional paper-based methods. The researchers found that participants who used the interactive system showed significantly better comprehension of study information, including details about randomization and potential side effects.

Limited Understanding of Basic Trial Concepts

Many studies indicate that some participants only have a poor understanding of even the basic aspects of the clinical trials they join [1], sometimes participating out of altruism rather than informed decision-making. An example of this challenge is the "therapeutic misconception," which means that participants mistakenly believe that the clinical trial is designed to address their personal medical needs. This misconception leads them to overestimate the benefits and underestimate the risks involved.

Growing Complexity

Modern clinical trials may include decentralized elements, intricate treatment approaches, and adaptive study protocols. At the same time, participants expect to receive clear, truthful information about the trial's purpose, procedures, alternatives, and potential risks and benefits. Often, the technical jargon and volume of information can be overwhelming.

Lack of Respect for Autonomy

Informed consent is fundamental for ethical clinical trials because it respects participants' rights to make their own decisions. However, true autonomy is achieved only when consent is fully informed. Thus, facilitating consent is provided entirely voluntarily, free from undue pressure or deception.

KEY FINDINGS

Key findings from this study include:

- Participants using the interactive system spent more time reviewing the consent information.
- The interactive group showed better understanding of the study, with higher quiz scores on consent-related questions.
- Participants reported higher satisfaction with the interactive consent process.

To overcome these challenges, this article focuses on patient-centered forms of providing information, leveraging innovative technology like synthetic avatars when explaining key trial elements as a preparatory step during recruitment or when educating the patient before an interview with clinical staff and obtaining formal consent.

TAKING A LIFE CYCLE APPROACH

As described in *ISPE GAMP® 5: A Risk-Based Approach to Compliant*

GxP Computerized Systems (Second Edition) [4], a thorough life cycle approach to computerized systems provides a robust foundation for safe and effective support of GxP-regulated processes. Integrating life sciences validation concepts and data science methods to achieve fitness for the intended use of the system, the guide's Appendix D11 has established a dedicated life cycle model, including three key phases: concept, project, and operation.

This case study's main focus is the concept phase, with an outline of the subsequent project phase. Taking a patient-centered design and implementation approach is required in the context of informed consent, keeping in mind the particular needs of patients as direct end users of the system. In addition, regulatory requirements in a GCP context need to be considered, including Institutional Review Board (IRB) review and approval.

A particular point of interest in this case study is the close collaboration between a site owner and a solution provider collaboratively exploring the potential of synthetic avatars in informed consent. Following this collaborative approach, an implementation roadmap was created. These insights may serve as input for further innovation initiatives in GCP and the use of AI.

Concept Phase

The concept phase includes the business opportunity or challenge to define the intended use, identify data and modeling options, perform initial risk assessment activities, and may include a prototype to demonstrate technical feasibility.

Project Phase

The project phase includes the specification of model requirements, preparation of data including data engineering and data splitting, and iterative experimentation and fine-tuning of models to derive a release candidate and perform formal acceptance testing.

Operation Phase

The operation phase, which guides the AI-enabled system throughout subsequent iterations, leverages data for ongoing monitoring and change management to maintain a validated state and maximize potential for improvement.

UNDERSTANDING PARTICIPANT NEEDS IN INFORMED CONSENT

Building on the previous section's exploration of challenges in the informed consent process, a more participant-centered, adaptable approach is required to address the key issues identified [14]. In summary, participants often face barriers to understanding the trial due to complex language, static formats, and a lack of personalized engagement, which can diminish their ability to make fully informed decisions and reduce overall trial retention.

Taking a patient-centered view, key challenges that participants face are described in more detail in this section. Understanding these barriers is essential for developing a patient-centered approach to avoid possible confusion and mistrust or hesitance in participation.

Excessive Length

ICFs are frequently criticized for being too lengthy, which discourages thorough reading and leads to poor comprehension. Studies show that longer documents can overwhelm participants, reducing their understanding and retention of key information. For example, a study published in the *Journal of Patient Experience* [15] found that rural patients are underrepresented in cancer trials, and a study comparing short (2,000-word) vs. long (6,000-word) consent forms found that among 240 patients, 89 (37%) were rural. Seventy-one (80%) rural and 117 (77%) nonrural patients signed a consent form of any length ($P = .68$). Forty-one of 47 (87%) rural patients signed a short consent form; in contrast, 30 of 42 (71%) signed a long form. This underscores the importance of how simplifying ICFs could improve accessibility, understanding, and engagement, particularly among underrepresented populations [15].

High Complexity and Readability

In addition to length, the complexity and readability of ICFs present a significant barrier. Most ICFs are written at or above a tenth-grade reading level, far exceeding the recommended eighth-grade level, which makes them difficult for many participants to understand (further information on grade systems can be found at "Good Calculators" [16]). This challenge is further compounded in low- and middle-income countries, where high illiteracy rates and the use of vernacular languages add another layer of difficulty.

Legal Protection Focus

Although simplifying language can aid in readability, it is equally important to shift away from the legal-heavy focus that dominates many ICFs. Often, these forms are primarily designed to protect institutions, investigators, and sponsors legally, rather than to ensure clarity for participants. This focus on legal protection leads to overly complex clauses that may seem confusing or even unfair to participants.

Mistrust and Anxiety About Clinical Trials

This need for transparency becomes apparent through the lack of familiarity with the process, and prior negative experiences contribute to participant anxiety and hesitation. This stigma around clinical trials, particularly for those who have not previously participated, often acts as a barrier to recruitment. For example, a study on different types of distrust in clinical research among White and Black Americans found that Black Americans were significantly more likely than White Americans to believe they could be "used as guinea pigs" without their consent (54% vs. 28%) [17].

Common to these challenges is the divide between sponsors, CROs, and other healthcare organizations on the one hand and patients on the other, with differing levels of experience and domain expertise. Thus, proactively understanding these challenges and addressing the diverse needs of participants through new approaches to the communication of information during informed consent holds high potential for fairer clinical trials.

CONSENT STRATEGIES FOR DIVERSE POPULATIONS

Addressing challenges and needs identified in the previous section is at the core of selecting a solution approach, addressing key challenges in understanding and agreeing to risks, obligations, and responsibilities as provided in ICFs. In addition to general aspects, such as the use of simpler language, a more engaging presentation of information in informed consent through video and audio elements may help demystify complex aspects of clinical trials. This could enable participants to better understand the purpose, risks, and protocols involved.

Such methods of presentation may also involve personalized elements, tailored to the needs of subpopulations or even on a patient level. With the goal of providing further, more engaging and interactive means of presentation of content, synthetic avatars were identified as a way to achieve a more engaging experience in providing content. These avatars can articulate content, including mimics and gestures, and allow for a multi-channel experience instead of plain text.

In this context, a study published in *JMIR Formative Research* [18] found that participants who used short-form, video-based eConsent demonstrated higher satisfaction (83.2% vs. 76.3%, $P = 0.047$) and improved understanding of risks, privacy, and procedures compared to those using traditional written consent forms. This supports the potential value of incorporating multimedia tools, such as synthetic avatars, to further enhance engagement and comprehension in the informed consent process.

The complexity and heterogeneity of approved study materials and cultural preferences need to be reflected to promote inclusivity and reduce the stigmas that may discourage participation, and to help achieve diverse patient populations in trials. Therefore, the avatar should match the target population in ethnicity and gender, whereas further configuration elements, such as the voice and tone, should be selected to mirror the professional environment of clinical trials. Further design elements and requirements were established:

- Provide information in sections, with stepwise coverage of the ICF's content.
- Patients must not be able to skip content. They must confirm understanding of information before proceeding.
- Patients may be able to repeat passages and sections, as per their understanding and the complexity of content.

CONSIDERATIONS FOR BUSINESS PROCESS INTEGRATION

This solution is applied at the intersection of participant recruitment and the informed consent process, extending to boundary activities such as registration and participant education or interviews with an investigator or clinician. To effectively integrate the digital solution within the clinical trial process, the following aspects were considered:

- Synthetic avatar videos are prepared based on the ICF, tailored to a set of patient subpopulations. These videos are embedded in a solution that guides the patient through education on the informed consent information. To this end, avatar synthesis was used as a

service, configuring the synthesis behavior without fine-tuning the AI components generating the avatar.

- The solution enhances initial participant engagement by simplifying registration when individuals first encounter information on the clinical trial, leading to a more streamlined participant experience.
- Following registration, the approach aims to support education through interactive modules, including controls such as ensuring coverage of the complete ICF. This approach not only facilitates a deeper understanding, but also ensures that all interactions are grounded in clarity and compliance.
- The informed consent process is concluded by an interview with an investigator or clinician, with patients being better prepared so that the focus is shifted to more personally relevant elements like potential benefits and risks for the patient.

STAKEHOLDER ENGAGEMENT AND PERSPECTIVES

Integrating synthetic avatars offers a wide range of benefits for both patients and clinical trial stakeholders.

- **Patients:** ICFs facilitated by avatars can make complex information more accessible and can help patients better understand study protocols, thereby increasing engagement and comprehension. As avatars can explain procedures at the user's preferred pace, patients' anxiety may be lowered.
- **CROs and Site Management Organizations (SMOs):** By educating patients more effectively, avatars streamline the consent process, reducing the time and resources typically spent on participant education. This efficiency improves participant retention and allows CROs and SMOs to manage trials more effectively, showing strong support for sponsor goals and minimizing delays or risks due to misunderstandings.
- **Clinical staff:** When patients are well-informed about trial procedures, clinical staff can dedicate less time to addressing patient concerns or confusion. This enables them to focus on more personalized aspects in support of the participant or productive research activities rather than clarifying procedural details.
- **Private site owners:** Following innovative approaches may offer smaller, diverse private sites a chance to differentiate themselves from the competition in a competitive marketplace.
- **Sponsors:** For sponsors, AI-driven consent solutions like avatars lead to cost savings and resource efficiencies by accelerating the trial pipeline and improving participant retention.

Grounded in GCP guidelines and the *ISPE GAMP® Good Practice Guide: Validation and Compliance of Computerized GCP Systems and Data – Good eClinical Practice (Second Edition)* [4], this multi-stakeholder approach illustrates how avatar-supported informed consent can enhance trial quality, participant experience, and operational efficiency across clinical research settings. In particular, the risk of participants having incomplete or misunderstood information may be reduced, which promotes patient safety, increases efficiency, and mitigates the technical risks of the study.

A RISK-BASED APPROACH TO AVATAR IMPLEMENTATION

A risk-based approach allows for the focus of resources on relevant areas, taking a forward-looking approach based on process understanding. The possible impact on patient safety at the initial field study level with a limited number of patients, hazards, potential risk impacts, and mitigation strategies has been identified for the synthetic avatar implementation, and examples are displayed in Table 1. Here, we follow a user-centric approach with particular focus on the patient, as recommended by the eClinical Good Practice Guide [5].

ETHICAL CONSIDERATIONS AND IRB SUBMISSION

Given the selection of risks described in the previous section, implementing an avatar-based informed consent solution requires careful attention to ethical concerns and adherence to GCP principles. As with standard advertising processes, scripts for avatars are developed following rigorous GCP guidelines and are submitted to institutional review boards for review. These scripts are quality controlled to align with approved materials, ensuring that content remains accurate, clear, and ethically sound. Only after institutional review board approval are the final synthesized videos delivered and ready for patient use. In this context, the following aspects are of high relevance.

- **Transparency and disclosure:** Patients should be fully informed of the avatar's purpose and role in the consent process, emphasizing that this approach supplements, rather than replaces, discussions with clinical staff.
- **Accessibility options:** To accommodate diverse needs, the avatar solution should provide both audio and video formats, allowing patients to choose their preferred way of accessing information. This multimodal approach addresses participants with varying levels of literacy, language skills, or accessibility requirements.
- **Patient diversity and representation:** Recognizing the importance of patient diversity, avatars should be tailored to reflect the cultural and demographic characteristics of study populations. For instance, a Black avatar with an authentic, culturally resonant voice can be used to better connect with Black patients to match their background, fostering a sense of familiarity and reducing perceived barriers to participation.

Incorporating these considerations, the integration of synthetic avatars in the informed consent process supports both ethical transparency and patient-centered communication, ensuring that the technology meets the highest standards of accessibility and cultural compatibility.

PROTOTYPE IMPLEMENTATION

Building on previous design, ethical, regulatory, and cultural considerations, the concept phase continues with the development of a prototype. This prototype combines selected components designed to enhance patient understanding and engagement while adhering to GCP guidelines. The selection process, quality assurance measures, and site preparations were highly relevant to

Table 1: Hazard–risk impact and mitigation strategy adopting synthetic avatars for informed consent.

Hazard	Risk Impact	Mitigation Strategy
Synthetic avatar's articulation does not match the exact content as provided in the ICFs.	Patient confusion of informed consent information may lead to deviation from the clinical trial protocol and thus post risks to patient safety (GxP risk) and regulatory acceptance (regulatory risk), and create legal implications due to failure in appropriately educating the patient (legal risk).	Carefully review the input provided to the avatar synthesization solution, ensuring it matches the exact approved version of the ICFs, and conduct a careful assessment of completeness and accuracy of the synthesized materials.
Gestures and mimics do not match the natural flow of human interaction.	Patients may miss crucial information with similar consequences as the first hazard, due to distraction by the unusual appearance of the synthesized avatar.	Carefully review synthesized materials with a focus on human interaction, carefully considering the cultural background and technical aspects such as the “uncanny valley” effect of close-to-human robots.
Patients may be distracted, e.g., browsing the internet while being educated about the trial by the avatar.	The patient may miss crucial information due to losing interest or attention, rendering the avatar ineffective in educating the patient, with similar consequences as the first two hazards.	Quiz the patient on crucial information to ensure that they have a clear understanding. Have the investigator interview the patient to ensure the effectiveness of the information conveyed. Provide information in chunks with deliberate prompts promoting attention to the content.
Patients may skip information.	Risk impact is similar to that in the case where the patient is distracted.	Do not enable fast-forward functions in the system.

Figure 1: Synthetic avatar workflow for informed consent





Figure 2: Results of the initial field study

ensure that the prototype is fit for purpose. The following elements have been considered.

- **Selecting and customizing components to meet patient needs:** Key design components—such as avatar’s appearance, script language, and interactive features—were carefully chosen to support clarity, accessibility, and patient-centered communication. Special attention was given to verifying that the avatar’s mimicry and pronunciation meet high standards of authenticity and clarity. Pronunciation, tone, and facial expressions were chosen to convey empathy and professionalism, improving participant trust and comprehension. Thorough testing ensured meeting stated objectives, considering risks as outlined previously.
- **Maintain alignment and consistency with approved ICF content:** The avatar’s spoken content and visual representations were aligned with the approved ICF. Every script follows the exact language of the approved materials, with adjustments made for simplicity and clarity where appropriate. The outcome was reviewed by the quality assurance unit to verify completeness and accuracy, thus providing a reliable resource for participants consistent with subsequent steps in the process and the original ICF.
- **Site preparations and testing:** Before deployment, site preparations were conducted to ensure that the prototype integrates smoothly within the clinical process. This includes

configuring the system to support seamless access to the avatar solution, training the site staff on effective use, and establishing supporting information to address participant questions or technical issues. Regular checks were conducted to ensure that the avatar performs reliably, with responsiveness to any errors or inconsistencies that could affect patient comprehension and safety.

The prototype implementation resulted in an avatar solution that meets high standards of accuracy, accessibility, and ethical transparency. By embedding these measures into the development of the avatar tool, the prototype solution lays a strong foundation for patient-centered communication that supports participants’ understanding and trust throughout the informed consent process. Data collection for initial use of the solution is described in the next section.

FIELD STUDY RESULTS

Data were collected to evaluate the effectiveness of the avatar-supported prototype in supporting informed consent processes. Both quantitative and qualitative data were gathered, including comprehension levels, engagement metrics, retention intentions, and efficiency in the consent process to assess how well the avatar tool supports patient understanding, satisfaction, and retention in clinical trials.

As displayed in Figure 2, the synthetic avatar explanation provided benefits to patients:

- Patients preferred the synthetic avatar, with no reports of a “fair” or lower rating, unlike the paper-based informed consent.
- Patients reported the avatar to be more engaging, with a majority of responses expressing that the avatar was very engaging, whereas the majority of patients reported the paper-based informed consent to be either not engaging or neutral.
- 100% of respondents found the AI avatar format to have an adequate length, compared to 60% who did so for the paper format.
- All participants expressed they felt very confident in deciding whether to participate in the study when having access to the synthetic avatar, whereas 40% reported some level of hesitation (“somewhat confident”) when only having access to the paper-based ICF.

Even though the number of patients is rather low ($n = 5$), the data align with findings from the *JMIR Formative Research* study [18]. This study highlights the role of short form video-based eConsent tools in enhancing patient-centered communication and informed decision-making in clinical trials. The preliminary data and prototype approach have demonstrated significant potential to refine and expand the solution, maximizing its effectiveness in the informed consent process.

CHALLENGES AND CONSIDERATIONS

As the AI-powered avatar solution for informed consent progresses toward broader implementation, several challenges are anticipated and require careful planning.

Coverage Across Diverse Trial Complexities

One significant challenge is ensuring that the AI-powered avatar solution can adapt to various levels of trial complexity. Different protocols may necessitate unique or adaptive consent elements that require the same level of flexibility in the avatar approach to ensure accuracy in conveying the trial information. Application across a range of protocols will help improve its adaptability, enabling it to support diverse informational needs and foster greater retention by providing clear, protocol-specific information. Combining the use-case scenarios with a comprehensive functional risk assessment form should create the basis for a testing strategy. This will demonstrate the fitness for intended use for wider application of the synthetic avatar solution.

Language Barriers

Providing language support for less frequently spoken languages poses a challenge for the avatar synthesis technology in ensuring inclusivity and accessibility in the consent process, given the high-quality required. If these language needs are unmet, there's a risk of alienating participants from specific demographics, potentially affecting trial enrollment and participant diversity. Integrating translation capabilities and partnering with language

experts should help the avatar provide clear communication for all subpopulations and patients.

Consent Management

Managing multiple versions of the consent process for various subpopulations is essential for maintaining compliance and patient understanding. Thorough version control is required to manage the baseline synthesization model, content, and configurations for various trials. Monitoring should ensure that the chosen configuration for a trial yields the expected outcomes. This should allow for the leveraging gathered data for planning the application of the synthetic avatar in further trial settings.

Established eConsent Platform Integration

For the AI-powered avatar solution to enhance rather than disrupt the informed consent workflow, it must integrate seamlessly with existing eConsent platforms.

Supplier and Partner Relationship Management

While providing a specific application for use in a clinical trial setting, the synthetic avatar solution will be dependent both on supplied components (like the synthesization model) and integration with eConsent platforms. Robust supplier and partner management, including change management and incident management processes, are important to maintain the fitness for intended use.

Legal Considerations for Data Capture and Storage

The avatar's interactions with patients involve patient-specific data, which raises legal considerations around data capture, storage, and usage. Failure to comply with privacy regulations could undermine patient trust and compromise trial compliance. Furthermore, such data is of high relevance to assess the effectiveness of the avatar or identify weaknesses.

Jurisdictional Variability in Regulatory Expectations

With clinical trials often spanning multiple jurisdictions, each with unique regulatory requirements, the synthetic avatar solution must be adaptable to meet these diverse standards. Failure to address jurisdictional variations could lead to regulatory noncompliance, which could potentially impact trial outcomes. By proactively addressing these challenges and drawing on successful approaches from similar projects, the team is laying the foundation for a scalable, adaptable, and compliant AI-powered avatar solution.

CONCLUSION

The integration of AI methods into informed consent processes—coupled with expert oversight and thorough quality assurance processes aligned with standards set by the respective institutional review board and ethics committee—offers substantial potential in clinical trials. With the goal of improving participants access to ICF information, participant comprehension, engagement, and satisfaction can be improved. These objectives were verified

in a field study, providing quantitative and qualitative insights into the real-world benefits of the use of synthetic avatars in the informed consent process. These findings indicate that the approach may support the success, diversity, and ethical integrity of clinical trials, contributing to more inclusive and representative research that benefits a broader range of participants.

In addition to the use case explored in this article, AI-enabled approaches may not only elevate the participant experience but also open avenues for more dynamic engagement throughout the entire clinical trial process. For instance, interactive avatars can support participants throughout the trial by guiding them through study protocols, explaining risks and benefits, and answering common questions. This interactive model may help participants better understand and adhere to the study, ensuring they feel supported at every stage.

However, thorough data and risk management are required in environments such as clinical trials. Control measures should be considered (e.g., involvement of human experts when interactive avatars hit limitations) and avatar interactions should be regularly reviewed to reduce the risk of errors and implications for patient safety or data integrity. Considering further innovative approaches like interactive avatars will require thorough evaluation, demonstrating fitness for intended use across a broad range of scenarios, thus necessitating a representative test data set [4].

Adopting these innovative approaches requires a practical implementation approach and rigorous quality considerations, e.g., by leveraging recently published guidance as in the *ISPE GAMP® Good Practice Guide: Validation and Compliance of Computerized GCP Systems and Data – Good eClinical Practice (Second Edition)* [5].

Looking forward, the potential of AI in clinical trials extends beyond informed consent. AI-driven systems may support more patient-centered clinical trials by playing a central role in trial engagement, safety monitoring, and participant support, paving the way for more effective, ethical, and inclusive trials that benefit all stakeholders involved. 

Acknowledgments

The authors would like to thank the ISPE GAMP Global Software Automation and Artificial Intelligence Special Interest Group for its support in the creation of this article. We would like to thank Keith Berelowitz, Ebone Jenkins, Lia Hunter, Jennifer Lechner, Ulf Menzler, and Laila Rasmy-Behket for their review of this article and insightful discussions during the writing process.

References

- Pietrzykowski, T., and K. Smilowska. "The Reality of Informed Consent: Empirical Studies on Patient Comprehension—Systematic Review." *Trials Journal*. 22, no. 57 (2021). <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04969-w>
- Afolabi, A., E. Cheung, J. C. Lyu, and P. M. Ling. "Short-Form Video Informed Consent Compared with Written Consent for Adolescents and Young Adults: Randomized Experiment." *JMIR Formative Research* 8 (2024).
- Covington news alert. "FDA Proposes Rules on Informed Consent and Institutional Review Boards." 12 October 2022. www.cov.com/en/news-and-insights/insights/2022/10/fda-proposes-rules-on-informed-consent-and-institutional-review-boards
- International Society for Pharmaceutical Engineering. *ISPE GAMP® 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition)*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2022.
- International Society for Pharmaceutical Engineering. *ISPE GAMP® Good Practice Guide: Validation and Compliance of Computerized GCP Systems and Data—Good eClinical Practice (Second Edition)*. North Bethesda, MD: International Society for Pharmaceutical Engineering, 2024.
- U.S. Food and Drug Administration. "Key Information and Facilitating Understanding in Informed Consent, Guidance for Sponsors, Investigators, and Institutional Review Boards. Draft Guidance." March 2024. www.fda.gov/media/176663/download
- U.S. Food and Drug Administration. "Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors." <https://www.fda.gov/media/88915/download>
- DLRC. "Rare Disease Day: Regulatory Challenges in Rare Disease Drug Development." 28 February 2024. www.dlrcgroup.com/rare-disease-day-regulatory-challenges-in-rare-disease-drug-development/
- U.S. Food and Drug Administration. "Use of Electronic Informed Consent Questions and Answers, Guidance for Institutional Review Boards, Investigators, and Sponsors." Procedural. December 2016. www.fda.gov/media/116850/download
- National Health Service. "What Is Dynamic Consent?" Updated 5 March 2019. www.hra.nhs.uk/about-us/news-updates/what-dynamic-consent/
- European Union (EU). "Regulation (EU) 2016/679 of the European Parliament and of the Council on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data, and Repealing Directive 95/46/EC (General Data Protection Regulation)." 27 April 2016. <https://eur-lex.europa.eu/eli/reg/2016/679/oj>
- U.S. Department of Health and Human Services. Office for Human Research Protections. "Federal Policy for the Protection of Human Subjects ('Common Rule')." Last reviewed 27 March 2024. www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html
- Biesecker, B., M. Raspa, D. Rupert, R. Moultrie, R. Furberg, and L. A. McCormack. "Making Clinical Trials More Patient-Centered Using Digital Interactive E-Consent Tools." Research Triangle Park, North Carolina: RTI Press, 2019.
- Krishnamurti, T., and N. Argo. "A Patient-Centered Approach to Informed Consent: Results from a Survey and Randomized Trial." *Medical Decision Making* 36, no. 6 (2016):726–40. doi:10.1177/0272989X16636844
- Wieland, J., Satele, D., Almodallal, Y., Novotny, P., Pritzl, S. L., Mandrekar, S. J., and A. Jatoi. "Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded Study." *Journal of Patient Experience* 9 (2022): 1–5. <https://doi.org/10.1177/23743735221107242>
- GoodCalculators.com. "Flesch-Kincaid Calculator." <https://goodcalculators.com/flesch-kincaid-calculator/>
- Verheggen, F. W. S. M., and F. C. B. van Wijmen. "Informed Consent in Clinical Trials." *Health Policy* 36, no. 2 (May 1996):131–53. www.sciencedirect.com/science/article/abs/pii/0168851095008055
- Abujarad F., Peduzzi P., Mun S., Carlson K., Edwards C., Dziura J., Brandt C., Alfano S., Chupp. "Comparing a Multimedia Digital Informed Consent Tool With Traditional Paper-Based Methods: Randomized Controlled Trial." *JMIR Formative Research*. 19 May 2020. doi:10.2196/20458 <https://formative.jmir.org/2021/10/e20458>

About the authors

Ina Burgstaller, MSc, is Founder & CEO of Bionabu, a health and life sciences company that specializes in AI-powered pediatric patient engagement and clinical trials. She is on a mission to advance healthcare communication by integrating AI-driven solutions that enhance patient education, informed consent, and clinical trial efficiency. Building on her expertise in the pharmaceutical and CRO industry, she established AI ICFs, virtual patient engagement platforms, and digital training programs for clinical professionals.

Martin Heitmann, MSc, has over a decade of consulting experience. He applies process design, data science, and large-scale implementation expertise to digital transformation projects across pharma and healthcare areas. He is currently Secretary of the ISPE GAMP® Special Interest Group on Software Automation and Artificial Intelligence, a member of the ISPE Steering Committee of GAMP D-A-CH, and is a frequent contributor to the ISPE magazine, *Pharmaceutical Engineering*, and ISPE Good Practice Guides. He has been an ISPE member since 2022.

LaToya Hinton, MPH, is CEO and Research Director of Next Innovative Clinical Research, a site management organization that specializes in facilitating and managing multi-specialty research sites in Houston and Chicago. With 13 years of pharmaceutical research experience, including positions at Northwestern University, Rush University, and The University of Chicago, Hinton brings extensive expertise across multiple therapeutic areas, including women's health, dermatology, gastrointestinal, cardiovascular, respiratory, and oncology.

Brandi Stockton, MBA, is Founder and Managing Partner of The Triality Group, LLC, a firm specializing in quality, regulatory, and compliance consulting services for the life sciences industry. She brings over 20 years of industry experience, with a focus on computer systems quality and data integrity. Stockton joined ISPE in 2014 and currently serves as a member of the GAMP Global Steering Committee, Chair of the GAMP Americas Steering Committee, and Co-Lead of the GAMP Global Software Automation and Artificial Intelligence Special Interest Group.

VISUAL INSPECTION IS KEY TO ENSURING PATIENT SAFETY

in US Pharmaceutical Compounded Products

By Kristopher Le, PharmD, Craig Mastenbaum, Anil Mathai, Deborah McHugh, Shelley Preslar, David Short, Christopher Smalley, PharmD, PhD, Willis Triplett, PharmD, and Rebecca Welton

Visual inspection is nothing new to professionals who make, prescribe, prepare, and/or administer pharmaceutical parenteral products to patients of all backgrounds, especially those who may have immunity concerns. The pharmaceutical industry has tried to ensure that companies enact the best quality standards that are consistent with Current Good Manufacturing Practices (CGMPs) to prevent an adulterated product from entering the market.

For companies that compound drug products in the United States—whether regulated as a 503A (Compounding Pharmacy) or 503B (Outsourcing Facility)—these procedures also apply, and if followed, will simultaneously meet requirements enacted by the US Food and Drug Administration (FDA) and/or multiple State Boards of Pharmacy (SBOP). While the concepts in this article reference FDA and SBOP standards, they may also apply to other regions. However, each region has specific requirements. Manufacturers should be aware of regulatory requirements in regions where they operate.

Visual inspection can be done via a manual process or through an automated process. Traditional pharmaceutical manufacturers are more likely to utilize automated Visual Inspection processes. However, compounding entities are likely to continue using manual Visual Inspection processes because developing automation when batch sizes are small may not be practical. The focus of this article is the manual aspect of Visual Inspection and not on specific products or defect troubleshooting.

Visual inspection may actually be a bit of a misnomer, as it isn't an assessment, but a step in the manufacturing process by which defects are found and removed from the batch. This can


encompass multiple aspects, including examining the physical characteristics of the container (cracks, defects, bad crimp), but it primarily focuses on inspection for visible particulates. Per the FDA Draft Guidance for Industry, "Inspection of Injectable Products for Visible Particulates" (December 2021), the following definitions should be utilized in visual inspection [1]:

- Particulates refer to mobile, undissolved particles—other than gas bubbles—that are unintentionally present in an injectable product. They vary in nature (e.g., metal, glass, dust, fiber, rubber, polymer, mold, degradant precipitate) and can be categorized into three types:
 - Inherent particulates are an innate product characteristic (e.g., protein aggregation).
 - Intrinsic particulates originate from the manufacturing equipment, product formulation, or container system (e.g., syringe fibers).
 - Extrinsic particulates originate from the manufacturing environment and are foreign to the process (e.g., metal particulates).

This article focuses on 503B Outsourcing Facilities, which produce tens of thousands of units daily across the United States for patients in all fifty states. Currently, there are more than 90 registered Outsourcing Facilities [2], ranging from small producers (<1,500 units per batch) to large producers (>5,000 units per batch), using both manual and automated visual inspection processes. Therefore, the focus on visual inspection and the creation of uniform practices is vital to ensuring patient safety across 503B compounded products.

REGULATORY OVERVIEW

Section 501(b) of the Federal Food, Drug, and Cosmetic Act [3] states: "A drug shall be deemed to be adulterated if the methods used in, or the facilities or controls used for, its manufacture, processing,

Figure 1: Flow diagram of the components of a visual inspection program [7]

packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this Act as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.”

The information in the United States Pharmacopeia (USP) <790>, “Visible Particulates in Injections” (official as of May 2016) [4] and <1790>, “Visual Inspection of Injections” (official as of May 2017 [5], provides the basis of how visual inspections can be conducted. However these chapters are not detailed enough to guide implementation or address regulatory expectations.

The FDA Draft Guidance for Industry, “Inspection of Injectable Products for Visible Particulates” (December 2021) [1] states: “The guidance also clarifies that meeting an applicable United States Pharmacopeia (USP) compendial standard alone is not generally sufficient for meeting the current good manufacturing practice (CGMP) requirements for the manufacture of injectable products. The guidance does not cover subvisible particulates or physical defects that products are typically inspected for along with inspection for visible particulates (e.g., container integrity flaws, fill volume, appearance of lyophilized cake/suspension solids).”

503-registered outsourcing facilities are expected to comply with FDA CGMP requirements as outlined in 21 CFR Parts 210 and 211, with some minor exemptions. As of December 2020, the FDA has exercised enforcement discretion during 503B inspections, in alignment with its Draft Guidance for Industry,

“Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act” [6]. The guidance states that limits and tests for visible particles shall be established for drug solutions purporting to be sterile. The guidance also references USP Chapter <790>, “Visible Particulates in Injections” [4], implying that the FDA may enforce visual inspection requirements consistent with those outlined in the USP chapter. However, the draft guidance does not provide sufficient detail on how a company should establish and implement its visual inspection program.

Each company must develop a program tailored to its unique products and manufacturing environment. However, the following principles must always be met and form the core of any approach a site chooses to adopt:

- The inspection process shall be designed and qualified to ensure that every lot of all parenteral preparations is essentially free from visible particulates.
- Every container that shows evidence of defects (e.g., visible particulates) shall be rejected.

MANUAL VISUAL INSPECTION

Most 503B compounders reference the following sources when developing their visual inspection programs: 21 CFR 211, FDA guidance, USP Chapters <790> and <1790>, International Society for Pharmaceutical Engineering (ISPE) guides, and Parenteral Drug Association (PDA) publications. However, these documents do not provide sufficient detail to ensure consistency and uniformity,

particularly when addressing manual visual inspection.

A robust visual inspection program should include several key components: a defect library, test sets, a defect categorization system, reference photos, limits for each defect category, and a method for analyzing relevant data. These elements should all be managed through the site's change control system. See Figure 1 for a depiction of how to set up a visual inspection program.

In addition, there must be a training program and a process to qualify and requalify personnel performing visual inspections (hereafter referred to as operators).

Each site will need to develop (or could purchase from a vendor a defect library [5] specific to their products. The library should include defects that may be observed for each product family and container size, and should consider the following (non-exhaustive) elements:

- Examples of the types of defects that could occur and have been observed during visual inspection.
- The defect library will be used for training and serve as a baseline for images and examples to be included in the site SOP.
- The defect library can be organized by product or designed to account for the different container sizes, solution or suspension types, product color, and the opaqueness of the container.
- Ensure particle sizes are appropriate. Particles should not be too large or too obvious—typically 150-250 µm (approximately 400 µm in length for fibers).
- Defect libraries should not be used indefinitely; they should have a requalification date. Any units no longer representative of the defect should be replaced.
- Defects should be analyzed annually (or more frequently) to determine if the defect library needs to be expanded to include newly observed defects.

Each company will need to develop a test challenge set [5] (also known as a training set) specific to its products, which may be organized by product family or other bracketing approach. The test set is used to train operators and assess their ability to detect defects. The following recommendations apply to test sets (non-exhaustive):

- The test set should include all representative defects relative to the site's products. It must include examples of inherent, intrinsic, and extrinsic particulates. Vendors are available to create these sets.
- Test sets should include container defects, regardless of the product, for qualification purposes. These should include both naturally occurring defects and defect-free containers.
- A test set should include >90% of defect-free units, with defective units not to exceed greater than 10% of the total number of units in the test set.
- Defects within a test set should include critical, major, and minor rejects.
- The test key (identifying which units are defective) must be maintained separately by quality.
- Best practice is to use the entire test set for operator qualification. Justification is recommended if this is not the approach taken.
- Procedures must be established to ensure qualification container

sets are updated as needed to remain representative of naturally occurring defects. The test sets should be periodically re-evaluated to determine if units need to be replaced.

- Test sets should be periodically assessed to ensure only intended defects are present. Procedures should also be in place to ensure newly identified defects are included in the challenge set.
- For smaller test kits, rotate units frequently or maintain multiple sets so personnel do not memorize them.
- Each container within a test set should be identified with a unique ID in a non-readable format (e.g., barcode or QR code) that, when scanned, returns the ID number/code and its expected result.
- Each site should also establish a defect categorization system [5] for its products. Parameters should be defined for acceptability of each category, which typically include:
 - Critical: Defects that may cause patient injury, such as extrinsic particles, leaks, or container/closure defects compromising integrity of the container.
 - Major: Defects that reduce product usability but do not result in patient harm, such as underfill.
 - Minor: Defects that do not reduce usability of the product, such as cosmetic. (Note: Excessive defects in any category, even minor, may require 100% reinspection and lead to lot rejection.)
- Acceptance criteria for critical, major, and minor defects should be predefined and applied consistently across all products. Exceptions must be justified and acceptance criteria should be statistically justifiable.

It is beneficial to include photographic references of defects in SOPs and/or the defect library. These serve as visual aids for personnel during inspections.

A defined system must be in place for analyzing site data, including clear criteria for when re-analysis is permitted. There should be a periodic review of batch data to ensure the process has not shifted.

VISUAL INSPECTION CRITERIA

100% Visual Inspection

100% of the final containers of all parenteral preparations must be inspected, to the extent possible, for the presence of observable foreign and particulate matter in its contents [4]. This visual inspection should not be performed by the compounder of those units.

Operators should be trained to identify other defects, such as loose caps, cracks in the glass, or any other condition that would render the container unsuitable for use.

Manual visual inspection can be variable. Factors that can be minimized include fatigue, visual acuity, and distractions. These variables must be considered when setting up the visual inspection process as well as during training.

- Maximum inspection times followed by rest breaks must be provided to operators to maintain visual acuity.
- Inspection should not be performed by an operator for more than one (1) hour (or another qualified interval) continuously without a break.

Table 1: Example of a normal AQL inspection plan

Normal AQL Inspection Plan							
Lot/Batch Size	Minimum Sample Size	Critical (0.1%)		Major (0.4%)		Minor (4%)	
		Accept	Reject	Accept	Reject	Accept	Reject
281 to 500	80	0	1	1	2	7	8
3,201 to 10,000	315	1	2	3	4	21	22

Table 2: Example of a tightened AQL inspection plan

Reduced AQL Inspection Plan							
Lot/Batch Size	Minimum Sample Size	Critical (0.1%)		Major (0.4%)		Minor (4%)	
		Accept	Reject	Accept	Reject	Accept	Reject
281 to 500	32	0	1	0	2	3	6
3,201 to 10,000	125	0	2	1	4	10	13

- The duration of time each operator spends performing visual inspection must be documented.

Inspection Stations/Equipment

- The backdrop of the inspection station must include a background consisting of matte black and non-glare white panels to facilitate effective inspection [4] (see Figure 3).
- Inspection stations should be located in areas where background noise and distractions are minimized, preferably in a darkened room. At minimum, the inspection station must be shielded from natural light and other glare.
- Light intensity at the inspection station must be maintained between 2,000 to 3,750 lux. More difficult-to-inspect items may require higher lux levels to identify defects; however, this may also increase visual fatigue.
- Manual inspection stations must be periodically checked using a calibrated light meter to ensure that light levels remain within the required range.

ACCEPTABLE QUALITY LIMIT (AQL) INSPECTION

AQL testing is conducted by the quality unit on a selected sample set. It is used to assess a statistical representation of the batch and determine whether the inspection process was effective in identifying and removing defects—much like potency testing is performed by quality after manufacturing is complete [5].


- A statistical sampling must be conducted to determine AQL across the lot of all conforming material. These samples must be manually inspected.
- This AQL subset is part of the release criteria and serves as a verification of the 100% inspection performed on the lot. It must be done by the quality unit or under its supervision.
- The AQL samples should not be inspected by the compounder of the units or the operator who performed the initial 100% inspection.
- The number of samples selected for AQL [4,5] should be based on ANSI/ASQ Z1.4 [7] or ISO 2859-1 [8].

- Three general inspection levels—Levels I, II, and III—are outlined in Table 1. Unless otherwise indicated, Level II is the default. Level I may be selected when less stringent inspection is acceptable, while Level III is appropriate when more rigorous inspection is required. Four additional special inspection Levels—S-1 through S-4—are also provided in Table 1. These are intended for situations where smaller sample sizes are sufficient and a higher degree of sampling risk is acceptable [7].
- The general practice is to use inspection Level II with the single sampling plan when dealing with larger batch sizes. However, Level III may be used when targeting smaller batch sizes and when a higher level of risk is acceptable. Regardless of which inspection level is selected, a documented justification must be provided for that decision [7].
- AQL samples must be selected randomly across the lot.
- Depending on the circumstances, companies may apply normal, reduced, or tightened AQL acceptance criteria. For example:
 - Based on historical data, normal AQL inspection levels can be used and then reduced when consistent and acceptable justifications are available to do so.
 - If AQL results are routinely trending upwards, a tightened AQL may need to be applied. An example of a normal AQL inspection plan (see Table 1), a Tightened AQL inspection plan (see Table 2), and a reduced AQL inspection plan (derived from ANSI table, inspection Level III). However, the limits should be based on site data and must be justifiable based on a risk evaluation.
- The AQL inspection must follow the same inspection and qualification process as the 100% inspection.
- Any lot that fails to meet the AQL acceptance criteria must be investigated.

TRAINING AND QUALIFICATION

Paramount to the successful execution of any process is the consistent evaluation and enhancement of both the process itself and, more importantly, its personnel. Training is essential for processes

Figure 2: Visual inspection training program [7]



that rely on human intervention and activity. To ensure effective training, qualification is essential—particularly for consistent and robust evaluation of 503B products, especially when manual visual inspection is involved. Figure 2 outlines key components that a visual inspection training program should include.

In general, for manual visual inspection [5]:

- Inspectors must have 20/20 vision (corrected, if necessary) and pass a color deficiency test to be eligible for inspection duties. An annual re-evaluation is required.
- Inspectors must successfully pass manual performance qualification requirements, demonstrating consistent defect identification. Additionally, acceptance criteria must be clearly established for the performance qualification process.
 - Individual operators may not miss a critical defect during qualification.
 - Operators must detect a minimum number of defects for minor and major defects.

Acceptance criteria must be set for the maximum number of false rejections allowed.


- Performance qualification appraisal must also consider:

- Ranges of container sizes
- Product types (solution versus suspension)
- Product color (yellow, red, clear, etc.)
- Must be conducted in the same environment as inspections will be conducted (lighting, ergonomic considerations)
- Must encompass the same amount of time as an inspection period to account for potential fatigue. Ideally, it should be conducted at the end of a shift to simulate real inspection conditions, and a reasonable time limit for completion should be established.

Technique

- Each container must be inspected on two backgrounds, one black and one white [5].
- Each container should be inspected for about 10 seconds—or approximately 5 seconds against each background.
- No magnification should be used.
- Gentle swirling/inversion should be done to place into motion any

Figure 3: Illustration of a visual inspection station



particles laying on a surface. Swirling should not be so vigorous as to cause excessive air bubbles.

- The operator is looking for particulates that are intrinsic or extrinsic (e.g., glass, fibers, stainless steel, etc.). These units

should be removed to a separate area and are considered to be rejects.

- Units with particulates considered inherent product characteristics, such as product aggregates or precipitates, are not required to be removed from the batch as rejects, provided they have been previously identified as non-detrimental to product quality and are included as part of the product appearance specification.
- When intrinsic or extrinsic particulates are found and are not readily identifiable, the unit should be sent to a laboratory for particulate identification.

Inspection Challenges

- When the nature of the contents or the container-closure system limits full inspection of the unit, 100% lot inspection must be supplemented with destructive testing of a subset of the lot.
 - This may include inspection of reconstituted samples for dried samples (e.g. lyophilized), or for a dark amber container withdrawal of the contents of a sampling of containers from the lot may be required.
 - Samples must be selected randomly across the lot.
 - The number of samples selected should be based on ANSI Z1.4 [6] or ISO 2859-1 [8] using Inspection Level S-1.
 - Alternative sampling plans that provide equivalent or greater protection are acceptable, provided that appropriate justification is documented.
- An investigation must be conducted when an AQL failure occurs. If adequate justification is established supported by a risk evaluation, reinspection may be performed in accordance with site SOPs [5]. Furthermore:
 - A deviation should be initiated.
 - The process should be pre-defined in the standard operating procedure (SOP or equivalent guiding document).



HOST AN ISPE WEBINAR!

Share your expertise with a global audience of pharmaceutical professionals by hosting an ISPE webinar. Whether showcasing innovative technologies, regulatory insights, or industry best practices, ISPE's platform connects you with decision-makers who matter.

Learn more and email Sales@ISPE.org

- Acceptance criteria for the reinspection must be pre-defined and should have tightened limits for the categories.
- A tertiary re-inspection is not typically justifiable.

In traditional pharmaceutical manufacturing, there is more time allocated for the development, testing, and refinement of production processes that support large-scale, long-term manufacturing. This allows for extensive research, validation, and optimization.

In contrast, pharmaceutical compounding often requires a time-sensitive response, whether due to the need to address drug shortages or in response to changing customer needs and shorter shelf life of their products. As a result, there is generally less opportunity for comprehensive process development, with greater emphasis placed on the rapid production of needed medications.

CONCLUSION

Visual inspection is a critical component in the compounding and manufacturing of parenteral products. Each facility should establish a program tailored to its specific products, environment, and applicable regulatory requirements. Effective training and clearly defined criteria are essential for the successful implementation of a visual inspection process, which serves as a cornerstone in demonstrating product quality. 🌐

Acknowledgements

This article was written as a collaboration by the ISPE Pharmaceutical Compounding Community of Practice (CoP). If you are interested in being more involved with this or any other CoPs, please visit [ispe.org/Communities-Practice](https://www.ispe.org/Communities-Practice)

References

1. US Food and Drug Administration. Center for Drug Evaluation and Research. "Inspection of Injectable Products for Visible Particulates. Draft Guidance for Industry." December 2021. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inspection-injectable-products-visible-particulates>
2. US Food and Drug Administration. "Compounding Quality Center of Excellence." 2024. <https://www.fda.gov/drugs/human-drug-compounding/compounding-quality-center-excellence>
3. US Food and Drug Administration. "Current good manufacturing practice (21 CFR § 225.1. Section 501b)." Electronic Code of Federal Regulations. 2024. <https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-225/subpart-A/section-225.1>
4. United States Pharmacopeia. "Visible Particulates in Injections." 1 May 2016. United States Pharmacopeia—National Formulary. https://doi.usp.org/USPNF/USPNF.M7197_01_01.html
5. United States Pharmacopeia. "Visual Inspection of Injections." United States Pharmacopeia—National Formulary. 1 May 2024. https://doi.usp.org/USPNF/USPNF.M7198_07_01.html
6. US Food and Drug Administration. Center for Drug Evaluation and Research. "Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B Of The FD&C Act (Draft Guidance for Industry)." January 2020. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-guidance-human-drug-compounding-outsourcing-facilities-under>
7. ANSI/ASQ Z14-2003 (R2018). "Sampling Procedures and Tables for Inspection by Attributes." American Society for Quality (ASQ), 2018. <https://asq.org/quality-resources/z14-z19>

8. ISO 2859-1:1999/Amd 1:2011. "Sampling procedures for inspection by attributes — Part 1: Sampling schemes indexed by acceptance quality limit (AQL) for lot-by-lot inspection." International Organization for Standardization (ISO), 2011. <https://www.iso.org/obp/ui/en/>

About the authors

Kristopher Le, PharmD, serves as the Chief Executive Officer and Managing Partner of Amicus GMP Consultants, a firm dedicated to supporting US FDA-regulated manufacturers in achieving and sustaining the highest standards of quality and safety. Dr. Le brings extensive expertise pharmaceutical compounding, aseptic processing, and current Good Manufacturing Practices (cGMP). An active member of ISPE since 2022, he currently holds the position of Co-Chair for ISPE's Compounding Community of Practice.

Craig Mastenbaum, MBA, is Senior Vice President of cGMP Operations at Wedgewood Connect and Wedgewood Pharmacy, overseeing all aspects of current Good Manufacturing Practices (cGMP) operations at multiple sites. He has more than 40 years of experience in cGMP operations in big pharma, biotech, contract manufacturing organizations, and 503B (outsourcing facilities). Mastenbaum has a BA in Microbiology from Rutgers University and an MBA from Gonzaga University.

Anil Mathai, BSChE, MBA, CQA, LSSBB, is the Chair of the ISPE Pharmaceutical Compounding Community of Practice. He is a graduate of Drexel University (BSChE) and Pennsylvania State University (MBA), with a Certified Quality Auditor (CQA) and Lean Six Sigma Black Belt (LSSBB). Currently a consultant with Global Light Enterprises LLC, he has more than 28 years of experience, working with companies such as KMI/Parexel, Centocor (JNJ), Schering-Plough, Merck, Bonfils Blood Center, Jubilant, and STAQ Pharma. He joined ISPE in 1996.

Deborah McHugh, MPH, is Vice President of Quality for Fagron North America. Deborah has spent 30 years in quality for diagnostics and pharmaceuticals, with the past eight years in 503B compounding. She has supported ISPE since 2022, presenting in the first 503B webinar, and as an inaugural member of ISPE's steering committee for the Pharmaceutical Compounding CoP. She has a biochemistry degree from Wheaton College and Master's Certificate of Public Health from Harvard T.H. Chan School of Public Health.

Shelley Preslar, MBA, is the Chief Visionary Officer and Founder of the Panacea Group, a consulting firm that specializes in aseptic manufacturing, 503B outsourcing, and regulatory compliance, among other areas. She has nearly three decades of life sciences expertise and specializes in aseptic manufacturing, 503A/503B compounding, regulatory compliance, training, validation, and quality systems. She joined ISPE in 2000.

David Short is the Chief Quality Officer for QuVa Pharma, Inc. He has over 30 years of experience in pharmaceutical quality and parenteral drug manufacturing. He previously led quality and research and development departments at Par, JHP, and Hospira for sterile injectables, and worked with Johnson & Johnson, Pfizer, Pharmacia, and Upjohn. Short serves as Co-Chair of the Compounding Interest Group off the Parenteral Drug Association (PDA) and is also a member of ISPE's Pharmaceutical Compounding CoP. He joined ISPE in 2024.

Christopher J. Smalley, PhD, MBA, MSc, has served in the pharmaceutical industry for over 30 years, holding director-level roles at Merck—where he worked in biostereile validation—and at Wyeth Pharmaceuticals, where he was Director of Quality Operations with global responsibility for setting validation standards and overseeing validation activities. He also served on the Board of Directors for the Parenteral Drug Association (PDA). Currently, he works as a consultant, focusing primarily on compounding pharmacies. He joined ISPE in 2012.

Willis Triplett, PharmD, is a Principal at 503 Quality Matters, LLC, where he supports clients with regulatory compliance, inspection readiness, and other services. He is also the Principal of Compoundium Media, LLC, the publisher of the FDA-Rx Newsletter, and serves on the Steering Committee of ISPE's Pharmaceutical Compounding Community of Practice (CoP). With over 40 years of experience in the healthcare and pharmaceutical industries, he brings deep expertise in sterile compounding practices and related areas. He joined ISPE in 2022.

Rebecca Welton is a Principal Consultant in regulatory practice at Lachman Consultant Services, Inc. She has more than 30 years of experience in the pharmaceutical industry. She was lead author on the *ISPE Guide: 503A Compounding – Regulatory Basis and Industry Good Practices for Pharmacies* and the *ISPE Guide: 503B Compounding – Regulatory Basis and Industry Good Practices for Outsourcing Facilities*. She currently serves as Co-Secretary for the ISPE Pharmaceutical Compounding CoP. She joined ISPE in 2023.

Tee Off for a Cause: Join Us at the Annual ISPE Foundation Golf Tournament

By Tori Johnson

The pharmaceutical industry is experiencing a significant talent shortage, particularly in the areas of manufacturing and regulatory affairs. As innovation in biotechnology, artificial intelligence, and personalized medicine accelerates, the demand for a highly trained workforce continues to outpace supply.

This talent gap presents a critical challenge to the industry's ability to meet the needs of patients. With companies struggling to fill key roles in manufacturing, engineering, regulatory affairs, and other areas—the timely and reliable delivery of treatments for patients may be at risk. The ISPE Foundation is addressing this challenge by investing in education and training programs to build a skilled workforce in manufacturing, engineering, operations, and regulatory fields, among other areas. This pool of expertise is essential to the development, approval, and distribution of safe and effective medicines worldwide.

By supporting the workforce of the future, the industry will be better prepared to meet the rapidly evolving needs of the industry worldwide.



©ISPE

Here's why what we do is important:

- The industry is changing fast with advances in biotechnology, digital health, AI, and personalized medicine. Professional development is essential to preparing a workforce with the skills and knowledge it needs in today's highly technological environment.
- The safety, efficacy, and availability of medicines depend on the expertise of professionals in drug development, manufacturing, and regulatory compliance.
- Continuing education is necessary to develop innovative thinkers and problem-solvers. From the integration of AI and digital technologies to global regulatory compliance, the industry needs to be prepared to address complex global issues.



The ISPE Foundation continues to stand as a beacon of hope and opportunity for young professionals looking to enter the pharmaceutical industry.

This year, through the Scholarships and Grants pillar, the Foundation has awarded professional development grants to students and recent graduates to attend ISPE conferences. Multiple students have been awarded academic scholarships, providing continuing education financial support to future industry leaders. Through these impactful initiatives, the ISPE Foundation is shaping the future of the pharmaceutical industry by creating inclusive opportunities for emerging professionals and addressing the industry's critical need for a highly trained workforce.

The ISPE Foundation fuels industry careers by supporting professional development.

About the Author

This article was written by **Tori Johnson** during her tenure as Director of Development and Foundation Operations for the ISPE Foundation. She has since departed from the organization. We thank her for her contributions and for helping to shape the Foundation's ongoing mission.



- These training programs are designed to prepare professionals to navigate both scientific and regulatory environments effectively.

The ISPE Annual Foundation Golf Tournament plays a vital role in advancing our mission to support workforce development. While the tournament offers an opportunity for networking and community engagement, it is an opportunity to raise essential funds for scholarships, grants, and professional development programs.

This year's tournament will take place at Highland Creek Golf Club on 30 October in Charlotte, North Carolina, US, alongside the 2025 ISPE Annual Meeting & Expo. For organizations looking to make an impact, sponsorship opportunities are available beyond the tournament. Collectively, small donations of even \$5, or the cost of one cup of coffee, can make a significant difference in funding scholarships, grants, and professional development opportunities for the next generation of pharmaceutical leaders.

We invite you to join the movement to build a brighter future for skilled professionals in the pharmaceutical industry.

To learn more about how you can support the ISPE community and the workforce of the future, or for more information about golf tournament sponsorship opportunities, visit www.ispefoundation.org 



Investing in **People.** Building the **Future.**

Please consider making a charitable donation to the ISPE Foundation.

Your donation is needed to help fund key Foundation programs that positively impact patient populations across the globe both now and in the future.

WAYS TO DONATE

- Online at ISPEFoundation.org/donate
- Scan the QR code



2025 ISPE ANNUAL MEETING & EXPO

26-29 October | Charlotte, NC, USA

WHAT'S AHEAD AT #ISPEAM25

EXPLORE TECHNICAL TRACKS TAILORED TO YOUR FOCUS AREA:

- Digital Transformation
- Regulatory, Compliance, and Quality
- Sustainability and Supply Chain Resiliency
- Advanced Therapy Medicinal Products (ATMPs)
- Manufacturing, Quality Control, and Operational Excellence

LOOKING FOR EVEN MORE REASONS TO ATTEND?



Up to 1.63

Continuing Education Units (CEUs)



60+ Hours

Expert-led technical education sessions



5 Interactive Workshops

Hands-on learning experiences



200+ Exhibitors

The latest tools, technologies, and solutions



175+ Expert Speakers

Thought leaders and regulators offering real-world expertise



12+ Hours of Networking

Connect with peers from around the world



Learn more and
register at ISPE.org/AM25



2025 ISPE Annual Meeting to Deliver Cutting-Edge Education and Networking Across Five Tracks and 70+ Sessions

By Marcy Sanford

The 2025 ISPE Annual Meeting & Expo scheduled for 26–29 October in Charlotte, North Carolina, US, will give attendees the knowledge and expertise to tackle future challenges in the pharmaceutical industry while helping them connect with colleagues who will become invaluable professional resources.

The increasing impact of new technologies—such as artificial intelligence (AI), machine learning (ML), and automation—is sparking interest in many areas of development and chemistry, manufacturing, and controls (CMC), fundamentally reshaping the pharmaceutical industry's future. More than ever, an emphasis on cross-discipline collaboration is needed to implement and integrate these groundbreaking technologies while ensuring organizational readiness and preparing the workforce of the future.

To support this transformation, the Annual Meeting will bring together a diverse community of industry professionals, thought leaders, and innovators. More than 100 speakers and over 200 exhibitors are expected to convene in Charlotte, where attendees will also benefit from more than 12 hours of networking opportunities.

PHARMA 4.0™

A key topic of this year's conference is Pharma 4.0™, focusing on the end-to-end implementation of digitalization across all stages of project execution, manufacturing, and regulatory processes. Additionally, the comprehensive education program offers innovative technical sessions that will shed light on the latest advancements in areas like the manufacturing of advanced therapy medicinal products (ATMPs); digital transformation; manufacturing, quality control, and operational excellence; regulatory, compliance, and quality; and sustainability and supply chain resiliency. With five tracks and 70 concurrent educational sessions, as well as five workshops, attendees can earn 1.63 CEUs.

KEYNOTE SPEAKERS

One of the highlights of every ISPE Annual Meeting & Expo is the keynote talk from a patient or patient advocate about their journey. This year, attendees will hear from John Daniel, a heart

Pharma 4.0™ will take the spotlight at the ISPE Annual Meeting & Expo, with a strong emphasis on digitalizing everything from project execution and manufacturing to regulatory compliance. Expect deep dives into AI, machine learning, and automation.

transplant recipient and veteran human resource executive with deep experience in leading people and creating a positive company culture. He is a recognized thought leader and speaks at various organizations on culture, leadership, human behavior, and change management. He and his wife, Leslie, were honored in 2022 with the Living Heart Award by the American Heart Association (AHA) for their contributions to the AHA.

Other keynote speakers include Brendan O'Callaghan, Executive Vice President of Manufacturing and Supply at Sanofi, and Elaine Shannon, Global Quality Officer with Takeda. O'Callaghan leads an international network of manufacturing and distribution sites. His ambition is to enable successful commercialization of Sanofi's diverse pipeline, to build world-class standards of manufacturing and supply chain excellence, and to future-proof Sanofi's manufacturing network, leveraging the latest digital, process, and technology solutions to ensure the continued reliable supply of essential, high-quality medicines to patients worldwide.

As the Global Quality Officer at Takeda, Shannon oversees the enterprise quality organization that establishes consistent quality management systems and programs across the network. She leads best-in-class global quality operations, through one quality management system.

This signature gathering is not only an opportunity to learn, but also one to connect and have some fun.

CONTINUED ON PAGE 102

ISPE Europe Annual Conference Reaches New Heights with 1,200 Attendees

CEO Addresses Global Community with Bold Vision for Innovation

By Scott Fotheringham, PhD

Mike Martin, President and CEO of ISPE and the ISPE Foundation, speaking in May in London at the ISPE Europe Annual Conference.

During his welcome address on 12 May in London at the 2025 ISPE Europe Annual Conference, Mike Martin, President and CEO of ISPE and the ISPE Foundation, set the stage for what would become the most well-attended Europe Annual Conference to date, drawing 1,200 participants. He opened the conference by sharing how his background as an engineer has shaped his involvement with ISPE. While engineering is the technology-based discipline at the core of the organization, ISPE encompasses other key disciplines as well, such as quality, science, and operations.

Martin highlighted key areas where ISPE is shaping the future of the pharmaceutical industry. First, he emphasized the organization's role in preparing and publishing guidance documents, which have become essential tools for knowledge sharing and industry best practices. The guides are created largely by volunteer experts within the ISPE network. He pointed to the recently published *ISPE Good Practice Guide: Digital Validation* as an example of ISPE's commitment to equipping professionals with relevant insights in an ever-evolving technical landscape.

He also noted ISPE's growing membership base, which at 22,500 members worldwide, provides a platform for connection and shared learning through conferences like the Europe Annual Conference, as well as training and development opportunities, such as the newly launched ISPE Academy—a continuing education and professional development program. The Academy reflects ISPE's mission to provide accessible, high-quality training opportunities and to support lifelong learning.

He recognized ISPE's member volunteers who contribute their time and talents to the organization's initiatives. Behind every conference, training session, and guidance document are dedicated individuals who give their time and talent to create something useful and important, he said. He reserved a special thank you to the program committee and chair, Heather Watson, whose leadership helped bring this year's conference to life.

Martin also spoke appreciatively for the essential support of sponsors and corporate partners. Their contributions, he said, are

critical in making ISPE events possible and ensuring that knowledge-sharing continues year-round. He described it as a powerful network of collaboration among organizations, individuals, and industries working together to advance pharmaceutical science and manufacturing.

Another highlight of Martin's address was his recognition of the next generation of industry professionals. He acknowledged the 14 students in attendance who received scholarships and grants funded by donations from ISPE members and their companies. Their presence, he said, represents the energy and passion that will carry the life sciences industry into the future.

Martin celebrated three important ISPE milestones: the 45th anniversary of the organization's founding, the 20th anniversary of the Facility of the Year Awards (FOYA), and the 15th anniversary of the ISPE GAMP Community of Practice in the United Kingdom. These milestones demonstrate the power of a committed group of volunteers to shape the industry.

Martin mentioned the upcoming *ISPE AI® GAMP® Artificial Intelligence Guide*—an example of the organization's forward-thinking regarding emerging technologies.

He discussed ongoing efforts to create a new strategic vision for ISPE, to be unveiled at the 2025 ISPE Annual Meeting & Expo in Charlotte, North Carolina, US, in October. This vision, Martin said, will look beyond the traditional focus on facilities, manufacturing systems, and regulatory frameworks. Instead, it will focus on a broader mission: enhancing the quality of human life. It will be grounded in personal and organizational values—integrity, collaboration, and curiosity.

He outlined the three pillars on which ISPE stands:

- **Knowledge:** Lifelong, collective learning, sharing best practices, and continuously growing together.
- **Community:** Emphasizing connection, enthusiasm, shared experiences, and opportunity.
- **Innovation:** Sharing ideas to build better solutions through collective creativity.

Martin described the concept of the pre-competitive space, an environment fostered by ISPE that motivates an open exchange of ideas in a safe and collaborative setting. This space, he said, is essential to driving continuous improvement and innovation.

In closing remarks, he shared his vision that ISPE members experience the power of knowledge, community, and innovation. Through their involvement, he said, they will not only be able to advance their careers but also contribute to the growth and learning of their peers. 

ISPE Engages with Global Regulators at EMA's GMDP IWG to Advance GMP Standards

By Alice Redmond, PhD

ISPE participated in a Good Manufacturing Practice and Good Distribution Practice Inspectors Working Group (GMDP IWG) meeting hosted by the European Medicines Agency (EMA) on 13 March. The group included global stakeholders, including senior inspectors from across Europe and observers from global regulatory bodies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO), among others.

THE GMDP IWG MEETING

The GMDP IWG includes senior Good Manufacturing Practice (GMP) inspectors from the European Economic Area member states (European Union countries, plus Norway, Iceland, and Liechtenstein), representatives from the European Commission (DG Enterprise and Industry), and observers from the European Directorate for the Quality of Medicines (EDQM), FDA, WHO, EU accession countries, and nations with Mutual Recognition Agreements or trade agreements.

ISPE, a recognized EMA stakeholder and part of the 16-association group coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), has contributed to the EMA IWG since 2013.

The interested parties are invited to meet with the GMDP IWG annually. In the months leading up to each meeting, the associations propose topics for discussion with the EMA, often accompanied by an industry position brief. These briefs are drafted by the association designated as the lead on the topic, with input from supporting associations.

ISPE Served as the Lead for the Following Topics

- EU-GMP Chapter 1: Quality Risk Management
- Annex 11/Chapter 4: Computerized System Validation and Documentation
- Annex 15: Process Qualification and Validation
- Drug Shortages Prevention

ISPE also acted as a supporting association for:

- Annex 1: Sterile Manufacturing
- Annex 21: GMP for Importers

Since October 2023, over 250 people—including 60 EMA inspectors—have completed PIC/S quality risk management training.

Updates and Collaboration

The 13 March meeting included updates on several GMP/GDP guidelines in the IWG Working plan:

- The Annex 15 revision, with a focus on facilities, equipment, and process validation draft, will be available later this year. Advanced manufacturing technologies and advanced therapy medicinal products (ATMPs) are not included in Annex 15.
- The Annex 11 revision will be split into two separate Annexes: the existing Annex 11 (20 pages) and a new Annex 22 (8 pages) on artificial intelligence.
- Proposed changes to EudraLex Part 1/Chapter 4 documentation are extensive and will be aligned with the proposed changes to Annex 11, e.g., electronic signatures.
- Since October 2023, PIC/S quality risk management training has reached over 250 participants, including 60 EMA inspectors.

In 2025, the EMA Quality Innovation Group will focus on personalized medicines, decentralized (point of care) manufacturing, and 3D printing.

A standout feature of the meeting was the constructive, structured dialogue and an atmosphere of mutual confidence. The EMA demonstrated genuine openness to feedback and a strong commitment to enhance regulatory processes and collaboration with industry. The EMA's engagement with industry representatives demonstrated a strong willingness to strengthen its relationship with interested parties.

CONTINUED ON PAGE 98

CONTINUED FROM PAGE 97

Preparation

Preparation played a crucial role in the meeting's success. The pre-meeting discussions with the EMA proved highly beneficial, ensuring that all topics were adequately addressed and the dialogue remained focused and productive. One of the key discussion points during the meeting was the need for EU-wide metrics on inspection findings. Although this was not considered a current priority, it was suggested that the parties consider identifying the top 10 inspection findings to enhance regulatory oversight and improve compliance standards.

Another critical topic was Annex 1, with key issues associated with Annex 1 implementation being discussed. The responses provided were perceived as highly dependent on individual opinions from local health authorities and inspectors. It is clear that industry and regulators need to continue to work together to understand the challenges manufacturers and regulators face collectively and how this can be addressed.

The meeting also shed light on the growing workload of the EMA IWG in 2025. The agency's increasing responsibilities highlight the importance of harmonization efforts, particularly through organizations like the PIC/S. This aligns with industry expectations for greater regulatory consistency and streamlined compliance frameworks across different jurisdictions. The EMA's

continued willingness to accept comments on drafted guidelines and targeted Q&A sessions was also acknowledged as a positive step toward achieving this goal.

Outcomes

The meeting was regarded as the most successful IWG-IPM, characterized by a high level of collaboration, mutual respect, and a strong commitment to process improvement. A key takeaway: the voice of the industry was heard. The level of preparation by industry stakeholders and the preparation calls with the EMA contributed to the meeting's success.

The ability to align diverse associations and maintain a well-organized approach to engagement proved instrumental in achieving meaningful outcomes. The meeting set a high benchmark for future engagements, demonstrating that structured, transparent, and well-prepared discussions can lead to tangible improvements in regulatory processes. Continuing collaboration and proactive engagement will be essential in addressing the remaining uncertainties and in ensuring that industry concerns are effectively integrated into the EMA's regulatory framework.

LOOKING AHEAD

It was suggested that an in-person meeting be scheduled for June 2026, with discussion topics due in February 2026. A face-to-face meeting could consolidate the importance and effectiveness of this collaboration even further. The 2025 interested parties include:

- Active Pharmaceutical Ingredients Committee
- Affordable Medicines Europe
- AnimalhealthEurope
- Association of the European Self-Care Industry (AESGP)
- European Association for Logistics and Transportation in Healthcare
- European Compliance Academy
- European QP Association
- European Federation of Pharmaceutical Industries and Associations
- European Healthcare Distribution Association
- European Industrial Pharmacists Group
- International Pharmaceutical Excipients Certification
- International Pharmaceutical Excipient Council
- International Plasma and Fractionation Association
- ISPE
- Medicines for Europe
- Parenteral Drug Association
- Plasma Protein Therapeutics Association
- Vaccines Europe 

About the author

Alice Redmond, PhD, is Chief Strategy Officer with CAI. She has more than 30 years of experience in life cycle management of pharma facilities inclusive. Alice is chair of the Guidance Documents Committee, serves on the ISPE C&Q Community of Practice Steering Committee, is co-chair of the Regulatory Quality Harmonization Committee's Europe-Middle East-Africa Regional Focus Group, and is a member of the Regulatory Steering Council. She joined ISPE in 2002.



ISPE

GOOD PRACTICE GUIDE:

Validation 4.0

Validation 4.0 ensures that validation processes are not a bottleneck but a strategic enabler of innovation, quality, and compliance.

GET THE GUIDE

ISPE | PHARMA 4.0™

GOOD PRACTICE GUIDE:

Validation 4.0

A Continuous Validation Framework

Quality Risk Management

Quality by Design

Real-Time Monitoring

Robotic Control Strategy

Celebrating 25 Years of ISPE Singapore's Legacy

By Geoffrey Brown, Sia Chong Hock, Shanshan Liu, Vee Revithi, PhD, Bob Tribe, and Pierre Winnepenninckx

This year, the ISPE Singapore Affiliate proudly marks 25 years of advancing pharmaceutical engineering and technology. It has played a pivotal role in shaping the pharmaceutical and biopharmaceutical industries in the region, fostering a strong community focused on education, collaboration, and innovation. As we reach this remarkable milestone, we reflect on the journey and look ahead to an exciting future.

PIONEERS AND THEIR VISION

ISPE Singapore was established by visionaries who recognized the need for a local Affiliate to support the region's rapidly evolving pharmaceutical landscape. Founding members recall the challenges of building a strong foundation while promoting professional competence and training.

"Celebrating its 25th anniversary, ISPE Singapore stands as a pillar in advancing pharmaceutical engineering and technology," said Geoff Brown, who served as the ISPE Singapore President from 2016 to 2018. "During my presidency, we focused on fostering education programs, enhancing professional competence, and integrating industry stakeholders. Growing to over 300 members with a 20-plus-member executive committee, we promoted dialogue and knowledge sharing through regular workshops and events. I'm particularly proud of the growth of our annual conference and exhibition, which has flourished into the leading pharma and life science event in Singapore."

SINGAPORE: A GLOBAL PHARMA HUB

Over the past 25 years, Singapore has emerged as a global leader in pharmaceutical and biotechnology manufacturing, research, and regulatory excellence. The city-state's strategic business environment and strong regulatory framework have positioned it as a hub for innovation. ISPE Singapore has been instrumental in supporting this growth by fostering collaboration between industry and regulators, offering training, and providing networking opportunities.

Bob Tribe, the Regulatory Advisor for ISPE Singapore, says of the Affiliate's impact: "The close collaboration between the Affiliate and regulators has brought mutual benefits, fostering open communication and a deeper understanding between industry and regulatory authorities. This partnership enables



the industry to better grasp regulatory requirements, ensuring product quality and compliance, while also providing regulators with insights into industry challenges and the latest technological advancements."

MEMORABLE MOMENTS AND COMMUNITY SPIRIT

ISPE Singapore's annual conference and events are cherished for their professional insights and the strong sense of community they nurture. Vee Revithi, a long-time Singapore Conference supporter, reflects on the Affiliate's legacy: "It has been a long time since I started participating at the conferences and events as a regulator, as an industry representative, and as a consultant. Throughout those years, I found the conferences not only interesting and professional, but always very pleasant and satisfying, as people were happy to get together, learn, and communicate. The close collaboration between the Affiliate, regulators, and industry has brought mutual benefits, fostering open communication and a deeper understanding between them. And one more factor for the success: the kind and warm hospitality of the ISPE Singapore Affiliate, always finding solutions while keeping high professionalism."

Reflecting on the early days, it is worth mentioning a notable event from 2001, when the founding CEO of the newly established Singapore Health Sciences Authority (HSA), Clarence Tan, PhD, and Sia Chong Hock, the founding Director of the GMP Audit Unit at HSA, served as keynote speakers at the inaugural ISPE Singapore Conference.

"The new regulator, namely the Health Sciences Authority, will adopt high standards but will not impede industry growth. It will be a health inspector that is industry-friendly," Dr. Tan told the *Business Times*, a financial newspaper in Singapore.

LOOKING TO THE FUTURE

As the pharmaceutical and biopharmaceutical industries continue to evolve, ISPE Singapore remains committed to addressing

CONTINUED ON PAGE 103

VOLUNTEER
PROFILE

BEN STEVENS, PHD

ARTIFICIAL INTELLIGENCE COMMUNITY OF PRACTICE (COP) CHAIR

Ben Stevens serves as Director of Chemistry, Manufacturing, and Controls (CMC) Policy and Advocacy at GSK. He has over 15 years of experience in the industry having worked for Alnylam Pharmaceuticals where he led the global CMC regulatory development of vutrisiran (a treatment for polyneuropathy and cardiomyopathy), and oversaw its US New Drug Application and the EU Marketing Authorization. He's also served as a Principal Consultant for Parexel International Corp., and as acting Branch Chief for the Office of New Drug Products at the US Food and Drug Administration (FDA).

Ben earned a PhD in chemistry from the University of Pittsburgh, Pennsylvania, US, and a Master of Public Health from Johns Hopkins University, Baltimore, Maryland, US. He has co-authored over 30 publications and patents. He chairs the ISPE Artificial Intelligence Community of Practice (CoP), is a member of the ISPE Regulatory Quality Harmonization Committee (RQHC) Process Modeling Team where he co-chairs the Americas Regional Focus Group.

WHAT DREW YOU TO THE PHARMACEUTICAL INDUSTRY?

During my undergraduate research at the University of Rochester (New York, US), I worked in an organic chemistry lab, which sparked my interest in organic synthesis. Then, a course on molecular pharmacology piqued my interest in drug discovery and I ended up following that path through graduate school when I realized that I wanted to work in the pharmaceutical industry.

WHAT DO YOU DO IN YOUR CURRENT ROLE?

Our broader regulatory CMC and nonclinical group is a mix of different functions, but the goal of the CMC policy team is to be informed and aware of the high-priority emerging regulatory CMC topics across the industry and to ensure that the company's position is reflected in the growing consensus-building process. We do a lot of work behind the scenes internally to build consensus across departments and to help support our regulatory colleagues in their work toward generating filings for clinical trials and licensure.

For the past two and a half years, process modeling—including AI and machine learning models—has been a priority for us. GSK has been a strong advocate for the use of these technologies and the broader application of mathematical models and model-based control to pharmaceutical processes, such as drug substance and

drug product development and manufacturing. We're working to ensure regulators understand how we generate, use, and maintain these models from a technical standpoint, while also collaborating to build and adapt a regulatory framework that facilitates innovation.

WHAT DO YOU ENJOY MOST ABOUT YOUR WORK?

It's very rewarding to work together with teams on cutting edge regulatory issues where there aren't a lot of black and white answers. Working in these teams allows me to continually learn and improve my ability to negotiate and build consensus. Given the challenge in getting consensus between so many groups or industry members, it's particularly rewarding when you see the ultimate success of all the earlier and often long-term investment. I also get to work with a lot of folks from very different backgrounds who are incredibly knowledgeable subject matter experts. I enjoy helping these experts turn their deep knowledge, expertise, and passion into positions that are incredibly useful for guiding policy and regulation—and are often the foundation of many longer-term initiatives.

TELL ME ABOUT A PROJECT YOU'RE PROUD OF.

I'm excited about the growing interest in and potential applications of process modeling and AI, and the emerging regulatory frameworks shaped on many of the discussions we've been part of over the years. It's rewarding to have been engaged in this ongoing dialogue with regulators and to then see them recognize the importance of this space and work to adapt our input into practical and beneficial guidance. Previously, the industry had little guidance about process modeling and AI, but now the European Medicines Agency's Quality Innovation Group has issued a concept paper informed by ISPE member companies. Likewise, the FDA's recent AI guidance has been highly informative and reflects much of the industry perspective and input that has been provided over the last few years.

TELL US ABOUT THE AI COP.

The AI CoP pulls from all of the expertise across ISPE, including GAMP® and Pharma 4.0™, and then we take it to the next level. We've been working to establish sub-teams to work on important areas of AI, such as regulatory, preparedness and workforce, and applications and data. We welcome participation from across the industry. We'd love to hear from members who are interested in joining and are always open to new ideas. 

VOLUNTEER PROFILE



ANDREA MARTINA ZOBEL, PHD INVESTIGATIONAL PRODUCTS EUROPE COMMUNITY OF PRACTICE (COP) CHAIR

As the Senior Director of Personalized Supply Chain at Cencora World Courier (formerly AmerisourceBergen), Andrea Zobel leads the cell and gene therapy (CGT) and direct-to-patient service lines for this specialty logistics provider. With a background that includes experience gained across academia, pharmaceutical services, and clinical trials logistics, Andrea focuses on defining strategy, driving growth, and solving operational and process challenges that arise from the complexity of shipping medicinal products around the world.

Andrea holds a diploma in biochemistry from the Freie Universität Berlin, Germany, and a PhD from the Max Planck Institute for Molecular Genetics in Berlin, Germany. She has 12 years of research experience in gene technology, pharmacology, and preclinical development, both in academic research and with biotechnology companies. She is a passionate author, lecturer, and trainer for pharmacology, regulations, and clinical trial logistics. She has been an active member of ISPE since 2009 and is also a member of the Association of German Biotechnology Companies (VBU).

WHAT DREW YOU TO A CAREER IN THE PHARMACEUTICAL FIELD?

In my final school years, I learned about molecular biology and gene technology. I was fascinated by the potential to use these technologies to develop therapies to cure diseases. I decided to study biochemistry, with the goal of developing gene-based therapies.

I describe my career as moving from gene to last mile, having worked across all phases of drug development—from target identification to clinical development—and now I'm helping deliver cures worldwide. While working on my diploma and PhD, I studied diseases like AIDS and cancer. I transitioned to pharmacology and joined a biotechnology company to test drug candidates in preclinical development, followed by gene therapy when the field was very new. Today, I'm involved in clinical and pharmaceutical logistics. Some of the drug candidates I helped develop in the very early stages are now being shipped to patients in clinical trials.

WHAT DO YOU DO IN YOUR CURRENT ROLE?

At Cencora, I'm responsible for the personalized supply chain for both CGT logistics and logistics for decentralized clinical trials where clinical trial participants receive supplies for the trial at home.

Radiopharmaceutical therapies, which is a growing pipeline of personalized medicine, also need specialized logistics and expertise. It can be challenging because we're shipping highly regulated products to patients' homes. Many of these products have special requirements, such as short shelf lives and strict temperature requirements—they must reach the right patient within a specific timeframe or risk losing effectiveness. The shipping is very complex and requires specialized expertise.

For instance, we've found that some companies require their CGTs to avoid airport X-ray machines, fearing the radiation will cause damage. However, the amount of radiation on a plane is actually higher than the amount of radiation in the X-ray machine. To address this, I've been setting up partnerships with universities and X-ray manufacturers to conduct research and testing that demonstrate that nothing happens to the therapy when it goes through X-ray screening. We use these findings to educate our clients.

WHAT DO YOU ENJOY MOST ABOUT YOUR WORK?

It is satisfying to use the experience from so many years in pharmaceutical development to develop solutions for actual problems. We work on global projects with global distribution, and it is a great thing to work with so many people from so many cultures. I often start my day with talking to people in Singapore, then India, Russia, and other European countries. Later I'll talk to people in America and Latin America. We work on a global level, but everybody has the same goal: to develop and deliver cures to patients.

WHAT ADVICE WOULD YOU GIVE EMERGING LEADERS?

Have goals that motivate you—ones you're really burning for—and use them to make career choices. Ask yourself, "Will this job help me reach my goal?" It's much easier to make decisions when you know where you want to go. It's also important to reflect on your strengths and try to find a job where you can apply them.

WHAT DO YOU ENJOY ABOUT BEING A MEMBER OF YOUR COP?

Everyone comes from a similar work environment, but each company tackles challenges differently. Being a part of the CoP gives you a safe space to exchange ideas and information with colleagues and to learn how others have dealt with the same issues you are having. 

— Marcy Sanford, ISPE Publications Manager

CONTINUED FROM PAGE 95

NETWORK AND CONNECT

Numerous networking events such as the Sunday Social, Welcome Reception, and Tuesday Night Celebration at the NASCAR Hall of Fame give everyone from emerging talents to seasoned executives the opportunity to meet. Special events such as the Facility of the Year Awards (FOYA) Banquet, Women in Pharma® networking event, and Hackathon give attendees additional opportunities to mingle with colleagues and help upcoming professionals. There are also opportunities to expand your professional network, improve your resume, get lots of great swag, and learn about the latest technologies and services in the Expo Hall, with more than 200 exhibitors, and special talks and demonstrations.

GET TO KNOW THE HOST CITY

Located in the southwestern part of North Carolina, Charlotte is the largest city in the state. It's also a major financial hub, home to the East Coast headquarters of Wells Fargo and the headquarters of Bank of America. It also has growing sectors in healthcare, technology, and life sciences. It is home to the University of North Carolina at Charlotte (UNC Charlotte) and the NASCAR Hall of Fame. And for those of you seeking adventures in nature after the Annual Meeting, the closest major national forest, Uwharrie National

Annual Meeting keynote speakers include:

- **Brendan O'Callaghan** – Executive Vice President, Manufacturing and Supply, Sanofi
- **Elaine Shannon** – Global Quality Officer, Takeda
- **Jehr Collins, PhD** – Chief Technical Operations and Quality Officer, Moderna
- **Jerry Greco, PhD** – Chief Quality Officer, Baxter International Inc.
- **John Daniel** – Veteran HR Executive & Author

Forest, is about 50 miles away. Hotel information is available on the conference travel page and all recommended hotels are within walking distance from the convention center.

For more information and to register for the meeting, visit ispe.org/conferences/2025-annual-meeting-expo 



Meet the
ISPE STAFF



KATIE LECHASE

Hometown:
San Diego, Calif., US

In each issue of *Pharmaceutical Engineering*®, we introduce a member of the ISPE staff who provides ISPE members with key information and services. Meet Katie LeChase, Director of Communications.

Tell us about your role at ISPE: What do you do each day?

I help drive and support communications efforts for ISPE in collaboration with our marketing and communication team. This includes spearheading our media relations program, overseeing our iSpeakblog, developing communications materials such as the ISPE Annual Report and ISPE press releases, and mapping out communications plans with our colleagues across various departments.

What do you love about your job?

My favorite part of my job is helping bring stories to life and support knowledge-sharing. I've

worked in the communications field for more than 16 years. I love working with thought leaders to develop, crystallize, and disseminate insights and perspectives that educate and inspire audiences. It's always very rewarding to see the articles I've worked on with journalists get published and to celebrate those successes with the subject matter experts who are featured.

What do you like to do when you are not at work?

I live in sunny San Diego now and am originally from wintry Rochester, New York, so I love spending lots of time outside. Some of my favorite outdoor activities include hiking, biking, stand-up-paddleboarding, going for light runs on the boardwalk or a nearby beach, reading outside, and taking my 16-year-old dog to nearby parks. I'm also starting to get back into tennis, which I've loved playing since I was a kid.

CONTINUED FROM PAGE 99

emerging challenges, including digital transformation, sustainability, and regulatory advancements. The Affiliate will continue to empower the next generation of leaders, fostering innovation while upholding the highest standards of quality and compliance.

JOIN THE CELEBRATION

As we celebrate 25 years of ISPE Singapore, we invite the global ISPE community to join us at the ISPE Singapore Annual Conference 27–29 August. Let us continue to shape the future of pharmaceutical engineering together, with Singapore at the forefront of industry excellence. 

About the authors

Geoffrey Brown, MS, is an APAC Regional Program Manager for Data Center Construction Quality at Google in Singapore. He has extensive experience in the industry, specifically in incorporating current industry best practices for quality, commissioning, and qualification that comply with the regulatory requirements using a science and risk-based approach. He holds a Stanford LEAD Professional Certificate from the Stanford University Graduate School of Business. Brown served as ISPE Singapore President from 2016 to 2018. He joined ISPE in 2009.

Sia Chong Hock, MSc with Distinction, is Director of Quality Assurance and Senior Consultant of Audit and Licensing at the Health Products Regulation Group of the Singapore Health Sciences Authority (HSA). He has a keen interest in good manufacturing practices, quality assurance, pharmaceutical data and supply chain integrity, and international harmonization of regulatory frameworks to ensure accessible, safe, and good quality APIs, as well as pharmaceutical and biopharmaceutical products for patients and consumers. He played a pivotal role in making HSA

the first PIC/S member in Asia. He chairs the Association of Southeast Asian Nations Joint Sectoral Committee on GMP Inspection. He joined ISPE in 2005.

Shanshan Liu, MSc, is Technical Director at No deviation Ptd. Ltd. in Singapore and is an associate faculty member at the Singapore Institute of Technology. She serves on the ISPE International Board of Directors and is a past President and Vice President of the ISPE Singapore Affiliate. She has over 18 years of global experience in the pharmaceutical industry, first in engineering and in more recent years focusing on quality, compliance, and regulatory affairs. She has assisted pharmaceutical and medical device manufacturers in establishing quality systems, remediating quality and compliance risks, and developing regulatory strategies. She joined ISPE in 2010.

Vee (Vasiliki) Revithi, PhD, is a Senior Consultant to pharmaceutical regulatory authorities on Good Manufacturing Practice and Good Distribution Practice standards. Her works include working with global regulatory authorities to become a member of Pharmaceutical Inspection Co-operation Scheme (PIC/S) having successfully worked with Turkey TMMDA, Armenia Medicines Agency, Jordan FDA, and the China NMPA. She is the past Head of External Relations Europe for Roche and the past Head of Good Manufacturing and Distribution Practice (GMDP) for the National Organization for Medicines in Greece.

Bob Tribe is an Australian-based consultant to GMP regulatory authorities. With over 30 years of experience in regulatory and compliance affairs in the pharmaceutical industry, he advises regulatory authorities globally to assist them in preparing for PIC/S membership, including agencies in Russia, Jordan, Pakistan, the Philippines, Azerbaijan, and Ethiopia. Formerly Chief GMP Auditor at Australia's Therapeutic Goods Administration for 23 years, he played a key role in shaping modern GMP standards. He also served as Deputy Chairman and Chairman of PIC/S. He joined ISPE in 1996.

Pierre Winnepenninckx is the CEO of No deviation Pte. Ltd. and a seasoned Commissioning & Qualification (C&Q) professional with extensive international experience. Based in Singapore since 2008, he brings a passion for science, engineering, and knowledge sharing to his work. Winnepenninckx joined ISPE in 2011 and became active in the ISPE Singapore Chapter in 2012, contributing to the advancement of pharmaceutical engineering in the region. He has worked with AbbVie, Novartis, and GSK, among others. He is a past President and Vice President of ISPE Singapore Affiliate.

INTRODUCING THE NEW ISPE ACADEMY

This comprehensive continuing education program offers five specialized certificates:

- Biopharmaceutical Essentials
- GAMP® Essentials
- GMP Refresher
- Good Engineering Practices
- Pharmaceutical Water Systems



Learn more at
ISPE.org/ISPE-Academy



 **ISPE ACADEMY®**

INDEX

Arcadis	Back Page
COPA-DATA	Inside Cover
Elettracqua Srl	Back Page Inside
Endress+Hauser Group Services AG	1
GF Piping Systems	3
Intelligen, Inc.	15
MicronView LLC	27
Pharma Access Pvt. Ltd.	5
ValGenesis, Inc.	35

CLASSIFIEDS

CONSULTING

Arcadis
959 Concord Street
Suite 100
Framingham, MA 01701
1-508-532-6760
www.dpsgroupglobal.com

CONTAINMENT

GF Piping Systems
9271 Jeronimo Road
Irvine, CA 92618
+1 800-854-4090
www.gfps.com/us

ENGINEERING & DESIGN SERVICES

Pharma Access Pvt. Ltd.
702 Supreme Chambers,
Andheri West, Mumbai
Maharashtra, India 400053
+91 22 6819 3888
www.pharmaaccess.net

INFORMATION TECHNOLOGY

COPA-DATA
Karolingerstrasse 7b
Salzburg, Austria 5020
+43 662-43-10-02-0
www.copadata.com

INSTRUMENTATION

Endress & Hauser Group
Service AG
Kaegenstrasse 2
4153 Reinach BL, Switzerland
+41 61 715 7700
www.endress.com

MicronView LLC
2300 Highway 365 Suite 110
Nederland, Texas 77627
+1 520-528-1882
www.micronview.com

SOFTWARE SIMULATION & PROCESSING SYSTEMS

Intelligen, Inc.
2326 Morse Avenue
Scotch Plains, NJ 07076
+1 908-654-0088
www.intelligen.com

VALIDATION—MANUFACTURING

ValGenesis, Inc.
395 Oyster Point Boulevard
Suite 228
South San Francisco, CA
94080
+1 510-445-0505
www.valgenesis.com

WATER TREATMENT & PURIFICATION

Elettracqua Srl
Via Adamoli 513
16165 Genoa, Italy
+39 010-8300014
www.elettracqua.com

PLEASE SEE THE ADS FOR EACH OF
OUR ADVERTISERS IN THIS ISSUE.



ELETTACQUA

pure water technologies

SINCE 1966

PHARMACEUTICAL WATER SYSTEMS



DESIGN AND CONSTRUCTION OF PURIFIED WATER PACKAGES ♦
DOUBLE PASS REVERSE OSMOSIS ♦ R.O. +
ELECTRODEIONIZATION HOT WATER SANITIZABLE ♦
ULTRAFILTRATION ♦ MULTIPLE - EFFECT DISTILLATION UNITS ♦
PURE STEAM GENERATORS ♦ STORAGE AND DISTRIBUTION
LOOP ♦ COMPLETE TURNKEY PROJECTS ♦ VALIDATIONS IQ, OQ

www.elettacqua.com



Combining engineering excellence and our consultancy experience to deliver end-to-end sustainable solutions.

Our services include:

- Process architecture and process engineering
- Commissioning, qualification, and validation (CQV)
- Construction management
- Strategic consulting
- Product stewardship and environmental services
- Decarbonization
- Managed services
- Technical services

Learn more at arcadis.com/life-sciences